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ABSTRACT 
Angiotensin-1 converting enzyme (ACE) is a zinc metallopeptidase that consists of two 
homologous catalytic domains (N and C) with different substrate specificities. ACE is a central 
component of the intrinsic brain renin angiotensin-aldosterone system (BRAAS), well 
renowned as the regulator of blood pressure. The BRAAS has alternate functions that extend 
beyond fluid and blood pressure homeostasis into areas such as neurological function. As a 
result, it is implicated in many neurodegenerative diseases including Alzheimer’s disease (AD).  
ACE’s specific mechanistic role in AD is not entirely clear and is somewhat controversial. 
However, it has been shown that ACE hydrolyses the amyloid beta (Aβ) peptide, the putative 
causative agent of AD.  
This study aimed to investigate the molecular basis of ACE hydrolysis of Aβ by determining: 1) 
the kinetic parameters of five different forms of human ACE with various N-terminal amyloid 
beta (Aβ) substrates; 2) the specific active site determinants of Aβ-domain selectivity; and 3) 
the high-resolution crystal structures of the N-domain of ACE in complex with Aβ(1-16), 
Aβ(10-16), Aβ(4-10), the FRET Aβ(4-10)Y and Aβ(35-42) peptides.  For the physiological Aβ(1-
16) peptide, a novel ACE cleavage site was found at His14/Gln15. Furthermore, Aβ(1-16) was
preferentially cleaved by the truncated N-domain; however, the presence of an inactive C-
domain in full-length ACE greatly reduced enzyme activity and affected domain-selectivity.
Two fluorogenic substrates, designed specifically to assess ACE’s mechanism of Aβ hydrolysis
Aβ(4-10)Q and Aβ(4-10)Y, underwent endoproteolytic cleavage at the Asp7/Ser8 bond. The
Aβ(4-10)Q peptide was a poor substrate of ACE but was N-selective, with a selectivity driven
largely by interactions with the domain-specific residues of the S2 and S2’ pockets. The
selectivity of the S2’ residues were confirmed with a similar, more physiological, fluorogenic
Aβ(4-10)Y peptide. This work provides further understanding towards the substrate
determinants of N-selectivity, highlighting the importance of the S2’ Ser357. ACE C-domain
hydrolysed Aβ(4-10)Y with modest efficiency compared to the other substrates, where
hydrolysis under the same conditions did not occur. Moreover, Aβ(4-10)Y also displayed N-
domain selectivity. In contrast to Aβ(1-16) and Aβ(410)Q, both sACE and the double C-domain
(CC-sACE) construct showed positive domain cooperativity towards Aβ(4-10)Y. The high-
resolution crystal structures of the N-domain in complex with five Aβ peptide fragments
provided an overlapping, conserved, molecular mechanism of peptide binding and evidence of
the enzyme’s broad exoprotease activity. In addition to the kinetic and structural studies,
ACE’s signalling response to the N-selective Aβ(1-16) and Aβ(1-42) was investigated using
immunodetection and mass spectrometry. Similar to the ACE inhibitor lisinopril, the Aβ
peptides elicited ACE signalling by phosphorylation of the cytoplasmic Ser1270 residue and
JNK activation. The signalling response of ACE was coupled to increased ACE activity and
expression on treatment with Aβ(1-42). These studies allowed us to rationalise the increased
ACE activity and expression found in AD, may arise through direct interactions with Aβ.
This work provides a kinetic, structural and mechanistic understanding of the selective 
cleavage of Aβ by the N and C catalytic sites of ACE. Due to the broad substrate specificity of 
the two domains of ACE, and the overarching N-selectivity of Aβ hydrolysis, these findings 
provide rationale for further in vivo pharmacological studies on the mechanism of action C-
domain-selective inhibitors, in the context of AD 
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1 CHAPTER 
Literature Review 
1.1 Alzheimer’s disease.  
In an aging world population, developments in healthcare are prolonging our life span and 
improving quality of life. Today in most developed countries, life expectancy is above 80 years 
of age.  
There is however, a yin to this yang: non-communicable diseases are more prevalent due to 
increased life span and stand out as huge financial and health care burdens to society. One 
such major contributor is Alzheimer’s disease (AD). AD is an extremely debilitating disease 
that destroys its victim’s personality, and motor and cognitive abilities. It is the most common 
form of dementia (60-80 %) and in these cases, the final manifestation of aging (Alzheimer’s 
Association, 2013). Dementia is a term used to describe a broad spectrum of diseases and 
conditions that arise from neuronal loss of normal function or cell death. In AD, neuronal cells 
die off gradually, slowly impairing an individual’s ability to carry out basic bodily functions 
such as walking and swallowing, and is ultimately fatal (Braak and Braak, 1991).  
The World Health Organisation (WHO) estimates that 35.6 million people live with dementia 
worldwide. It is projected that by 2030, the incidence will double and by 2050 more than 
triple (World Health Organization, 2012). The current global cost of dementia is approximately 
US$ 604 billion, of which 89 % is incurred in high-income countries. Predictions for low-
income countries, whose financial status are dependent on and converge with high-income 
countries, are more severe. Here, the immediate families bear the largest brunt emotionally 
and financially, as there are poor community services and little institutionalization. WHO’s 
prerogatives are to seek out a cure and to identify and improve the knowledge surrounding 
primary prevention indicators. Evidence to date has pointed out a number of risk factors. 
These are largely related to life style, genetic predisposition and cardiovascular disease (CVD). 
Changes need to be implemented to decrease the risk of CVD, and thus AD, by improving 
access to education and countering risk factors for vascular disease, including diabetes, 
midlife hypertension, midlife obesity, smoking, and physical inactivity. For humanity to have 
hope of finding a cure, the underlying mechanism and primary causes of AD development 
need to be elucidated. 
1.2 The amyloid hypothesis.  
The most prominent pathology of AD is the presence of intercellular neurofibrillary tangles of 
hyperphosphorylated tau protein and large extracellular masses of β-amyloid (Aβ) protein 
plaques (Grundke-Iqbal et al., 1986; Masters et al., 1985). Aβ was first observed, without 
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causality, by Alois Alzheimer in 1907 in the brain of a middle aged woman who displayed, 
what we now know as, classic symptoms of AD (Alzheimer, 1907). The amyloid beta peptide 
itself was only isolated and biochemically characterised almost 80 years later with the 
development of new protein isolation and extraction techniques (Glenner and Wong, 1984; 
Masters et al., 1985; Roher et al., 1993b).  
Through the pioneering work of Glenner and Wong (1984) on brain tissue from Down´s 
syndrome (DS) patients, the foundations for what we now know as the amyloid hypothesis 
were laid (Glenner and Wong, 1984). These scientists first described and named the 4kDa 
“amyloid β protein”, isolated from meningeal vasculature and, later the same year, linked it to 
AD by mapping the gene encoding the amyloid precursor protein (APP) to chromosome 21 
(Kang et al., 1987). Due to the observation that most DS patients develop the 
neuropathological criteria for AD by the age of 40 (Zigman et al., 2008) and that DS patients 
have two extra copies of APP (Tanzi et al., 1987) a causal link was thus established between 
AD and Aβ. This, taken together with the hallmark Aβ plaque observed in post mortem 
analysis of both DS and AD patients, lead to the formation of a hypothesis that the 
accumulation, oligomerization and eventual fibril and plaque formation of Aβ, is the primary 
causative factor in AD pathologies (Hardy and Selkoe, 2002; Hardy and Higgins, 1992). These 
pathologies are facilitated via tau neurofibrillary tangle formation, leading to synaptic loss and 
neuronal cell death (Jin et al., 2011; Pooler et al., 2014; Rapoport et al., 2002; Roberson et al., 
2007; Vishnu, 2013). Thus, it was proposed that alleviating the accumulation and plaque 
formation of Aβ would cure AD. This hypothesis propelled research around AD and the Aβ 
peptide for many years. Although recently under great scrutiny, this hypothesis is 
fundamental to on-going research efforts as more light is shed on the molecular and biological 
mechanisms of AD. 
The discovery of the amino acid sequence of Aβ from the analysis of fibrils deposited in 
vasculature (Glenner and Wong 1984) and neuronal plaques (Masters et al. 1985) led to a 
movement of several different research groups to isolate APP (Goldgaber et al., 1987; Kang et 
al., 1987; Tanzi et al., 1987). Genetics, fundamental in teasing apart initial and seemingly 
unrelated molecules, led to further understanding of the mechanism of Aβ in 
neurodegeneration. Autosomal dominant mutations are linked to familial Alzheimer’s disease 
(FAD), which has an early onset with the youngest diagnosis from age 40. These genetic 
mutations provided greater insight into the disease, as most FAD mutations are found in 
genes related to the processing of APP that ultimately lead to increased production of Aβ. The 
mechanism of production and breakdown of the Aβ peptide has since been elucidated. The 
peptide itself is linked to the disruption of calcium homeostasis, apoptosis and to the 
generation of cell membrane pores (Carvalho et al., 2009; Curtain et al., 2001; De Felice et al., 
2007; Morishima et al., 2001). It also activates the complement immune response, is 
associated with oxidative stress and many other neurotoxic processes (Varadarajan et al. 
2000; Velazquez et al. 1997; Johnstone et al. 1999; Amor et al. 2010; Larson et al. 2012; Fu et 
al. 2012). 
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 Processing of APP and production of the Aβ peptide. 1.2.1
The accumulation of Aβ occurs from an imbalance between its anabolism and catabolism, 
resulting in the characteristic neuron-coating amyloid plaques. The Aβ peptide is a cleavage 
product of protease activity on the transmembrane protein APP and this process has been 
comprehensively reviewed by numerous groups (Annaert and De Strooper, 2002; De Strooper, 
2010; Haass et al., 2012; Nalivaeva and Turner, 2013). APP is a naturally occurring 
glycoprotein expressed in both somatic tissues as well as neuronal tissue. It is a type-1 
membrane protein with a large, heavily glycosylated, extracellular N-terminal region, a 
transmembrane region and a relatively short cytoplasmic C-terminus (Kang et al., 1987). 
Several isoforms of APP exist, however, APP695 is the most abundant form found in neuronal 
tissue and it is the shortest isoform, lacking a kunitz-type protease inhibitor sequence (Hardy, 
1997; Mattson, 1997). All APPs generally enter into the secretion pathway where they can 
form homodimers and be processed once on the cell membrane (Ben Khalifa et al., 2012). 
APP695, however, preferentially undergoes proteolytic processing within the slightly acidic 
endosomal compartment.  
There are two distinct pathways by which APP undergoes processing: The minor 
amyloidogenic pathway, which leads to the generation of Aβ; and the major non-
amyloidogenic pathway, which does not liberate Aβ (Figure 1.1). Dysregulation of the 
amyloidogenic pathway via environmental or genetic predisposition causes Aβ accumulation 
and is associated with development of AD. 
 
Figure 1.1 The traditional APP processing pathways.  The non-amyloidogenic pathway is initiated by α-
secretase cleavage, whereas amyloidogenic processing pathway is initiated by β-secretase cleavage.  Both 
pathways generate soluble, functional ectodomains of APP (sAPP α and sAPP β) and two transmembrane C-
terminal fragments (C83 and C99, respectively). Subsequent γ-secretase cleavage within the transmembrane 
domain yields the 3 kDa p3 peptide and the roughly 4 kDa Aβ, respectively. The signalling cytoplasmic 
polypeptide AICD is released simultaneously.  
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Only 10% of all APP enters the amyloidogenic pathway. The other 90% enters the non-
amyloidogenic processing pathway, initiated by the α-secretase, now known as A Disintegrin 
And Metalloproteinase (ADAM) 10 (Donmez et al., 2010; Parkin et al., 2011), followed by 
cleavage by the γ-secretase. ADAM 10 hydrolyses APP at a site within the Aβ region liberating 
Aβ(17-X) peptides (X, refers to multiple C-termini positions), sAPP α and the p3 peptide 
(Figure 1.1) (Annaert and De Strooper, 2002; Dulin et al., 2008). 
Aβ production occurs via the constitutive action of two aspartyl proteases, namely β and γ-
secretases (Nalivaeva and Turner, 2013; Seubert et al., 1993; Shoji et al., 1992; Wilquet and 
Strooper, 2004). Cleavage by β-secretase, beta-site APP-cleaving enzyme (BACE-1), results in 
the formation of the N-terminus of Aβ and initiates its production. This enzyme liberates the 
large ectodomain (sAPP β) of APP into the extracellular fluid. Left behind within the cell 
membrane is the carboxy-fragment known as C99 (Cai et al., 2001; Vassar et al., 1999). C99 is 
then cleaved by the γ-secretase within the hydrophobic membrane of the cell which 
ultimately releases the Aβ peptide into serum or cerebral spinal fluid (CSF) (Ehehalt et al., 
2003; Lichtenthaler et al., 2011). The cytoplasmic fragment, also known as the APP 
intracellular cytoplasmic domain (AICD) (Figure 1.1), has both protective and detrimental 
contributions to the pathology of AD and is liberated from both pathways (Beckett et al., 
2012; Gao and Pimplikar, 2001). APP695 and its endosomal pathway enable a preferential 
association with BACE-1 thus liberating Aβ and ACID in an amyloidogenic mechanism 
mediated by cholesterol and lipid rafts (Ehehalt et al., 2003; Nalivaeva and Turner, 2013). APP 
belongs to a highly conserved protein family however, knockouts of APP alone are not lethal 
but double null mutants with APP-like-Protein-2 lead to early postnatal lethality in mammals, 
suggesting a functional redundancy between the two (von Koch et al., 1997). Furthermore 
mice homozygous for APP null mutation have abnormal forebrain commissures, and reduced 
neuromuscular function (Magara et al., 1999; Zheng et al., 1995).  Several knock in, mouse 
lines expressing various sections of APP have provided further evidence of APPs multifaceted 
function (reviewed in Guo et al., 2012). Specifically with regard to the Aβ fragment, the 
pathology related to AD proceeds independently of the C-terminus of APP (H. Li et al., 2010). 
Thus, hinting that the two functions could possibly be uncoupled genetically.  
1.2.1.1 Aβ structure and aggregation. 
Despite intensive research on the Aβ peptide, once liberated from APP its natural role and 
pathological mechanisms are not clear. Aβ appears to influence numerous systems including: 
kinase activation (Tabaton et al., 2009); scavenging metal ions and protecting against metal–
induced oxidative damage through regulation of cholesterol transport (Fantini and Yahi, 2010; 
Igbavboa et al., 2009); and affecting glutamatergic neurotransmission (Govoni et al., 2014). 
Interestingly, Aβ has been shown to cycle with wakefulness and sleep. Wakefulness is 
associated with high synaptic activity, extensive long term potentiation (LTP) of neurons and 
low interstitial fluid levels of Aβ while sleep is generally accompanied by the opposite 
conditions (Kang et al., 2009; Vyazovskiy et al., 2008). As Aβ is known to dampen LTP and 
neuron excitation, the accumulation of Aβ could possibly play an important role in sleep (Kang 
et al., 2009; Musiek et al., 2015).  
Amyloid β toxicity appears to be dependent on the structural conformations adopted by 
varying forms of Aβ. Aβ isolated from soluble, fibrillar masses and plaques has a large amount 
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of heterogeneity at both N-and C-termini (Hardy et al., 2014; Nhan et al., 2014; Portelius et 
al., 2010a). The toxicity and biochemical properties of this molecule have been shown to be 
dependent on the length and composition of the terminal residues which dictate its 
secondary, tertiary and quaternary structure (Glabe, 2008; Lindgren and Hammarström, 2010; 
Nhan et al., 2014; Sakono and Zako, 2010; Youssef et al., 2008).  Mature fibril formation can 
be described as an uncharacterised, nucleation-dependent polymerization reaction. The exact 
mechanistic process of the aggregation into fibrils is as yet unknown. It is largely due to the 
stochastic accumulation of various Aβ forms leading to a heterogeneous mix. Fibril and plaque 
deposits are relatively, but not permanently, stable and uniform. The dissolution of plaques 
into oligomers is one way in which plaques may generate a perpetual toxicity (Broersen et al., 
2010; Serpell, 2000). Amyloid fibrils are at the core of dense and diffuse amyloid plaques. 
These can be found within the brain parenchyma and/or accumulate in the cerebral blood 
vessel walls in the form of cerebral amyloid angiopathy. These fibrils are the end-point of Aβ 
oligomerization. They develop via numerous molecular signals that induce sequential 
modification, binding and stacking of monomeric forms of Aβ.  
Central to the theory of Aβ aggregation are monomeric peptides, activating through 
conformational changes into either α-helices or anti-parallel β-sheet secondary structures, 
which recruit more Aβ and stack to form protofibrils (Bartolini et al., 2007; Taylor et al., 2003). 
These soluble protofibrils then associate to form fibres and fibres associate to form plaques 
(Ahmed et al., 2010; Benseny-Cases et al., 2007; Chimon et al., 2007). However, recently 
Cohen et al. have shown that monomers require fibrils in order to induce activation and 
subsequent aggregation (Cohen et al., 2013). 
Soluble globular oligomers of Aβ or Aβ-derived diffusible ligands (ADDLs) are well-renowned 
for their low-dosage, extreme and specific synaptotoxicity (Haass and Selkoe, 2007; S. Li et al., 
2010; Mattson, 2004; Rosenblum, 2014; Tomic et al., 2009). The fibril form of amyloid plaque 
has been proposed as a molecular sink for soluble forms of Aβ, like ADDLs, acting as Aβ 
scavengers of oligomeric and soluble forms in a protective manner (Hane, 2013). Soluble Aβ 
oligomers correlate better with disease progression, loss of synaptic density and cognitive 
decline (Haass and Selkoe, 2007; Lesné et al., 2013; S. Li et al., 2010; McLean et al., 1999; 
Rosenblum, 2014; Tomic et al., 2009). These species of soluble oligomers, globular and 
protofibrillar amyloid are now considered the first toxic species as they present 
presymptomatically and prior to any neurofibrillary tangles (with their associated toxicity) and 
plaque deposition (Hane, 2013; Larson et al., 2012; Sakono and Zako, 2010; Tomic et al., 
2009). The very nature of soluble Aβ-intermediates makes them difficult to characterise 
structurally and in terms of toxicity profiles. Numerous studies have indicated many different 
forms as causative of AD. Some of the more important forms of Aβ species are discussed in 
this chapter. 
1.2.1.2 Aβ derived from C-terminal secretase action on APP 
In almost every case of FAD the genetic mutations (in APP, or components of the γ-secretase) 
induce an increase in the production of long Aβ (Aβ(1-42) – Aβ(1-52)) (De Strooper, 2010; 
Haass et al., 2012; Lesné et al., 2006). The most studied variations are those of the carboxy 
terminus, where two peptides have been the focus in AD research, namely Aβ(1-40) and Aβ(1-
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42). Aβ(1-40) is by far the most abundantly produced, yet longer C-terminal residues are 
known for their increasing aggregation and toxicity.  
The production of all Aβ peptides greater than Aβ(1-17) is dependent on γ-secretase activity. 
However, the exact molecular mechanism by which γ-secretase accesses this Aβ(1-17) 
cleavage site, located on the extracellular side of the membrane, is currently unknown (Beher 
et al., 2002). A number of elegant studies led to the proposed mechanism of γ-secretase 
processing of the α- and β-secretase cytoplasmic fragments (Qi-Takahara et al., 2005; Sato et 
al., 2003; Takami et al., 2009; Yagishita et al., 2008). If primary cleavage occurs at the ε site to 
release AICD 50 and Aβ(1-49), then the subsequent cleavage, at three residue intervals in each 
turn of the APP helix would release 46, 43 and 40 residue Aβ peptides. If cleavage initiates the 
release of AICD 51 and Aβ(1-48), then Aβ peptides of 45, 42 and 40 residues would follow 
generating C-terminal Aβ heterogeneity (Figure 1.). An alternate processing pathway, 
independent of γ-secretase action, also exists whereby the C99 fragment is processed further 
by the α-secretase leading to the release of Aβ(1-15) and Aβ(1-14) (Beher et al., 2002). Thus, 
Aβ(1-14) and Aβ(1-15) are specific products of α- and β-secretase concerted cleavage (Figure 
1.). These short isoforms are present in CSF along with Aβ(1-40) and Aβ(1-42) in AD patients 
and are used as diagnostic markers of both FAD and sporadic AD (SAD) (Pannee et al., 2014). 
Aβ(1-16) production appears to be dependent on all three secretases. The mechanism behind 
this is still unclear (Pannee et al., 2014; Portelius et al., 2010a, 2010b, 2006). A natural 
function has been assigned to the Aβ(1-16) fragment, as it has recently been shown to amplify 
and induce fear conditioning via the nicotinic receptors. Also, its activity is regulated by the 
metal binding domain YEVHHQ (Lawrence et al., 2014). With regard to toxicity in AD, Aβ(1-16) 
has a controversial role, implicated as both inert and cytotoxic (Du et al., 2011; Liao et al., 
2007; Ramteke et al., 2014). The potential cytotoxic properties of Aβ(1-16) are linked to the 
metal binding domain, known for its role in producing detrimental reactive oxygen species 
(ROS) and aiding oligomerization on its own and within the full-length Aβ(1-42) (Bush, 2003; 
Curtain et al., 2001; Du et al., 2011; Minicozzi et al., 2008; Ramteke et al., 2014). This peptide, 
Figure 1.2. Secretase cleavage sites of Aβ. The amino acid sequences (with numbering based on the APP695 
isoform) are shown incorporating the largest Aβ sequence found between APP670-APP720. The cleavage 
sites for both N- and C-terminal secretase-truncations are indicated along with the ε-site (black) of γ-
secretase (red) association. The β and β’ are shown in black and the α-secretase alternate processing sites 
are indicated in green. The amino acid numbers are indicated for the full-length Aβ(1-42), as well as the 
position of Aβ(1-49/50/51). The orange highlighted amino acids from Aβ(1-16) indicate the region of metal 
binding and posttranslational modification.  
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however, occurs at higher concentrations in AD patients’ CSF in comparison to controls 
(Portelius et al., 2010a, 2010b). The reason for the upregulation of the Aβ(1-16) generating 
pathway in AD is unknown. One proposed possibility is that there is an increase in α-secretase 
activity in an attempt to counteract the dysregulation of APP processing (Portelius et al., 
2011).  
1.2.1.3 N-terminally truncated Aβ peptides derived from APP. 
The formation of the N-terminus of Aβ (position Asp 1) normally occurs via BACE-1 cleavage 
(Figure 1.). Truncations of the N-terminal region are extremely prevalent and are toxic, as are 
most forms of Aβ (Pike et al., 1995). N-terminal truncations also make up a large portion of 
the aggregated and stable plaques of AD patients (Bayer and Wirths, 2014; Guzmán et al., 
2014; Portelius et al., 2006; Youssef et al., 2008). 
There are a number of different N-terminal truncations of the full-length Aβ(1-40/42). These 
include peptides beginning with Ala-2, Glu-3, pyroglutamate Glu-3 (pG3), Phe-4, Arg-5, His-6, 
Asp-7, Ser-8, Gly-9, Tyr-10 and pyroglutamate Glu-11 (pG11). BACE-1 is responsible for the 
formation of Aβ(11-X) at the β’-site (Figure 1.) which, in older deposits and in AD, Aβ 
undergoes post-translational modification to form pG11. Aside from this cleavage site it is 
unclear exactly what pathways and enzymes are responsible for other N-terminal truncations, 
most of which arise independently of BACE-1 (Bayer and Wirths, 2014). 
Aβ(2-X), increases in the brain tissue from AD patients but decreases in CSF (Bibl et al., 2012). 
The formation of this peptide is not entirely independent of BACE-1 cleavage. It has been 
suggested that Aβ(2-X) occurs via the combined action of BACE-1 and aminopeptidase A. 
Meprin-β, however, sheds APP independent of BACE-1, generating the same cleavage sites 
until APP is overexpressed. Only then does meprin-β produce a large amount of Aβ(2-X) (Bien 
et al., 2012; Broder and Becker-Pauly, 2013). The zinc metalloprotease neprilysin (NEP) is a 
major Aβ degrading enzyme. It does, however, also produce the truncations Aβ(3/4/6-X) 
(Leissring et al., 2003b) which are all BACE-1 independent sites. The Aβ(3-X) species undergo 
pyroglutamylation over time to form pG3 (Jawhar S, Wirths O, 2011). This along with Aβ(4-X) 
are the two N-terminal truncations most consistently reported in AD (Bayer and Wirths, 
2014). They also have severe toxicity associated with their rapid, low dose aggregation into 
soluble oligomers (Bayer and Wirths, 2014; Jawhar S, Wirths O, 2011; Kummer and Heneka, 
2014; Youssef et al., 2008). The Aβ(5-X) site corresponds to cleavage by another amyloid 
degrading enzyme, the serine protease plasmin (Carson and Turner, 2002; Tucker et al., 2000). 
A different metalloprotease and the focus of this study, angiotensin converting enzyme (ACE), 
has been shown to hydrolyse Aβ between residues Asp7-Ser8 and is a candidate protease for 
the formation of Aβ(8-X) (Hu et al., 2001; Kumar et al., 2012; Oba et al., 2005). In the search 
for early diagnostics of AD, the N-truncated Aβ variants Aβ(2/pG3/4/5/8/9-X) provide good 
correlations to disease onset and severity in both SAD and FAD (Bayer and Wirths, 2014; 
Guzmán et al., 2014; Kummer and Heneka, 2014; Moore et al., 2012; Pannee et al., 2014; 
Sergeant et al., 2003).  
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Modifications to the N-terminus of Aβ induce greater toxicity. 1.2.2
The N-terminal region of Aβ, between residues 1-16, constitutes the minimal metal ion 
binding site (Inoue et al., 2009; Minicozzi et al., 2008; Uversky, 2010). Metals like Cu+, Cu2+, 
Zn2+ and Fe2+ bind to soluble, monomeric or oligomerized forms of the peptide and co-
precipitate in AD (Caragounis et al., 2007; Hureau, 2012; Karr et al., 2004; Kowalik-Jankowska 
et al., 2001; Minicozzi et al., 2008; Shi et al., 2014; Zirah et al., 2006). Both Zn2+ and Cu2+ are 
produced from active synapses during normal neural transmission and are essential for 
normal brain development and function (Assaf and Chung, 1984; Bush, 2003; Hartter and 
Barnea, 1988; Howell et al., 1984). 
The Aβ peptide may interfere with iron homeostasis as it has a strong affinity for iron, both 
Fe2+ and Fe3+, that is 8 orders of magnitude greater than that of transferrin (Jiang et al., 2009). 
In mouse models of AD, regardless of Aβ, over expression of APP decreases the level of metal 
ions at a constant rate throughout the animals’ lifespan (Bush, 2003). Based on this, it has 
been suggested that Aβ and APP are upregulated in response to the metal ion increase (Bush, 
2003; Maynard et al., 2002). APP indeed is regulated by a novel iron-regulatory element (IRE-
Type II) within the 5’-untranslated region upstream of its gene (Rogers et al., 2008). In 
addition, APP exhibits Fe2+ oxidizing activity mediated by a conserved H-ferritin-like active site 
(Duce et al., 2010). This active site is inhibited by Zn2+. APP oxidizes Fe2+ to Fe3+ and loads Fe2+ 
into transferrin promoting Fe export from the neuron. In AD, Fe detrimentally accumulates in 
the cell cytoplasm (Duce et al., 2010). The excessive Zn present in Aβ aggregates in AD neural 
tissue inhibits ferroxidase activity of APP. This in turn inhibits the efflux of Fe2+, which 
promotes pathology. 
Zn2+ has a far greater affinity for Aβ than either Cu or Fe. Binding of low micro molar amounts 
of Zn2+ induces rapid precipitation of soluble Aβ into aggregated fibres; furthermore, plaques 
appear to be Zn sinks as abnormally high levels are found within them. This is because Zn 
coordinates intermolecular interactions between two molecules and/or fibres of Aβ by 
His(Nτ)-Zn2+–His(Nτ) bridges. Similar coordination of Cu+ occurs to His13 and His14 in a linear 
fashion in monomeric forms of Aβ, whereas in soluble oligomeric forms Cu2+ has been 
described in a tetrahedral coordination, inducing increased reactivity towards O2 (Karr et al., 
2004; Nhan et al., 2014). In this way, the toxicity of Cu ions is two pronged. After binding and 
inducing aggregation they also induce enhanced ROS production (Bush, 2003; Hureau, 2012). 
Overall, Cu ions have an exacerbating effect on AD (Deshpande et al., 2006; Dolev and 
Michaelson, 2006; Jiang et al., 2009).Binding of Aβ to Fe and Zn, similar to Cu, regulates their 
redox cycling which produces more ROS (Bush, 2003; Huang et al., 1999; Nishino and Nishida, 
2001). This then causes more oxidation of reducing agents and an overall imbalance in the 
cellular environment by further production of ROS and depletion of reducing agents and O2 
(Bush, 2003; Hureau, 2012; Jiang et al., 2009). The Aβ(1-16) peptide has been used as a model 
for metal binding and peptide aging in NMR studies (Figure 1.3) (Zirah et al., 2006). This 
peptide was able to undergo Zn-induced helix formation and isomerization related to aging 
(Figure 1.3 A). Specifically, Zn binding stabilized the apo-structure (Figure 1.3 B) and induced 
N-terminal folding into an α-helix (Figure 1.3 C) (Zirah et al., 2006). This could be a possible
mechanism for the molecular switch of Aβ from the innocuous to the toxic form.
Kate Larmuth  CHAPTER 1 Literature Review 
 9 
Isomerization and racemization of N-terminal Aβ, are modifications which occur in older 
plaque cores, where the Asp1 and 7 residues are converted from D to L-isoforms (Inoue et al., 
2014; Roher et al., 1993a; Tambo et al., 2013). These modifications occur more frequently in 
brain parenchyma than in vascular deposits (Fabian et al., 1994). It is thought that these 
changes can be induced by ROS and exposure to free radicals (Huang et al., 1999) and may 
adversely affect clearance and proteolysis.   
Dysregulated brain glucose metabolism is a downstream effect of Aβ toxicity, and type-2 
diabetes mellitus exacerbates Aβ pathology in AD models. One example is that of glucose 
hypometabolism and its influence on the progression of AD, which occurs through the 
nutrient-responsive post-translational O-GlcNAcylation (O-GlcNA) of nucleo-cytoplasmic 
proteins (Hart, 1999; Zhu et al., 2014). Thus, impaired O-GlcNA in the brain could, in principle, 
contribute to Aβ toxicity (Zhu et al., 2014). Furthermore glucose metabolism may affect APP 
processing, as a mass spectrometry study on AD patients revealed multiple N-terminal Aβ(1-
15/16/17/18/19/20) and Aβ(3/4-15), Aβ(4/5-17) peptides were O-glycosylated (Halim et al., 
2011). The predominant glycosylated peptides being Aβ(1-15/17) to which glycosylation 
occurred at Tyr10. As there appeared to be no glycosylation on the full-length Aβ(1-40/42) 
Figure 1.3 The Zn coordination of Aβ(1-16). The peptide backbone is indicated in blue and the metal 
binding residues are coloured pink and labelled. All structures are modified from Zirah et al. (2006). 
A) Alpha-helical structure of Aβ(1-16) in solution of tetrafluoroethylene (80 %) and water (20%). B)
Aβ(1-16) apo structure unbound PDB 1ZE7 in aqueous solution . C) The Zn
2+
 bound Aβ(1-16) in
aqueous solution, PDB 1ZE9. Here coordination of all three His residues as well as the Glu11 to the
Zn
2+
 ion occurs, inducing structural stabilization. These images were generated using PyMOL software
(v 0.99, DeLano Scientific).
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peptide it was theorised that Tyr10 glycosylation of APP is protective as it is very close to the 
membrane and may prevent γ-secretase cleavage (Halim et al., 2011).   
Phosphorylation acts as a molecular recognition switch. There are many examples of 
extracellular kinases that could facilitate such a posttranslational modification of Aβ (Kummer 
and Heneka, 2014). There are three residues in Aβ that could act as potential phosphorylation 
sites: Ser8, Ser26 and Try10. In studies on NT2 neurons, phosphorylation of Ser26 was 
described as inducing greater toxicity to Aβ (Milton, 2001). This toxicity was again linked to a 
lack of fibril formation and an increase in soluble oligomers. Phosphorylation of Aβ at Ser8 is 
more prevalent and slightly more is known about it. Immunohistochemical studies indicated 
that Ser8 phosphorylated Aβ was localised to plaques in AD patients and transgenic mice 
(Kumar et al., 2011). Phosphorylation of this site promotes oligomerization, thought to 
nucleate fibrils, yet may paradoxically be protective. However, toxicity was increased in 
Drosophila models compared to the un-phosphorylated Ser6 Aβ molecule (Kumar et al., 
2011). Interestingly, this site affects proteolysis by both ACE and insulin degrading enzyme 
(IDE) and could reduce its clearance.  
The increased inflammation, found in AD, leads to the upregulation of nitric oxide synthase 
which creates more nitric oxide (NO) leading to an increase in NO-induced post translational 
modifications (PTMs). These modifications include the formation of S-nitrothiols at Cys 
residues and Tyr modifications, like nitration and dinitrotyrosine formation (Radi, 2004). The 
conversion of Aβ Tyr10 to nitrotyrosine was found at the core of Aβ plaque in mouse AD 
models and in human AD brains (Kummer et al., 2011). This same modification of Aβ, 
favoured by oxidative stress, has been shown to increase Aβ aggregation, inhibit LTP to a 
larger degree than the unmodified form and stabilize Aβ dimers (Varadarajan et al. 2000; 
Kummer et al. 2011; Kummer and Heneka 2014). As discussed, all PTMs whether by 
proteolysis, metal binding, isomerization, nitration, or pyroglutamylation all appear to 
accelerate Aβ nucleation and increase Aβ’s toxicity. The N-terminal region of Aβ, overall, has a 
dramatic influence on the pathogenesis of Aβ and often determines if these peptides 
precipitate into the proverbial fibril sink or form more toxic species like loose soluble 
protofibrils, dimers, ADDLs and circular structures that induce pore formations within cell 
membranes. All of these alterations have implications on clearance and processing of Aβ. 
1.3 Aβ Clearance and Degradation. 
AD is a complex disease that, in the majority of cases, has a more syndrome-like nature of 
onset. The more common sporadic form of AD has been linked to inefficient removal or 
increased influx of Aβ (Mawuenyega et al., 2010). Over the last two decades, it has become 
evident that AD is a result of disequilibrium between production and clearance of Aβ. This 
implicates tissues, outside of neurons and microglia, now considered important when 
addressing causation of AD, specifically: the status of the blood-brain barrier (BBB) (Bell and 
Zlokovic, 2009), the choroid plexus (Serot et al., 2012) and hepatic function (Kang and Rivest, 
2012). There are several mechanisms implicated in the influx and clearance of Aβ that fall into 
three categories, known as the 3Ds: (1) perivascular drainage, (2) transcytotic delivery and (3) 
enzymatic/glial degradation. 
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 Perivascular drainage. 1.3.1
The immunologically privileged central nervous system is devoid of conventional lymphatic 
vessels. This leaves only the perivascular drainage system to deal with all the functions 
normally assigned to lymphatic vessels and nodes (Weller et al., 2010). It is theorised that 
perivascular drainage occurs as a result of blood vessel pulsations (Schley et al., 2006). These 
pulsations supply a motive force to the interstitial fluid (ISF), a fluid almost completely 
separate from CSF, and its solutes (Szentistványi et al., 1984). Drainage begins as a process of 
diffusion of ISF from grey matter where its rate is influenced by the composition of solutes 
and metabolites, including the presence of Aβ, in the extracellular space (Syková and 
Nicholson, 2008; Weller et al., 2009). ISF then flows more rapidly along white matter tracts 
and perivascular drainage routes (Abbott, 2004; Weller et al., 2010). Aβ toxicity extends 
beyond soluble oligomers and plaque formation; it also accumulates in the walls of cerebral 
arteries and capillaries creating the prominent vascular pathology in AD, cerebral amyloid 
angiopathy (CAA) (Vasilevko et al., 2010). As neurons, astrocytes and other cells in the brain 
produce Aβ, it is expected to be cleared via perivascular drainage. Indeed, perivascular 
congestion has been linked to the pathogenesis of CAA, as its drainage route corresponds to 
the distribution of Aβ immunofluorescence in CAA (Preston et al., 2003). This phenomenon is 
further evidenced through the analysis of CSF, where, as more plaques form and sequester 
Aβ, CSF Aβ levels drop in AD (Sunderland et al., 2003). The levels of Aβ(1-40) in CSF however, 
are higher in AD patients and control groups compared to CAA groups (Verbeek et al., 2009). 
The level of Aβ(1-40) in CSF is a distinguishing factor between AD and CAA, as it drains better 
but paradoxically, if in excess deposits in the perivasculature. CAA is accelerated in immunized 
AD patients, whose Aβ plaques become solubilised, and the decrease in CSF Aβ 
concentrations in general are indicative of impaired perivascular drainage (Patton et al., 2006; 
Verbeek et al., 2009). Overall amyloid flows from the extracellular space, through perivascular 
drainage routes, out of the brain to the cervical lymph nodes. Following this, smooth muscle 
cells and perivascular macrophages take up Aβ for degradation and, in capillary endothelia, it 
is transported into the blood periphery as part of the Aβ elimination pathway. Aging stiffens 
arteries lowering the pulsative force causing CAA and, in AD, drainage is further hampered by 
the clogging effect of excessive Aβ (Hawkes et al., 2013, 2011). Thus, cardiovascular health is 
imperative in order to maintain suitable pulsation amplitudes and drainage (Arbel-Ornath et 
al., 2013). Inefficient perivascular drainage of Aβ and/or pre-existing CAA will induce either 
intracerebral haemorrhage or AD. 
 Transcytotic delivery. 1.3.2
Peripheral Aβ enters the central nervous system (CNS) via the receptor for advanced glycation 
endproducts (RAGE) receptor-mediated transport across the BBB (Deane et al., 2003) and 
exits via binding to the lipoprotein receptor-related protein-1 (LRP1) (Shibata et al., 2000). 
RAGE is a receptor and a member of the immunoglobulin superfamily with wide array of 
ligands (Stern et al., 2002). RAGE, unlike other receptors, can create and sustain positive feed-
back loops of expression in response to its ligands (Lue et al., 2001). Thus the expression of 
RAGE on cerebral vessels, neurons and microglia is increased in response to Aβ production 
(Deane et al., 2003). Aβ binding to RAGE induces oxidative stress, apoptosis, synaptic 
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dysfunction and microglial activation (Origlia et al., 2010; Yan et al., 1996). On the endothelial 
surface of capillaries, Aβ stimulated RAGE induced the production of pro-inflammatory 
cytokines and endothelin-1 (Deane et al., 2003) promoting vasoconstriction and aggravating 
pathology (Girouard and Iadecola, 2006; Kisanuki et al., 2010). RAGE also occurs in a soluble 
isoform (sRAGE) which scavenges and competes with membrane bound RAGE for ligands. 
sRAGE promotes the removal of circulating ligands like Aβ and its levels in AD are reduced 
(Emanuele et al., 2005). Higher concentrations of sRAGE correlate protectively against 
cardiovascular disease, hypertension, arthritis and AD (Emanuele et al., 2005; Falcone et al., 
2005; Geroldi et al., 2006).  
LRP1 is a receptor member of the LDLR family, like many LDLRs it is multifunctional, acting as 
both a scavenger and signalling receptor. It is expressed widely from neural cells to cerebral 
microvasculature (Kanekiyo and Bu, 2014; Wolf et al., 1992). LRP1 has multifaceted roles in 
AD in that it significantly regulates Aβ trafficking, endocytosis and subsequent lysosomal 
degradation. The trafficking of Aβ out of the CNS across the BBB occurs post Aβ binding to the 
ligands for several of the LDLR family, like apolipoprotein E (ApoE) or α2-macroglobulin (α2M), 
to be delivered to peripheral sites of degradation (Bu, 2009; Pflanzner et al., 2011; Shibata et 
al., 2000). There are three allelic polymorphisms of APOE (ε2, ε3 and ε4) with subtle protein 
structural differences defining their altered roles (Mahley et al., 2009; Zhu et al., 2012). The 
ApoE ε4 isoform has strong links to AD being the isoform most deficient at Aβ clearance via 
LRP-1 (Ladu et al., 2000; Riddell et al., 2008; Shibata et al., 2000) and associated with 
aggravated CAA with intracranial haemorrhaging (Biffi et al., 2010; Fryer et al., 2005).  
 Metalloproteases and Aβ proteolysis. 1.3.3
Degradation of Aβ occurs in the brain parenchyma by microglia and numerous proteases and 
is another major clearance mechanism for Aβ. Regardless of where the accumulation of Aβ 
occurs within the brain (in the interstitial extracellular space or within cells), glial cells are 
central to AD in that they both secrete ApoE and phagocytise Aβ (LaDu et al., 2000; LaFerla et 
al., 2007; Zhu et al., 2012). Glial cells accompany amyloid plaques and have both beneficial 
and aggravating effects towards the pathology of AD. Apart from glial phagocytosis there are 
many enzymes which have proven capable of hydrolysing Aβ both in vitro and in vivo (James 
Scott Miners et al., 2008; Nalivaeva et al., 2012). Generally, it is thought that these peptidases 
reduce the aggregating potential and toxicity of Aβ. The most well-known Aβ degrading 
proteases include insulin degrading enzyme (IDE) (Qiu et al., 1998; Vekrellis et al., 2000), 
neprilysin (NEP) (Iwata et al., 2000), endothelin-converting enzyme (ECE) (Eckman et al., 
2003), matrix metalloproteinase-9 (MMP-9) (Backstrom et al., 1996; Yan et al., 2006), plasmin 
(Tucker et al., 2000) and ACE (Hu et al., 2001; Scott Miners et al., 2011; Zou et al., 2007). In 
this literature review, I will focus on the metalloproteases NEP and IDE (discussed below) and 
ACE (section 1.4). 
Kate Larmuth  CHAPTER 1 Literature Review 
 13 
1.3.3.1 Neprilysin 
The most renowned Aβ-protease is neprilysin (neutral endopeptidase-24.11, enkephalinase, 
neutrophil cluster-differentiation antigen 10 or common acute lymphoblastic leukaemia 
antigen). In the brain NEP is found on pre- and post-synaptic membranes, within the tunica 
media and in cortical and leptomeningeal blood vessels endothelium where it is involved in 
synaptic signalling (Barnes et al., 1988) and the regulation of vascular tone. NEP expression 
patterns, all along perivascular drainage routes as well as in vessels, position it well as a major 
degrading enzyme of Aβ. NEP’s Aβ-degrading ability has been indicated both in vitro (Howell 
et al., 1995) and in vivo (Iwata et al., 2001, 2000). Over the years, Saido et al have proved that 
NEP is capable of reducing Aβ levels and is a major Aβ-degrading enzyme. They found that in 
mice lacking NEP AD pathology was exacerbated (Iwata et al., 2001) and, in turn, reversed by 
human NEP-targeted gene delivery to the brain of AD transgenic mice (Iwata et al., 2013, 
2004; Marr et al., 2003). The first clinical association of NEP with AD was revealed on analysis 
of mRNA levels in hippocampal and Aβ-burdened cortical tissues (Yasojima et al., 2001). NEP 
mRNA levels in AD were significantly lower compared to non-demented control patients. NEP 
was not only found to reduce plaque burden but also CAA pathology (Miners et al., 2006). In 
AD with CAA, both activity and expression of NEP were reduced and NEP was shown to 
protect cerebrovascular smooth muscle cells from Aβ-induced cell death (Miners et al., 2011). 
Furthermore the ApoE genotypes correlated to NEP activity as they do towards AD: NEP 
activity being greatest in APOE ε2/3 genotype > APOE ε3/3 > ε3/4, and lowest NEP and 
greatest risk levels associated with ε4/4 genotypes (Miners et al., 2011, 2006).  
On examination of the aging brain, NEP expression in AD affected tissue, both neuronal and 
vascular, decreased with age (Iwata et al., 2002; Nalivaeva et al., 2012). Although brain tissue 
expression appears to decrease astrocytic NEP, NEP expression has been shown to increase in 
astrocytes around Aβ plaques in an age-dependent manner (Apelt et al., 2003). NEP 
expression has recently been found to be regulated by AICD, a product of APP secretion 
(Figure 1.1), thought to negatively regulate the production of Aβ (Pardossi-Piquard et al. 
2005). AICD upregulates NEP expression and competes with histone deacetylase (HDAC)1 for 
binding to the NEP promoter region. HDAC inhibitors such as trichostatin A and valproic acid 
could upregulate NEP activity as well as expression (Beckett et al., 2012; Nalivaeva et al., 
2012). The upregulation of NEP makes for an interesting therapeutic advancement towards 
the treatment of AD. However, there are complications associated with NEP overexpression. 
These complications are most likely due to NEP’s cleavage and hydrolysis of many 
physiologically relevant peptides such as enkephalins, tachykinins and natriuretic peptides 
(Kenny et al., 1993; Turner et al., 2001). In hypertensive rat models, inhibition of NEP induces 
lower mean arterial blood pressure and increased natriuresis (Potter, 2011; Webb et al., 
1989). Thus, upregulation of NEP would exacerbate any cardiovascular pathology. Further in-
depth studies on transgenic mice indicated that NEP overexpression failed to ameliorate 
cognitive functions yet reduced the more pathogenic Aβ oligomers (Meilandt et al. 2009). 
Most NEP substrates are found within the mill molar range (Vijayaraghavan et al., 1990), 
subsequently it has been proposed that low (nano molar) Aβ concentrations, to which NEP 
has a KM of 2.5 micro molar (Iwata et al., 2000), make the physiological significance of this 
enzyme questionable (Shibata et al., 2000).  
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The crystal structure of NEP complexed with phosphoramidon has improved our 
understanding of substrate specificity and the catalytic mechanism for this enzyme (Oefner et 
al., 2000). A recent paper endeavoured to enhance NEP’s Aβ specificity and activity over its 
more natural substrates by directed evolution. They successfully mutated two amino acid 
residues which altered the active site accessibility to better accommodate the large Aβ 
substrate (Webster et al., 2014). These alterations generated a variant of NEP that has a 20-
fold increased catalytic efficiency for Aβ(1–40) and up to 3000-fold reduction in its ability to 
process a range of alternative substrates (Webster et al., 2014). Although these data lend 
themselves to the development of NEP overexpression or activation, further investigation is 
required to validate this enzyme as a drug target for AD. 
1.3.3.2 Insulin degrading enzyme 
Of the amyloid proteases, IDE (insulysin, insulinase, , EC 3.4.24.56) was the first identified as 
capable of Aβ-degradation and this has since been confirmed in both cell and animal models 
of AD (reviewed in Leissring, 2008; Nalivaeva et al., 2012). IDE overexpression has been shown 
to ameliorate any Aβ pathology induced by IDE knockout mice (Farris et al., 2003; Leissring et 
al., 2003a). IDE has a very interesting substrate specificity, in that its substrates share almost 
no homology other than their β-sheet-rich, amyloidogenic nature (Kurochkin and Goto, 1994; 
Kurochkin, 1998; McCord et al., 2013). These, often peptide hormone, substrates are also 
hydrolysed completely at multiple cleavage sites to ensure inactivation.  
IDE is most well-known for its role in diabetes, as the enzyme primarily responsible for the 
breakdown of insulin (Abdul-Hay et al., 2011; Maianti et al., 2014). However, AD has been 
implicated by some as a type-3 diabetes, due to the growing body of evidence implicating 
hyperinsulinemia as the cause of Aβ accumulation and associated pathologies (de la Monte 
and Wands, 2008). This theory was based on IDE’s specific substrate preference for large 
amyloid fibrils such as Aβ, whose catalysis is competitively inhibited by insulin (Craft and 
Watson, 2004; de Tullio et al., 2008; Farris et al., 2003). Furthermore, diabetes generates 
neuronal insulin resistance in response to hyperinsulemia, which causes local hypoinsulemia. 
This increases inflammation and could induce neuronal dysfunction. IDE is interesting in that 
its high affinity substrates, like insulin, bind directly to its active site (unlike most of its small 
substrates which bind to allosteric sites which induce inhibition rapidly) and induce substrate 
inhibition at higher concentrations (Noinaj et al., 2011; Shen et al., 2006). In contrast, small 
molecules that bind allosterically induce a conformational change that opens up the clam-like 
structure generally activating IDE. Insulin has been shown to regulate the levels of IDE, with 
insulin resistance blocking any positive feedback of IDE expression and causing an increase in 
Aβ, which is a result of both competitive substrate inhibition and a decrease of IDE levels in 
AD patients (Cook et al., 2003; Leissring et al., 2003b). Aβ oligomers disrupt insulin receptor 
signalling and reduce insulin binding to them, thus down regulating neuronal insulin receptors 
and promoting insulin resistance (Xie et al., 2002; Zhao et al., 2008). This provides further 
support for the link between type-3 diabetes and AD. 
Like NEP, IDE has a large repertoire of substrates other than insulin and Aβ. Interestingly, it is 
the main protease responsible for the degradation of AICD (Edbauer et al., 2002) thus 
potentially negatively regulating NEP cytosolically. Counteracting this, a well-known 
neuropeptide somatostatin regulated by NEP (Saito et al., 2005), binds allosterically to 
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activate and enhance IDE activity towards Aβ (Ciaccio et al., 2009; Tundo et al., 2012). Unlike 
NEP, IDE is primarily located in the cell cytosol, however, it is secreted in significant amounts 
into the extracellular milieu and CSF (Zhao et al., 2009). More importantly, it is found in the 
mitochondria of neurons, where Aβ induces irrevocable damage and, furthermore, the 
secreted form of IDE co-localised with Aβ in endosomes (Bulloj et al., 2010; Leissring et al., 
2004). The data implicating IDE as a major Aβ degrading enzyme in vivo are convincing (Farris 
et al., 2003; Leissring et al., 2003a). Like NEP, overexpression or activation of IDE is a tempting 
potential therapy for the treatment of AD, although not without its caveats.  
1.4 Angiotensin I-converting enzyme. 
The contribution of ACE and its fellow Aβ degrading proteases has been extensively reviewed 
before (Hooper & Turner 2000; Carson & Turner 2002; Turner 2003; Wang et al. 2006; Miners 
et al. 2008; Rosenberg 2009; Strooper 2010; Gough et al. 2011; Nalivaeva et al. 2012; Miners 
et al. 2014).  The exact role of ACE in AD pathology however, remains undefined (discussed 
below).  
ACE is most renowned for its dicarboxypeptidase conversion of angiotensin I (ANGI) to the 
vasoconstrictive angiotensin II (ANGII) and the breakdown of bradykinin (BK) (reviewed in 
Acharya et al., 2003; Riordan, 2003; Sturrock et al., 2012). This hydrolytic function places ACE 
as a central component of the renin-angiotensin-aldosterone-system (RAAS) - the hormonal 
system responsible for the maintenance and homeostasis of blood pressure (Ehlers and 
Riordan, 1989; Sancho et al., 1976; Shapiro and Riordan, 1984). Like NEP and IDE, ACE cleaves 
a wide range of physiological substrates and has many functions (for a thorough review see 
Bernstein et al. 2013); however the production of ANGII and breakdown of BK (major 
effectors of the RAAS) associate ACE activity primarily with cardiovascular disorders (reviewed 
in Zaman et al., 2002). Physiologically ACE is implicated in a multitude of functions and is also 
responsible for the breakdown of the tetrapeptide N-acetyl-Ser-Asp-Lys-Pro (AcSDKP) (P. Li et 
al., 2010; Peng et al., 2005). Ac-SDKP was first described as a natural regulator of 
hematopoietic stem cell proliferation (Bonnet et al., 1992). However, modulation of 
haematopoiesis was found to occur by ACE through other substrates like substance P or ANGII 
(Bernstein et al., 2011; Lin et al., 2011). Most importantly, with respect to therapeutic 
intervention, AcSDKP has been shown to prevent the proliferation of fibroblasts in the 
myocardium, aorta and the kidney in models of injury (Liao et al., 2010; Lin et al., 2008; Peng 
et al., 2001). In male mice spermatozoa, ACE regulates the GPI-anchored protein TEX101, 
whose removal is essential for fertility and may provide a novel target for male contraceptive 
medicine (Fujihara et al., 2013).  In vitro ACE caters to a large array of substrates including the 
breakdown of substance P (Skidgel et al., 1984), hydrolysis of gonadotrophin releasing 
hormone (GnRH) (Jaspard et al., 1993), neurotensin (Matsas et al., 1984; Skidgel et al., 1984), 
enkephalins (Deddish et al., 1997) and Aβ (Hu et al., 2001) to name a few. It is important to 
note that these latter substrates have not been validated convincingly in vivo.  
 ACE General Properties. 1.4.1
ACE is a zinc-dependent peptidase that requires specific post-transcriptional modifications 
and chloride in order to remain functionally active. The precise amino acids required for 
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chloride binding were identified and the functional concentration determined (Rushworth et 
al., 2008; Shapiro and Riordan, 1983; Tzakos et al., 2003; Yates et al., 2014). ACE is heavily 
glycosylated and the glycosylation pattern differs depending on the tissue in which ACE is 
expressed (Baudin et al., 1997). As with most eukaryotic proteins, glycosylation is required for 
correct intracellular folding and formation of the mature enzyme (Anthony et al., 2010; 
Baudin et al., 1997). It is important for ACE’s thermal stability and may play a role in 
dimerization and possibly effect inhibitor or substrate accessibility (Kost et al., 2003; Margraf-
Schönfeld et al., 2011; O’Neill et al., 2008). The large amount of glycan heterogeneity as well 
as the quantity (reported up to 22 % of the total enzyme mass) still proves an obstacle 
towards the crystallization of intact full-length ACE (Baudin et al., 1997; Deddish et al., 1994; 
Ripka et al., 1993; Yu et al., 1997).  The problem of glycosylation was overcome with the use 
of glycosidase inhibitors and the removal of glycosylation sites, by site directed mutagenesis, 
to yield crystal structures of minimally glycosylated truncated ACE (Anthony et al., 2010; 
Gordon et al., 2003; Natesh et al., 2003).  
The gene encoding ACE (Ace) is 21 kb long, with 26 exons (Figure 1.4 A), on the long arm of 
chromosome 17 at locus q23 and is found behind a promoter region regulated by 
glucocorticoid response element (Hubert et al., 1991). Through cloning of the Ace gene  it was 
discovered that ACE consists of two homologous domains (the N-domain and C-domain) each 
containing a zinc binding motif HEXXH (Soubrier et al., 1988) (Figure 1.4 A). This zinc binding 
motif typifies ACE as a member of the gluzincin family of the MA clan of zinc 
metallopeptidases, whose catalytic mechanism is dependent on the binding of divalent 
cations (Rawlings et al., 2010), these family properties have been well reviewed in Spyroulias 
et al., 2004 and in Turner and Hooper, 2002. A common polymorphism found within the Ace 
gene occurs as a 287 bp insertion/deletion within intron 16 (Rigat et al., 1990). Individuals 
homozygous for the deletion (D/D) mutation generally present with higher serum ACE activity 
than those homozygous for the insertion (I/I) (Rigat et al., 1992, 1990). 
There are two isoforms of ACE, somatic ACE (sACE) and testis ACE (tACE) (Figure 1.4).  sACE is 
expressed across a variety of tissue types: in large quantities within vascular endothelium (Ng 
and Vane, 1968, 1967), lung , renal epithelium (Cushman and Cheung, 1971a, 1971b), fatty 
tissue (Bӧttcher et al., 2006), ciliated intestinal epithelium (Bruneval et al., 1986; Wildhaber et 
al., 2005), monocytes, immune-activated dendritic cells (Friedland et al., 1978; Lin et al., 
2011), and in the brain (Defendini et al., 1983; McKinley et al., 2003). The testis isoform arises 
as a result of a tissue specific promoter found within intron 12 of the Ace gene (Figure 1.4 A). 
It is specific to male germ cells and its expression is regulated by cAMP response element 
(Howard et al., 1990; Langford et al., 1991). The somatic form of ACE is expressed, in its 
maturity, as a large 1 277-amino acid protein with two homologous catalytic domains 
(Bernstein et al., 1989; Soubrier et al., 1988; Wei et al., 1991) separated by a short linker 
region. Both isoforms are targeted to the cell membrane by N-terminal signal peptides (29 
residues in sACE and 31-residues in tACE) (Ehlers et al., 1989) and, being type I integral 
membrane proteins, contain membrane-anchoring hydrophobic regions as well as 
juxtamembrane stalk and ectodomains. ACE contains a short cytoplasmic tail with numerous 
Ser and Thr residues which allows for signalling capabilities (Hubert et al., 1991; Kohlstedt et 
al., 2004; Soubrier et al., 1988). Differing from sACE, tACE has limited tissue expression and is 
identical to the C-domain of sACE, barring the first 36 residues (Ehlers et al., 1989; El-Dorry et 
al., 1982). Both isoforms are proteolytically-shed from the cell membrane near the 
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transmembrane region by a yet unidentified ACE sheddase (Ehlers et al., 1996). Shedding of 
the high expressing sACE in vasculature and lung tissue promotes the formation of soluble 
ACE which forms part of the circulating RAAS (Ehlers et al., 1996; Woodman et al., 2000) 
(Figure 1.4). 
 
 
Figure 1.4 The two isoforms of ACE. A) A schematic representation of the Ace gene, with its 26 exons, and 
corresponding protein regions below, sACE 1277 amino acids long and the shorter tACE of only 701 amino 
acids. The grey exons represent the N-domain of sACE, and the sACE promoter position is indicated by 
grey arrows. The red exons beginning at exon 12 indicate those that encode for the linker region. The 
green arrows and corresponding exon indicate the site of the tACE promoter that transcribes the C-
domain (yellow). Exon 13 is seen as an intron and spliced out in the transcription of sACE.  B) A model 
based on the crystal structures of the individual N- and C-domains of ACE in the sACE format (Chen et al., 
2010) on the left and tACE on the right. The diagram depicts the proteins attached to the cell membrane 
and emphasises the overlap between tACE and the C-domain. Indicated by the star is the cleavage site of 
the ACE sheddase responsible for the formation of the circulating sACE.  
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 The two domains of ACE. 1.4.2
1.4.2.1 Structural similarities. 
The N- and C-domains of ACE can function independently of one another as they are 
individually able to hydrolyse substrates if the other catalytic site is inactivated (Wei et al., 
1992). Structurally, there are only minor differences between the two domains (89 % 
structural homology) (Figure 1.5) (Corradi et al., 2006). Both domains can be divided in to two 
sub-domains, between which lies a central cleft (Corradi et al., 2006; Natesh et al., 2003). This 
cleft contains the zinc bearing active site on helix α15, it has been suggested that substrate 
access to this buried active site occurs through hinge mediated opening (Anthony et al., 2010). 
Both domains have globular elliptical quaternary structures composed largely of α-helices but 
contain several flexible loops and 6 β-sheets (Corradi et al., 2006). There are three α-helices 
that form an N-terminal lid-like region, which are positioned over the active site cleft. This 
region is thought to play a role in substrate specificity and active site access as it has higher B 
factors suggesting some flexibility.  The lid regions on the N- and C-domains are associated 
with glycosylation sites shown to be important for the stability of the lid region and increased 
thermostability (Anthony et al., 2010; Watermeyer et al., 2006).  
There is no current crystal structure of sACE, only a low resolution electron microscopy 
structure, which gives some positioning information of the two domains (Chen et al., 2010). 
However, insight into the structure function mechanisms of both domains has been 
determined separately. Kinetic studies suggest interactions between the two domains alter 
both the binding and hydrolysis of substrates and inhibitors. The theory of interaction or 
cooperativity between the two domains postulates that the binding of substrates or inhibitors 
in one domain induces a conformational change in the other. Wherein, if the sum of the 
catalytic activity of one domain is less or greater than that of sACE, the cooperative effect is 
either negative or positive, respectively. Thus, sACE is said to display mostly negative 
cooperativity between the two domains towards substrates and inhibitors alike (Andújar-
Figure 1.5 Overall homology of the N- and C-
domain topology. An alignment of the N (sky blue) 
and the C-domain (tv green) PDB files 2C6F and 
1086 respectively, indicating the degree of similarity 
and positioning of the tertiary and quaternary 
structures of the two domains. The two zinc ions of 
each domain (grey,) overlap exactly and the two 
chloride ions in orange and purple bound within 
their respective pockets in the C-domain are 
represented. The deep central cleft can be observed 
diagonally from top left (N-terminals) to the C-
terminals of the molecules, in line with the zinc ion, 
resulting in two sub-domains. This image was 
generated using PyMOL software (v 0.99, DeLano 
Scientific). 
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Sánchez et al., 2004; Binevski et al., 2003; Rice et al., 2004; Skirgello et al., 2005). The one 
domain of sACE may also occlude substrate or inhibitor access to the other inducing a 
synergistic regulatory effect on each other (Skirgello et al., 2005; Sturrock et al., 1997; 
Woodman et al., 2005). Furthermore the proximity of the N-domain to the C, has been 
implicated as a modulator of sACE shedding, adding another level of regulation to substrate 
hydrolysis and control (Woodman et al., 2005). Resolution of the sACE crystal structure would 
help explain and expand how the two domains of ACE regulate one another.  
1.4.2.2 The C-domain. 
In vitro the hydrolysis of ANGI by the C-domain is approximately 3 times more efficient than  
the N-domain (Georgiadis et al., 2003; Wei et al., 1991). The development of ACE transgenic 
mice expressing single ACE isoforms, inactivated N- or C-catalytic sites or tissue-specific ACE 
has greatly increased our understanding of ACE’s function in vivo (Bernstein et al., 2011). 
Confirmation of ACE’s role in blood pressure came from ACE knockout mice that were 
hypotensive (Esther et al., 1996; Kim et al., 1995). Aside from being hypotensive, these mice 
had additional defects including anaemia, decreased renal function and fertility as well as 
severe physical abnormalities. The lack of fertility is attributed to the deletion of tACE, which 
is responsible for sperm motility within the oviduct and impaired binding to the zonae 
pellucidae (Hagaman et al., 1998; Krege et al., 1995). Thus, fertility is vitally dependent on 
tACE’s hydrolytic activity on an unknown substrate (Fuchs et al., 2005). Recently, more 
sophisticated and elegant mouse studies have further elucidated the functions of the N- and 
C-domains (Bernstein et al., 2011). These studies were performed on mice whose individual N- 
or C-domains had been inactivated through mutation of the zinc binding motif leaving only 
one functioning domain (Fuchs et al., 2008, 2004; Xiao et al., 2004). Mice whose N-domains 
were inactivated had no changes in blood pressure, renal function or hemocrit levels (Fuchs et 
al., 2004); however, C-domain inactivation resulted in a compensatory increase of renin 
expression and a concomitant increase in ANGI levels (Fuchs et al., 2008). These mice also 
lacked response on stimulation with ANGI. Together these results implicate C-domain 
principally in the conversion of ANGI to ANGII, however, both domains hydrolysed BK with 
similar efficiency (Fuchs et al., 2008).  
1.4.2.3 The N-domain. 
The N-domain of ACE catalyses a far more varied repertoire of substrates and is thought to be 
responsible for ACE’s endopeptidase activity (Ehlers and Riordan, 1991; Jaspard et al., 1993; 
Wei et al., 1991). In addition, it has a regulatory function on the shedding of sACE (Woodman 
et al, 2000). In sACE shedding is reduced in comparison to tACE and it is thought that the 
orientation and physical presence of the N-domain (within sACE) sterically hinders the 
sheddases access to the stalk region (Woodman et al., 2000). Thus, the N-domain could be 
important in regulating the amount of circulating ACE.  An active, N-domain of two different 
molecular weights (65 and 90 kDa) derived from sACE was discovered in ileal fluid (Deddish et 
al., 1994). Since this discovery, it has arisen in urine of hypertensive patients (Casarini et al., 
2001) and in spontaneously hypertensive rat models, with the 90 kDa variant thought to be a 
marker for hypertension (Bueno et al., 2004; Marques et al., 2003; Ronchi et al., 2005). The 
presence of the individual N-domain in isolation suggests an important physiological role in 
vivo. An abundance of N-domain may breakdown N-specific substrates, potentially altering 
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physiology. In vivo studies on mice with inactivated N-domain, however, indicated that it has 
little prominence within the RAAS as blood pressure was not affected, but Ac-SDKP levels 
increased by 6-fold (Junot et al. 2001; Fuchs et al. 2004;). Furthermore, in normal volunteers 
who were given ACE inhibitors , AcSDKP levels increased 5fold on acute administration and 
was generally elevated on continuous administration (Azizi et al., 2001, 1996). In vitro the 
binding for AcSDKP is equivalent across both domains of ACE, yet the N-domain has proven 
approximately 40 times better at its catalysis than the C-domain (Rousseau et al., 1995). The 
N-domain has also been found to have an immune function, as macrophages derived from N-
domain knockout mice had increased Tumor necrosis factor α (TNFα) compared to the C-
domain knockouts and wild type mice (Shen et al., 2012).  In conclusion, physiologically, the 
N-domain appears primarily responsible for ACE’s immune function and the hydrolysis of Ac-
SDKP, and the C-domain is primarily responsible for maintaining the RAAS function. 
 ACE signalling. 1.4.3
ACE inhibitors (ACEi) function on the premise of lowered ANGII and increased cardio 
protective BK levels (Hornig et al., 1997). BK increases endothelial production of autacoids of 
the likes of NO, endothelium-derived hyperpolarizing factor (vasodilator) and numerous 
prostacyclins (Danser et al., 2000). ACEi have been shown to have additional effects outside of 
this inhibitory mechanism.  Aside from prolonging the half-life of BK, ACEi also potentiate its 
vasodilatory responses through enhanced binding to the bradykinin-2 receptor (B2R) (Marcic 
et al., 1999). For example, the response to increased BK on ACE inhibition in porcine 
vasculature was observed within seconds of ACEi treatment. Although the half-life of BK in 
this tissue is approximately 10 minutes, mere increase in peptide could not account for the 
observed vasoactive response (Erdös et al., 1999). These and similar findings prompted 
research on the effects of ACE outside of its catalytic function. Indeed ACEi were shown to 
prevent the desensitization and membrane-mediated sequestration of previously activated 
B2Rs (Benzing et al., 1999). This implied an associative crosstalk between sACE and the B2R. 
Confirmatory experiments were performed on cells that lack endogenous expression of ACE 
or B2R (Minshall et al., 1997). Here, only cells transfected with both sACE and the B2R elicited 
an enhanced BK binding response, whereas cells maintaining sACE or B2R only did not 
(Minshall et al., 1997). The potentiation response occurs through a maintained affinity of B2R 
towards BK, and a reduction in B2R desensitization and internalization as a result of ACE 
inhibition (Erdös et al., 1999).  
1.4.3.1 ACE’s receptor-like function 
ACE has a receptor-like composition, with a short cytoplasmic tail that contains a number of 
serine residues. Of these Ser1253, Ser1263 and Ser1270 occur within the recognition motifs of 
protein kinase C (PKC), protein kinase A (PKA) and Casein Kinase 2 (CK2), respectively. ACE’s 
alternate, receptor-like function was proposed based on signalling mediated via 
phosphorylation of Ser1270 residue by CK2 in response to ACEi binding (Kohlstedt et al., 2002) 
(Figure 1.6). Inhibition of CK2 lead to a significant reduction of the phosphorylation of this site, 
suggesting that CK2 was specific to Ser1270 (Kohlstedt et al., 2002). The phosphorylation of 
Ser1270 appears crucial in maintaining sACE within the cell membrane as basal shedding 
levels were significantly increased in human umbilical vein endothelial cells (HUVEC) 
transfected with a non-phosphorylated mutant of sACE (Ser1270 converted to an Ala) 
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(Kohlstedt et al., 2002). As a cell’s actin cytoskeleton is thought to influence ectodomain 
shedding, immunoprecipitation experiments were performed on β-actin and the non-muscle 
myosin heavy chain IIA (MYH9) that associated, in a basally phosphorylated state, with the 
Ser1270 of sACE. The CK2 phosphorylation is not only specific to sACE but also to MYH9. 
Subsequent inhibition of CK2 attenuated ACE and MYH9 phosphorylation, disrupted their 
association, and enhanced ACE shedding (Kohlstedt et al., 2002). These experiments suggest a 
functional interaction between phosphorylation of the sACE’s cytoplasmic tail and cell 
cytoskeletal proteins. Thus, phosphorylation of sACE by CK2 could modulate ACE shedding, 
stabilising anchorage to the cytoskeleton.   
1.4.3.1.1 The signalling pathway 
Protein-Protein associations with ACE extend towards receptors of the RAAS, binding to ITGB1 
integrins (Clarke et al., 2012) and homozygous dimerization with itself (Kost et al., 2003, 
1998). The binding of ACEi is said to induce sACE dimerization, which corresponds in time to 
the point of greatest Ser1270 phosphorylation. Thus, ACE dimerization is thought to initiate 
the ACE signalling cascade, via CK2-mediated phosphorylation of Ser1270 (Kohlstedt et al., 
2006a). In porcine aortic endothelial cells, the absolute requirement for sACE signalling is the 
presence of a catalytically active C-domain. However, dimerization has been indicated to be 
dependent on the level of glycosylation of ACE (Kost et al., 1998). As ACE is heavily 
glycosylated the type and extent of glycosylation are dependent on the source of the enzyme 
(Ehlers et al., 1992; Hooper and Turner, 2000; Ripka et al., 1993; Ryan et al., 1993). Thus, one 
would expect different tissues to have different signalling effects if dimerization was indeed a 
determinant of sACE signalling. In support of the latter, the pathway seems to have cell or 
species specific functionality. Human sACE in porcine cells had a small signalling response to 
BK and no response to ANGI, yet murine sACE in CHO cells produced a significant signalling 
event towards ANGI, ANGII and BK (Kohlstedt et al., 2005; Sun et al., 2010). Furthermore, the 
N-domain in murine sACE was capable of inducing signal, albeit subdued in comparison to the
C-domain (Sun et al., 2010).
1.4.3.1.2 Activation of JNK and AP-1 and downstream effects 
The resultant downstream effect of sACE Ser1270 phosphorylation is the activation of c-Jun 
NH2terminal kinase (JNK). JNK is an effector of the mitogen-activated protein kinase (MAPK) 
signalling pathway. Indeed MAPK kinase (MAPKK) 7 was found to associate with 
phosphorylated Ser1270-sACE-CK2 immunoprecipitations. The JNK pathway can be activated 
by numerous stimuli, being a well-known stress response pathway especially in AD and 
dementia (Borsello and Forloni, 2007; Hashimoto et al., 2003; Morishima et al., 2001; Wei, 
2002; Yoon et al., 2012). JNK can be activated by cytokines and environmental stressors to 
mediate different cellular processes including, inflammation, differentiation, proliferation and 
apoptosis (Bogoyevitch and Kobe, 2006).  ACE signalling directs JNK activation, and induces 
downstream c-jun phosphorylation and translocation into the nucleus where it 
homodimerises to form the transcription factor apoprotein-1 (AP-1) (Kohlstedt et al., 2004) 
(Figure 1.6). AP-1 is a known transcription factor of the Ace gene and of the pro-inflammatory 
cyclooxygenase-2 (COX-2) (Figure 1.6). One would anticipate upregulation of ACE and COX-2 
to be detrimental to the treatment of cardiovascular disease. However, COX-2 inhibitors have 
proven a great risk to the development of atherosclerosis as they induce an increase in 
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platelet aggregation despite being anti-inflammatory. Overall, induction of the ACE signalling 
pathway by either inhibitor or substrate has both negative and positive implications 
theoretically in AD.  
Figure 1.6 ACE inhibitors and substrates increase ACE expression through ACE signalling. The ACE signal 
response is generated by inhibitor binding and molecular dimerization. On binding of the inhibitor 
phosphorylation of serine 
1270
, found in a highly conserved 13-amino acid sequence, occurs by a casein kinase 2 
(CK2) which stabilises ACE in the plasma membrane. Mutations of Ser 
1270
 or inhibition of CK2 promotes 
cleavage and secretion of ACE (Kohlstedt et al., 2002).  Other molecules are associated with the phosphorylation 
of Ser 
1270
 of ACE, the Mitogen-activated protein kinase kinase 7 (MKK7) and c-Jun N-Terminal Kinase (JNK) are 
both activated by a putative phosphorylation cascade initiated by the Ser 
1270 
residue. The JNK pathway 
activates the transcription factor c-Jun causing it to translocate and accumulate in the nucleus where it forms a 
homodimer that associates with activator protein-1 (AP-1) and binds to the cAMP responsive element sequence 
of the ACE promoter (Flemming et al. 2005, Eyries et al. 2002; Kohlstedt 2001, 2003, 2004). This results in the 
transcription (thick black arrows) of COX-2 and ACE 
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1.4.3.1 Insulin sensitivity and ACE signalling implications in AD. 
Hypertension and diabetes often present as comorbidities, a patient with one disease is at 
high risk of developing the other. As previously mentioned, AD has been termed a type-3 
diabetes and the link between AD and type-2 diabetes mellitus (T2DM) is well established 
being associated with major risk factors such as inadequate brain glucose metabolism and 
insulin signalling (Akter et al., 2011; Yang and Song, 2013). ACE signalling was examined in pre-
adipocytes to help describe the improved insulin sensitivity that ACE inhibition 
provokes (Bӧttcher et al., 2006). Analysis of differential gene expression, in cells expressing 
sACE or a signalling mutant, indicated that adiponectin was upregulated in the pre-adipocytes 
(Bӧttcher et al., 2006). Adiponectin is responsible for the promotion of fatty acid oxidation 
(reducing ROS), lowering glucose production and promoting glucose uptake (for a review 
associated with dementia see J. Song et al. 2014). ACE’s signalling pathway regulated cellular 
retinol-binding protein (CRB1) which could affect gene regulation via peroxisome proliferator-
activated receptors (PPAR) (Kohlstedt et al., 2009). Indeed, ACEi restoration of adiponectin 
was thwarted by inhibition of either JNK or PPARγ antagonism. Furthermore, in the ob/ob 
obese mouse model of diabetes ACEi restored adiponectin levels and potentiated the effects 
of the PPAR-agonist rosiglitazone (Kohlstedt et al., 2009). These experiments were further 
validated in patients with coronary artery disease (Kohlstedt et al., 2009). PPARs bind to 
target DNA response elements as heterodimers with retinoid-X receptor causing gene 
transcription as well as trans-repression of proinflammatory genes (Chen et al., 2012). This 
trans-repression interferes with the activities of other transcription factors of the likes of 
nuclear factor-κB (NF-κB) and AP-1 families (Schnegg et al., 2012). Although ACE inhibitors 
have not been tested as PPARγ receptor agonists, telmisartan is a partial agonist of PPARγ that 
leads to a decrease in ACE activity and an overall reduction of oxidative stress via p22phox 
inhibition (Takai et al., 2007). In AD patients PPARγ expression was shown to be elevated (de 
la Monte and Wands, 2006) most likely in a protective manner as it had promising 
neuroprotective effects (Combs et al., 2000). PPARγ activation of insulin-sensitizing 
thiazolidinedione (TZD) drugs, used to treat T2DM, slow onset and development of 
Alzheimer's and promote cell survival (Rodriguez-Rivera et al., 2011; Zolezzi and Inestrosa, 
2013)  
Another molecular switch related to AD, blood pressure and diabetes, is adenosine 
monophosphate-activated protein kinase (AMPK). AMPK also mediates adiponectin 
expression, which stimulates Glucose transporter type 4 (GLUT4) translocation and glucose 
uptake. Adiponectin binding to its receptors further perpetuates increased insulin sensitivity 
(Yamauchi et al., 2001) and improved vascular function (Fésüs et al., 2007; Gustafsson et al., 
2010) by activating not only AMPK (Iwabu et al., 2010) but p38/JNK MAPK (Miyazaki et al., 
2005) and PPARα (Qiao et al., 2011). PPARα has recently been shown to be responsible for the 
activity of ADAM 10, the α- secretase (Chen et al., 2012). In a study on ex vivo human 
peripheral monocytes/macrophages, increased expression of ACE has been shown to reduce 
their activation and pro-inflammatory cytokine production response (Kohlstedt et al., 2011); a 
response similar to that of non-steroidal anti-inflammatory drug (NSAID) treatment against 
Aβ-induced macrophage activation (Combs et al., 2000). 
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This, ACE signalling mediated mechanism is induced by lipids from adipocyte-conditioned 
media and resulted in a 4-fold increase in ACE expression. This was dependent on the 
presence of ACE and not its activity, as inhibition had no effect, yet gene-silencing ACE did. 
Mechanistically, the phosphorylation of AMPK was responsible for this increase in ACE 
expression. Moreover, in AMPKα1(-/-) mice, ACE expression was reduced in spleen derived-
monocytes compared to wild-type littermates (Kohlstedt et al., 2011). The same group 
determined later in endothelial cells that ACE expression is down regulated in response to 
shear stress along the same AMPK pathway that T2DM stimulates (Kohlstedt et al., 2013). The 
activation of AMPKα2 subunit results in subsequent phosphorylation of the pro-cell-survival 
site (Ser15) on p53. This p53 activation induced a post-transcriptional up-regulation of miR-
143/145 which decreased ACE expression (Kohlstedt et al., 2013). Taken together, from the 
upregulation of adiponectin and PPARs to the immune-modulating functions ACE may have, 
independent of its activity, ACE has a broad range of avenues through which its inhibition may 
influences outcomes in AD.  
1.5 The Brain Renin Angiotensin-Aldosterone System. 
There is increasing evidence that vascular disorders, like hypertension and atherosclerosis, are 
the primary cause of AD (Bell and Zlokovic, 2009; de la Torre and Mussivand, 1993; George-
Carey et al., 2012). Hypertensive patients are prone to the development of strokes, white 
matter lesions, silent infarcts, myocardial infarction and cardiovascular diseases (de Leeuw et 
al., 2002). Hypertension is often the introduction to conditions like diabetes mellitus, obesity 
and hypercholesterolemia (Kivipelto and Solomon, 2006; Launer, 2009; Ruitenberg et al., 
2001). Vascular diseases lead to dysfunctions of the BBB (Zlokovic, 2004), resulting in brain 
ischemia, and oxidative stress all of which can result in Aβ accumulation, synaptic loss, 
neurofibrillary tangles and ultimately AD (Farkas and Luiten, 2001; Hooijmans and Kiliaan, 
2008; Launer et al., 2000). Thus, there is support towards the notion that vascular disorders 
like hypertension induce chronic degeneration in AD. 
One of the systems responsible for blood pressure maintenance is the RAAS, a fundamental, 
conserved system that controls the cardiovascular system, renal function and fluid 
homeostasis (Fournier et al., 2012). Over activity of any of its components is generally 
associated with hypertension, renal disease and metabolic syndrome. The RAAS was initially 
described as a simple system whose rate-limiting factor was the conversion of 
angiotensinogen by renin into the inactive ANGI, which was subsequently converted to the 
vasoactive ANGII by ACE. It was thought that ACE was solely responsible for the formation of 
ANGII and that ANGII was the only active principle of the RAAS (Skrbic and Igic, 2009). We now 
know that there are many branches that stem from the classical RAAS axis. The classical axis 
consists of angiotensinogen, renin, ANGI, ACE, ANGII and the effector of blood pressure AT1R, 
which induces aldosterone secretion and triggers sodium reuptake (Figure 1.7). The extended 
RAAS encompasses the seemingly antagonistic arms of the classic RAAS. Aside from the 
peripheral RAAS there exists an independent brain RAAS (BRAAS) that extends its role beyond 
the classical fluid and blood pressure homeostasis into areas such as sexual behaviour, 
cerebroprotection, diabetes, psychological disorders and many neurodegenerative diseases 
including AD (Phillips and De Oliveira, 2008; Saavedra et al., 2011; Wright and Harding, 1997). 
The BRAAS, which, apart from the circumventricular regions which have no BBB, is a separate 
Kate Larmuth  CHAPTER 1 Literature Review 
 25 
system from the peripheral RAAS and contains all the components of the RAAS, the central 
classic axis as well as the branching axis (McKinley et al., 2003) (Figure 1.7). There appear to 
be two axes of the RAAS, the classic axis and the so-called good axis, which includes peptides 
ANGIII, ANGIV and ANG(1-7). As all the effects of BRAAS peptides are mediated by receptors, 
it is from this point of view that it will be described. 
Within the CNS, ACE is found at high levels in the choroid plexus, which may be the source of 
ACE in cerebrospinal fluid, subfornical organ, basal ganglia, substantia nigra and pituitary (Chai 
et al., 1987). Moderate expression of ACE occurs in the amygdala and in all cortical nuclei. In 
the cerebellum, dense labelling of ACE was observed in the Purkinje cell layer (Chai et al., 
Figure 1.7  An overview of the brain renin angiotensin-aldosterone system. The BRAAS appears to be 
upregulated along the classical axis of angiotensinogen, ANGI, ANGII and activation of the AT1R and 
AT2Rs in AD patients. ACE inhibition is one means to reduce the amount of the AT1R ligand, ANGII, 
which is broken down by aminopeptidase A (AP-A), and promote the axis of good via Mas and AT4R 
activation instead.  
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1987). ACE has also been found within the cortical perivasculature, speculated to be a result 
of interstitial drainage (J S Miners et al., 2008).  In the BRAAS the formation of ANGII is crucial 
as it has neurotransmitter-like functions (Ferguson and Washburn, 1998; Johns, 2005; Phillips, 
1987) and angiotensinogen is secreted from astrocytes and to help maintains the BBB (Yanai 
et al., 2000). Renin is formed from pro-renin and is responsible for the conversion of 
angiotensinogen to ANGI. Pro-renin levels in the brain are comparable to levels seen in the 
heart and are greater than the levels seen in the kidney, liver and pancreas (Nguyen et al., 
2002).  Pro-renin has receptor functions which induce signals much like that of the AT1R (see 
below) (Nguyen and Contrepas, 2008). Thus, it is important as most components of the RAAS 
system cannot cross the blood brain barrier (McKinley et al., 2003). In hypertension, which 
disrupts the BBB, peripheral ANGII mediates a feed-forward mechanism, promoting further 
BBB permeability and further ANGII access to brain regions which control blood pressure 
(Biancardi et al., 2014). The entire BRAAS, when upregulated, as it has been determined in AD, 
has both cognitive and pathological implications.  
 The angiotensin II type 2 receptor (AT2R). 1.5.1
ANGII is a substrate for numerous enzymes that liberate alternative bioactive substrates 
within the RAAS. ANGII, the product of ACE hydrolysis, and ANG III, which is formed from 
aminopeptidase A activity on ANGII, are agonists of the AT1R and AT2R subtypes. AT2Rs are 
less prominent compared to AT1R expression in the brain; however, they are upregulated 
under pathological conditions (Zhu et al., 2000). AT2Rs are found in the thalamus, 
hypothalamus, and specific brainstem nuclei, as well as in areas of motor and behaviour 
control (Sokol et al., 2004). Hippocampal administration of ANG II induces amnesia, an effect 
completely reversible by antagonists of the AT2R, without affecting locomotion, exploratory 
behaviour or anxiety (Kerr et al., 2005). AT2R stimulation promotes optic nerve and cell 
differentiation and both axonal and neuronal regeneration in the brain, and is linked to foetal 
brain development (Li et al., 2007; Mogi et al., 2006). 
 The angiotensin II type 1 receptor (AT1R). 1.5.2
AT1R is a G-protein coupled receptor which signals via phospholipase-C and calcium (de 
Gasparo et al., 2000; Dinh et al., 2001) and is found throughout the brain (Wright and Harding, 
2013). There are two subtypes, designated AT1AR and AT1BR, with the AT1AR being primarily 
responsible for BRAAS functions. It regulates the transcription of genes and expression of 
proteins which are involved in cellular proliferation and growth in many tissues (de Gasparo et 
al., 2000). It is also the major stress receptor; stress induces ANGII increases which bind to 
AT1ARs and promotes increased expression and release of norepinephrine via corticotrophin-
releasing hormone synthesis and subsequent adrenocorticotrophin release from the anterior 
pituitary (Gard, 2002; Saavedra et al., 2011). Stress is well documented as an etiologic factor 
in AD (Rothman et al., 2012) and contributes significantly to hypertension via the upregulation 
of the classic RAAS axis. This axial upregulation increases sympathetic nervous system activity 
via increased ANGII and amyloidogenesis (N. Li et al., 2010; S. Li et al., 2010; Savaskan et al., 
2001). AT1R receptor blockers (ARB) confirmed these findings as a number of studies 
concluded that ARBs, like olmersartan, candesartan, valsartan, losartan and telmisartan, 
improved memory and cognitive processing (Mechaeil et al., 2011; Ongali et al., 2014; Takeda 
et al., 2009; Tota et al., 2009; Wang et al., 2007). This occurs presumably by blocking the 
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action of ANGII, reducing blood pressure, stress responses and Aβ accumulation. Blocking the 
AT1R receptor subtype appears to prevent delay and/or reverse the memory deficits and 
damage associated with AD.  
 The angiotensin II type 4 receptor (AT4R). 1.5.3
The beneficial effects of ARBs are mediated by their antagonistic effect on ANGII binding to 
receptors, and as there is an increase in ANGII, provides more substrate for the formation of 
beneficial substrates of the branching RAAS axis. For instance the angiotensin IV (ANGIV) 
peptide is produced from consecutive hydrolysis of ANGIII by AP-A and binds with high affinity 
and selectivity to the AT4R (Bernier et al., 1998; Wright and Harding, 2008) and low affinity to 
AT1R and AT2R (Bennett and Snyder, 1976). AT4R actions appear to be modulated 
antagonistically by insulin-regulated membrane aminopeptidase (IRAP), leading some 
researchers to believe that the AT4R was indeed IRAP (Albiston et al., 2003; Chai et al., 2004). 
AT4R ligands block IRAP activity as all IRAP substrates are increased specifically, oxytocin, 
vasopressin and somatostatin, all of which have beneficial effects on cognition and facilitate 
learning and memory (Lew et al., 2003). Importantly it also regulates GLUT4 receptor vesicular 
trafficking to the cell surface, tying in to diabetes, it regulates glucose uptake through this 
mechanism (Fernando et al., 2008). ANGIV analogues also upregulate dopamine and 
acetylcholine levels, further increasing the learning and memory response (Braszko, 2004; 
Gard, 2008). Furthermore, chronic administration of ANGIV to ApoE-/- mice evoked a marked 
vasoprotective effect that appeared to be mediated by improved NO via AT4 and/or AT2R 
receptors (Vinh et al., 2008). ANGIV improves memory recall of passive avoidance tasks in 
dose dependent manner (Wright et al., 1993). 
 The Mas receptor. 1.5.4
The only other derivative of ANGI is ANG(1-9), which is the precursor for an important product 
within the BRAAS namely ANG(1-7). The hydrolytic product of ANG(1-9) by NEP or ACE, is 
ANG(1-7) which binds to the Mas receptor and forms part of the good axis of the BRAAS 
(Santos et al., 2003; Xu et al., 2011). The Mas receptor signalling counteracts inflammation, 
fibrosis and increases insulin sensitisation as well as glucose uptake which are often promoted 
by the actions of ANGII on AT1R or AT2R (Da Silveira et al., 2013; Passos-Silva et al., 2013; 
Simões E Silva et al., 2013). ACE2, removes the C-terminal Leu residue from ANGI to form 
ANG(1-9) (Donoghue et al., 2000) or the Phe from ANGII to form ANG(1-7) directly (Ferrario 
and Chappell, 2004). The ACE homologue, ACE2, also forms part of the extended good RAAS 
axis (Figure 1.7) (Ferrario, 2011; Tipnis et al., 2000). ACE2 is also a metallocarboxypeptidase 
that has been shown to convert Aβ(1-43) to Aβ(1-42) which can then be better cleaved by 
other Aβ-degrading enzymes like ACE (Liu et al., 2014). Interestingly dysfunction and/or 
dysregulation of IDE and NEP are also implicated in the pathogenesis of vascular disease. Both 
IDE and NEP are responsible for the hydrolysis of natriuretic peptides, importantly inactivating 
the vasodilator-atrial natriuretic peptide, which also regulate cardio-renal homeostasis 
(Potter, 2011; Volpe et al., 2014). NEP is also intimate within the RAAS, hydrolysing the 
bioactive components BK, ANGI and ANG(1-9) (Figure 1.7). Recently ANG(1-7) levels were 
found to correlate protectively against tau hyperphosphorylation, and ANG(1-7) decreased 
with progression of AD (Jiang et al., 2015). ANG(1-7) also facilitates LTP (Hellner et al., 2005), 
which correlates with the local of the Mas receptor, found in areas important to cognition and 
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memory, including the hippocampus and piriform cortices (Freund et al., 2012).  Several 
excellent reviews on the BRAAS and its receptor-subtypes with relevance to AD have been 
published over the last two decades (de Gasparo et al., 2000; Kehoe and Passmore, 2012; 
Phillips and Sumners, 1998; Wright and Harding, 2004; Wright et al., 2013).  
1.6 The ACE and AD debate. 
Considering the multifaceted role of the BRAAS in AD and the pivotal role of ACE in the RAS, it 
is  important to addreass the debate around ACE as a potential therapeutic target for AD. As 
previously mentioned the inhibition of ACE has far-reaching consequences (see section 
1.4.3.1) and in the context of AD, these mechanisms have not been investigated. Moreover, 
biochemically the involvement of ACE in AD remains unclear, as there are several lines of 
conflicting evidence.  
ACE was first linked to AD when various polymorphisms (Katzov et al., 2004) of the ACE gene 
led to variations in ACE expression and activity and increased susceptibility to AD in certain 
populations (see the accumulative database on all ACE polymorphisms and their association 
with AD: http://www.alzgene.org/geneoverview.asp?geneID=125) (Bertram et al., 2007). The 
insertion mutations (lower serum ACE levels) in ACE’s intron 16 are related to development of 
AD and the deletions (higher serum ACE levels) to protective functions against AD (Kehoe et 
al., 2003, 1999; Lehmann et al., 2005). These genetic findings indicating a role for ACE in AD 
were bolstered in 2001 by Hu et al. who discovered that ACE inhibited Aβ aggregation and 
polymerisation in vitro.  
Over a decade on, a lot of uncertainty still exists between evidence generated in cell based, in 
vitro assays and in vivo studies of ACE and AD. Cell based models prove that ACE does indeed 
cleave and clear both soluble and plaque forming versions of the Aβ peptide and that ACEi 
prevents this (Hemming and Selkoe, 2005; Hu et al., 2001; Oba et al., 2005). Furthermore, in 
SH-SY5Y neuronal cells oligomeric species of Aβ induced ACE expression (Ashby et al., 2009). 
In these in vitro studies, ACE upregulation could be interpreted as a homeostatic mechanism 
towards elevated levels of Aβ and cautions against ACE inhibition. However, the more recent 
studies on human neural tissue and cerebral amyloid angiopathy mouse models (in vivo) 
indicate that ACE may not have a physiological role in the clearance of Aβ peptides (Eckman et 
al., 2006; J S Miners et al., 2008). Evidence against ACE, as a metallopeptidase that 
catabolically maintains Aβ’s steady state, is that there is no change in Aβ plaque or level of 
soluble peptides, when ACEi are applied via direct intracerebroventricular (icv) injection to 
AD-mouse models (Eckman et al., 2006; Hemming et al., 2007; J S Miners et al., 2008). 
Furthermore, prolonged chronic treatment with captopril (a centrally active ACEi) in two 
human APP transgenic AD mice models, saw no increase in Aβ levels (Hemming et al., 2007). 
On further investigation, however, failure of captopril to affect Aβ hydrolysis was thought to 
occur due to a lack of inhibition of brain ACE activity while renal and arterial ACE inhibition 
was effective (Hemming et al., 2007). Perindopril, another centrally active ACEi, delivered 
intracerebrally prevented cognitive impairment in a mouse AD model compared to other 
centrally active ACEi which did not (Dong et al., 2011). Here, perindopril did not effect Aβ 
levels but reduced ACE activity in PS2APP mice, suppressing microglia and astrocyte activation 
and overall reducing oxidative stress (Dong et al., 2011). In a different model of AD, which 
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contains a double human APP mutation producing more Aβ, captopril administration resulted 
in a definite increase in Aβ deposition, specifically Aβ(1-42) (Zou et al., 2007). A most 
convincing study by Bernstein et al., which used ACE overexpression in myelomonocytes of 
APP(SWE)/PS1(ΔE9) mice demonstrated the protective effect of ACE against cognitive decline. 
This effect is most likely linked to an enhanced immune response, possibly activated by ACE 
(Bernstein et al., 2014). 
In post mortem studies there is a direct link between Aβ levels and an increase in ACE activity 
in the brain, specifically parietal cortex, caudate nucleus, cerebral cortex and hippocampal 
regions (Arriagada et al., 1992; Barnes et al., 1991; Savaskan et al., 2001). ACE protein levels 
were shown to increase concomitantly with severity of disease - attributed to Braak tangle 
stage (Ashby et al., 2009). In some AD patients cerebrocortical ACE activity is increased and 
serum activity decreased although this could be a phenomenon of genetics (Rigat et al., 1990). 
On this, there is a disparity between ACE activity and expression levels, independent of 
genetics, in AD patients, where CSF ACE activity is raised but expression is low in comparison 
to brain ACE activity and protein expression (Ashby et al., 2009; Zubenko et al., 1985). A 
possible cause to this disparity, could be that PTMs like glycosylation influence ACE activity or 
inhibition profile (Kost et al., 1998). However, it is most likely that tissue and space 
compartmentalisation are to blame for the variations in activity, as microenvironments affect 
ACE activity (Grinshtein et al., 2001). In contrast to their mouse findings Miners, et al, found in 
immunohistochemical studies that ACE expression and activity was increased in post-mortem 
studies of AD and directly correlated to parenchymal Aβ load. This study also revealed ACE 
within neurons and cortical blood vessels but the AD patients also had severe CAA, and 
consequently ACE was most abundant within the perivascular drainage routes (J S Miners et 
al., 2008).  
In general, it appears that, there is significant evidence to state that not only is the BRAAS 
upregulated in AD, but ACE is too. From the upregulation of ACE and subsequently the RAAS, 
the precise mechanism through which ACE may affect AD pathology remains unknown. There 
are three potential avenues through which ACE could exert influence, through the excessive 
formation of ANGII and its hypertensive ramifications, through ACE’s apparent 
immunomodulatory function, or ACE’s involvement is limited to the hydrolysis of Aβ. 
 Questions surrounding domain selectivity and Aβ. 1.6.1
The debate around ACE and AD continues in in vivo/cell based studies on Aβ cleavage. Since 
2001, ACE was proven in vitro to reduce aggregation and cytotoxicity of a variety of Aβ species 
(Hemming and Selkoe, 2005; Hu et al., 2001; Oba et al., 2005; Zou et al., 2009). Although no 
in-depth kinetics exists on ACE- Aβ hydrolysis, it is grouped amongst the metalloproteases, 
like NEP and IDE, responsible for the reduction and clearance of Aβ. Over the years, however, 
conflicting results have appeared from a number of studies (Table 1.1). Since there seems to 
be opposing thoughts as to which domain of ACE is primarily responsible for Aβ breakdown 
along with an apparent lack of cleavage site specificity. Hemming and Selkoe (2005), carried 
out active site mutations in both the N-and C-domain individually and as a double sACE 
mutant, inactivating the respective domains, yet maintaining sACE’s overall structure. Using 
these mutants, they then tested the amount of Aβ cleavage. They suggest that the truncated 
form of the C-domain results in downregulation of its function. As previously mentioned this is 
CHAPTER 1: Literature Review  Kate Larmuth 
30  
a plausible situation as there is evidence of inter-domain cooperativity in sACE (Binevski et al., 
2003). This study further stated that the C-domain may not function in Aβ recognition and 
cleavage in vitro if it is not part of the full-length enzyme (Hemming and Selkoe, 2005). The 
results of their experiments indicate that both the C- and the N-domain of ACE play a role in 
the cleavage of the Aβ-peptide (Hemming and Selkoe, 2005). Echoing Hemming and Selkoe, 
only using human and mouse forms of the enzyme (active site knockouts), Sun et al., (2008) 
found no difference between the two domains of murine ACE in the rate of hydrolysis, nor 
domain specificity to the Aβ peptide (Sun et al., 2008).  This was the first study looking at how 
mouse models of ACE-Aβ hydrolysis in AD may be compromised, as the amyloid that mice 
produce is not pathogenic and has an alternate sequence to human Aβ.  
In a study with His-tagged, truncated, individual domains of ACE, Oba et al., (2005) 
determined that the N-domain generated a much larger inhibition of Aβ(1-40) aggregation 
and cytotoxicity than the C-domain (Oba et al., 2005). They suggest that the N-domain is the 
primary active site for Aβ cleavage. Toropygin et al.,(2008) provided important data on the 
cleavage sites of the isomerized Aβ peptide using Bovine N- and C- truncated proteins. Like 
Oba et al., (2005), the N-domain was found to cleave the Aβ substrate and the C-domain did 
not. Similarly Zou et al.,(2009) found that the N-domain was responsible for the conversion of 
Aβ(1-42) to Aβ(1-40) (Zou et al., 2009). Zou and colleagues have proposed that Aβ(1-40) had 
protective effects over Aβ(1-42) and that the severity of AD lay in the ratio of Aβ(1-42)/ Aβ(1-
40) (Zou et al., 2003). However, they found that the C-domain and sACE also cleaved the Aβ(1-
42) peptide, butat alternate sites (Zou et al., 2009).  
Overall, the different cell types, experimental methodology and variants of ACE used across 
these studies (Table 1.1) come to no consensus as to which domain of ACE indeed hydrolyses 
Aβ preferentially. Furthermore, studies on truncated domains lose some physiological holding 
as in sACE domain selectivity is often altered due to cooperativity, and, as suggested by 
Hemming and Selkoe (2005), tethering to a cell membrane. Without any definitive kinetic 
data, or further mechanistic insight into ACE- Aβ hydrolysis this avenue around ACE’s exact 
role in AD pathology remains unclear.  
3
1 
Table 1.1 In vitro studies of ACE hydrolysis of Aβ. 
Author Cleavage site Aβ Peptide used ACE variant used Selectivity
Hu et al. 2001 Asp7-Ser8 1-40 Purified  human sACE NA
Oba et al. 2005 Asp7-Ser8 (same group) 1-40
Recombinant truncated His tagged 
human sACE and Ndom, Cdom
N-domain
Hemming and Selkoe. 2005 Asp7-Ser8 (assumed)
1-40, 1-42 expressing
cell lines
Membrane bound sACE and sACE N/C 
KO’s
Non-selective 
Zou et al.  2007 Val40-Ile41 1-42 Human Kidney sACE Non-selective 
Leu34-Met35, Lys28-Gly29, Ser26-Asn27, Glu22-
Asp23, Phe20-Ala21
Human and mouse  1-
40
Recombinant human sACE
His13-His14, Glu11-Val12
Human and mouse  4-
15
Recombinant mouse: sACE, Ndom, Cdom, 
sACE N/C KO’s and wtmACE
N-domain: Val40-Ile41
C-domain: Gly33-Leu34, Val24-Gly25, Ala21-Glu22
Kumar et al.  2012 Asp7-Ser8, Ser8-Gly9
1-40 and Phospho-
Ser8(1-40)
 Recombinant human sACE NA
KO, refers to active site mutaions disrupting zinc binding and inactivating one specific active site.
NA: not applicable, the study was not concerned with selectivity used sACE.
N-domain
Ndom
Non selective 
Zou et al.  2009 1-42
Recombinant truncated sACE, Ndom, 
Cdom, sACE N/C KO’s
1-16, 1-16isoAsp7
Sun et al.  2008
Toropygin et al.  2008 Arg5-His6
Recombinant bovine ACE truncated 
domains
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 The roles of ANGII in AD. 1.6.2
There are many negative effects of an upregulated or dysregulated ANGII-mediated BRAAS, as 
in hypertension, which have severe cognitive implications for AD (see section 1.5 and 1.6). Icv 
ANGII infusion has been shown to interfere with rabbit operative tasks (Melo and Graeff, 
1975) as well as in rat and mice acquisition training, where it blocked memory recall 
conditioned responses 1-2 days later (Lee et al., 1995; Morgan and Routtenberg, 1977). 
Similarly, icv ANGII infusions in rats impaired memory retention in trained immobilization 
stress, maze or passive avoidance tasks (Raghavendra et al., 1999). This effect appeared to be 
dose dependent and was blocked by ACEi and/or AT1R antagonists but not by AT2R 
antagonists (DeNoble et al., 1991). This suggests that AT1R mediates these ANGII memory 
defects. However, it may be that ANGII inhibits memory due to its anticholinergic effects 
(Barnes et al., 1990), independent of its AT1R action (Shepherd et al., 1996).  
In contrast, ANGII has been found to improve cognition and recall in some studies. It was 
suggested that low ANGII dosage induces memory inhibitory effects and higher doses 
facilitate learning  (Braszko et al., 1988, 1987). Furthermore microinjection of ANGII into the 
hippocampus has been shown to facilitate active avoidance learning in rats (Belcheva et al., 
2000). Object recognition, avoidance response conditioning and locomotive behaviour all 
appear bettered by ANGII infusion. These effects are motor and anxiety driven (Braszko et al., 
1995). It appears that the anxiety driven effects occur via AT1R and AT2R stimulation but the 
motor coordination ANGII effect occurs exclusively via AT1R (Braszko et al., 2003, 1998). These 
studies have one shortcoming in that they did not use ANGII analogues incapable of 
hydrolysis. Thus, many of these beneficial effects could be due to the upregulation of its 
hydrolytic products ANGIII, ANGIV and ANG(1-7) acting through the Mas and AT4R. 
Other detrimental aspects of ANGII include the promotion of neurovascular coupling 
impairment mediated by NADPH oxidase ROS production via AT1R (Bloch et al., 2015). ANGII 
also down regulates ACE2 expression, as mentioned ACE2 hydrolyses Aβ and is responsible for 
production of MAS-axis BRAAS components (Koka et al., 2008). Over production of ANGII 
promotes the secretion of fibrotic factors from the extracellular matrix, including fibronectin 
and transforming growth factor β (TGFβ-1) and its receptors associated with fibrotic disease 
(Crawford et al., 1994; Gao et al., 2009). All of these factors are elevated in AD and result in 
impaired perivascular drainage and accumulation of Aβ along these routes (Lesné et al., 2003; 
Wyss-Coray et al., 1997). ANGII also upregulates RAGE-receptors via AT1R stimulation (Ihara 
et al., 2007) and possibly upregulates transcytotic influx of circulating Aβ. In AD mouse models 
ANGII induces increased production of Aβ via upregulation of BACE-1 via AT1R signalling. This 
occurs via AT1R upregulation of NFκβ, AP-1, and cAMP response element binding protein 
(CREB), which bind to the BACE1 promoter (Bourne et al., 2007; Roßner et al., 2006). Most of 
these transcription factors are also regulated by ANGII through the activation of glycogen 
synthase kinase-3 (GSK-3β), by increasing its Tyr216 phosphorylation (Agarwal et al., 2013). 
This kinase was discovered and studied for its role in insulin-mediated glycogen metabolism 
and its dysregulation is renowned for increasing tau pathology by hyper-phosphorylation 
(Godemann et al., 1999; Israel et al., 2012). Phosphorylation of GSK-3β at Ser9 induces 
deactivation, which is mediated through PI3-Akt signalling pathway, regulated by ANGII 
though AT1R as well as TGFβ-1 (Agarwal et al., 2013; Hughes et al., 1993; Rylatt et al., 1980). 
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1.6.2.1 The pros and cons of ACE inhibition in AD. 
Inhibition of the BRAAS has been suggested as a therapeutic avenue for the treatment of 
various neurodegenerative diseases including AD (Kehoe and Passmore, 2012; Kehoe and 
Wilcock, 2007; Savaskan, 2005; Wright and Harding, 2010). The benefits or risk posed by ACE 
inhibition in patients with AD remains a controversial topic (Kalra et al., 2015; Khachaturian et 
al., 2006; T Ohrui et al., 2004; Takashi Ohrui et al., 2004; Sink et al., 2009). There is a scarcity 
of clinical evidence on the benefits of ACE inhibitors in AD (Louis et al., 1999; T Ohrui et al., 
2004; Sudilovsky et al., 1993; Weiner et al., 1992). In small observational studies, ACEi have 
proven to slow the rate of cognitive decline in patients with mild cognitive impairment (MCI) 
(Ashby et al., 2009; Hajjar et al., 2008; Rozzini et al., 2006) including peripherally acting ACEi 
(Qiu et al., 2013). 
ACEi do not fit so comfortably within the collective grouping of a class. This term, class, is 
based on biological function not on structural or chemical basis (Morice et al., 1987). 
Subgrouping ACEi into inhibitors with brain penetrating abilities was also somewhat limited, 
as there are conflicting reports on the central acting abilities of some ACEi (Cushman et al., 
1982; Gohlke et al., 1989; Sakaguchi et al., 1987; Tan et al., 2005). However distinctions 
between ACEi chemical properties does appear significant, dicarboxyl-containing ACEi like 
enalapril and lisinopril are associated with a 73-83 % reduced risk of developing MCI in 
hypertensives (Solfrizzi et al., 2011).  
The cognitive enhancing effects of ACEi are inherently linked to reduced blood pressure and 
inflammatory responses, and all the AT1R mediated effects of ANGII mentioned above. Other 
substrates are elevated on ACE inactivation like substance P which increases NEP expression 
and BK which activates IDE, both being proteases of Aβ (Kehoe and Wilcock, 2007). There are 
also, non-ANGII related benefits to ACE inhibition based on all the downstream signalling 
events that may occur most notably the upregulation of PPARs by a potential increase in 
adiponectin. PPARγ decreases oxidative stress and reverses ANGII induced fibrotic effects 
(Hao et al., 2008) and is a known regulator of Aβ production by repressing BACE-1 
transcription (Sastre et al., 2003). PPARα increases the anti-amyloidogenic processing of APP 
by upregulating ADAM 10.  Furthermore, peripheral macrophages activation and 
proinflammatory responses are dampened by an increase in ACE expression which could be 
induced by the ACE signalling pathway (Kohlstedt et al., 2011).  
Unfortunately, most of the non-ANGII mediated responses have not been tested in neuronal 
cell lines. Furthermore, ACE inhibition has one startling drawback, that this would block the 
hydrolysis of Aβ.  Furthermore, the upregulation of BK receptors on ACE inhibition could have 
dire consequences in AD. Blockade of the B2R protects against the memory deficits induced by 
Aβ peptide in mice. The Aβ-induced neuroinflammation in human cell lines and mice can 
occur through the B2R and B1R (Bicca et al., 2015). Synaptic antagonism of these receptors 
reduced microglial activation and the levels of pro-inflammatory proteins like COX-2 and a 
decrease in JNK and p38 kinases (for a review Bicca et al., 2015; Viel and Buck, 2011). 
Modern clinical inhibitors for the treatment of hypertension are not domain specific and 
inhibit both domains of ACE (Cushman et al., 1973; Michaud et al., 1997; Ondetti et al., 1977; 
Sturrock et al., 2012). As these two catalytically active domains of human sACE, despite their 
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similarity in sequence, display marked differences in substrate specificity and thus are possibly 
independently responsible for varying functions. This has led to side effects associated with 
ACEi usage, mostly related to the potentiation of the BK response (Hecker et al. 1994; Hecker 
et al. 1997; Erdös et al. 1999). Within the context of AD, it is important to understand both the 
domain specificity of the Aβ hydrolysis and which downstream effects Aβ hydrolysis may 
trigger through ACE.  For without clear molecular mechanistic information definitively 
implicating ACE activity as either beneficial or detrimental, the therapeutic implications of 
ACEi in AD are ambiguous.  
1.7 Research Questions. 
 Hypothesis statement.  1.7.1
The ACE substrate Aβ’s domain selectivity is driven by the presence of unique N- and C-
domain active site residues as well as the structural arrangement and cooperative effects that 
are found in sACE. Furthermore, upregulation of ACE protein expression may be augmented 
through the binding and hydrolysis of Aβ. 
 Aims and objectives.  1.7.2
The aim of this work is to further elucidate the structure-function and signalling relationship 
of ACE with the Aβ substrate through the development of a comparative enzyme kinetic 
assessment system. This includes the kinetic assessment of residues which contribute to Aβ 
processing. Furthermore, to determine any larger synergistic effects that the two domains 
may induce towards Aβ substrates as well as mammalian cell signalling effects of Aβ mediated 
by ACE. 
 
1.7.2.1 The objectives of the current studies are as follows:  
1. To investigate the cleavage specificity of Aβ peptides by the N- and C-domain catalytic 
sites of ACE across numerous ACE truncated and full-length variants.  
2. To kinetically assess the effect that active site residues contribute to domain-selective 
hydrolysis of Aβ using active site C-domain mutants with unique residues converted to 
their corresponding N-domain counterparts. 
3. To investigate any cooperative and selective effects that the sACE domain 
conformation may have on various N-terminal peptides of Aβ. 
4. To determine if Aβ affects ACE protein expression through the ACE signalling cascade. 
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2 CHAPTER 
Characterisation of Aβ cleavage by ACE variants. 
2.1 Introduction and aims 
Cardiovascular insult has been proven clinically, epidemiologically and pathologically to 
associate with AD and cognition.  However, with regard to the implication of ACE with AD, one 
might say that it may be a result of happenstance and perhaps circumstantial evidence 
through the years (See Chapter 1 section 1.6 for more associations of ACE with AD). In 2001, 
Hu et al provided the first concrete mechanistic link between ACE and AD.  Although clearly an 
irrefutable association, the cleavage of Aβ by ACE proved in the last decade to be more 
complicated than it appeared.  
In the study by Hu et al., in vitro purified sACE cleaved synthetic Aβ(1-40) at the Asp7-Ser8 
bond followed by further degradation (Hu et al., 2001).  The resulting product, a 33-residue 
peptide, had reduced aggregation, deposition and cytotoxicity profiles (Hu et al., 2001).  This 
was followed by efforts to characterise which domain of ACE was responsible for this 
cleavage, as it is well known that the two domains of ACE have varying substrate specificities 
(Araujo et al., 2000; Bernstein et al., 2013, 2011; Deddish et al., 1998, 1997; Fuchs et al., 2008; 
Jaspard et al., 1993; Rice et al., 2004; Rousseau et al., 1995; Shen et al., 2012; Tzakos et al., 
2003; Zou et al., 2009). Oba et al., used soluble His-tagged constructs of sACE and the N- and 
C-domains to show that the catalytic activity of sACE and Ndom, but not Cdom, caused
reduced Aβ aggregation and PC12h cell cytotoxicity (Oba et al., 2005). Characterisation of the
cleavage of the Aβ(1-40) revealed that the major product, generated by sACE and the N-
domain was the Aβ(8-40) peptide (Oba et al., 2005). They also determined that Aβ(1-7)
underwent further degradation by the N-domain after initial cleavage at the Asp7-Ser8 site
(Oba et al., 2005). The N-selectivity of cleavage was corroborated through the investigation of
synthetic Aβ(1-16) peptide and its modified Asp7 isomer (Aβ(1-16)-L-iso-Asp7), cleaved
between residues Arg5 and His6 by the N-domain (Toropygin et al., 2008). However, the C-
domain of ACE failed to hydrolyse either peptide variant (Toropygin et al., 2008).
Later the truncated N-domain was again shown to be selective towards Aβ(1-42), only 
cleaving in an exopeptidase fashion, converting the more toxic Aβ(1-42) to the Aβ(1-40) 
peptide (Zou et al., 2009, 2003). The specificity of the N-domain cleavage after Val40 was 
confirmed using domain inactivated mutants and western blotting, indicating that the N-
domain controlled this protective effects of this ratio (Zou et al., 2009).  The truncated C-
domain also hydrolysed the Aβ(1-42) peptide, at residues, Ala21, Val24, Lys28 and Gly33 
however (Zou et al., 2009, 2007). Thus, one cannot refute that the results from this study also 
implicate the C-domain in the cleavage and hydrolysis of Aβ. The authors proposed that the 
observed cleavage pattern was due to the use of full-length wild type human sACE with the 
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transmembrane region attached; as opposed to the seminal plasma secreted sACE and soluble 
recombinant constructs used by Hu et al and Oba et al, respectively. 
In contrast, Hemming and Selkoe implicated both the C and the N-domain of ACE in the 
hydrolysis of Aβ(1-40) and Aβ(1-42) (Hemming and Selkoe, 2005).  The ACE constructs used in 
this instance were discrete domain knockout mutants, wherein the N-or C-domain in sACE had 
been catalytically inactivated.  Here the N- and C-domains as well as wild type sACE decreased 
cell-derived Aβ levels equally and the effects were abrogated on treatment with captopril. 
 
In a study on the species specificity of sACE cleavage of Aβ, using human and mouse forms of 
the enzyme and substrate, Sun et al (2008) confirmed that ACE hydrolysed the N-terminal 
region of Aβ in both species despite differences in the N-terminal region of the peptide. They 
determined that murine ACE hydrolysed the human Aβ(4-15) peptide at positions Glu11-Val12 
and His13-His14 and that human Aβ was a better substrate of murine ACE. These cleavage 
sites were consistent across both wild type murine ACE, N- and C-domain active site knockout 
variants.  They then interrogated the human Aβ(1-40) with human ACE and confirmed Zou et 
al’s Lys28-Gly29 cleavage but also identified sites after residues Leu34, Ser26, Glu22 and 
Phe20. They concluded that there was no difference between the two domains of murine ACE 
in the rate of hydrolysis, nor domain specificity to the Aβ(1-15) peptide (Sun et al. 2008).  
The disparate number of cleavage sites of ACE towards Aβ (Figure 2.1) once again reiterates 
how little we know mechanistically about the substrate specificity of this enzyme and its two 
domains. With such a large amount of varying cleavage site data throughout the literature, it 
is very important to qualify which species of both enzyme and peptide one uses; as well as 
establish cleavage sites specific to experimental models, in order to perform any further 
enzymatic characterisation. 
The Aβ(1-42) peptide is notoriously difficult to work with because of its insolubility and 
subsequent ability to form fibrils.  The Aβ(1-42) has what is known as the central hydrophobic 
cluster (CHC) (Aviles et al., 2006).  Residues 17 to 21 (LVFFA) form the core of the CHC and are 
said to be important in aggregation since the peptide gains some solubility upon substitution 
 
 
 Figure 2.1 Cleavage specificity towards Aβ. Diagram illustrating the multiple cleavage sites of various 
ACE constructs throughout literature over the last decade and a half.  The colour coded author- 
cleavage site key is on the right hand side of the Aβ(1-42) amino acid sequence. 
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of any two residues (Hilbich et al., 1992).  This CHC segment of the Aβ(1-42) also appears to 
form part of the β-sheet core of mature fibrils (Morimoto et al., 2004; Williams et al., 2004).  . 
There are numerous reasons why the N-terminus of Aβ is indeed important and relevant to 
study (see Chapter 1 section 1.2.2).  It contains residues which form the zinc chelating group 
of Aβ, which include Asp7, His6, Glu11, His13 and His14 (Zirah et al., 2006). The Aβ(1-16) 
peptide itself contains the His6, Glu11, His13 and His14 residues which are key to the 
formation of inter-amyloid zinc binding, creating greater stability and peptide rigidity 
(Minicozzi et al., 2008).  As any ACE assay requires Zn2+, we thought it prudent to derive a 
shorter peptide with greater flexibility that retains the Zn2+ chelating ability without the inter-
molecular stacking that occurs in the Aβ(1-16).  Hence, the design and use of Aβ(2-11) 
peptide, which has increased flexibility, maintains some Zn2+ coordination and less defined 
secondary structure, making it more susceptible to proteolysis.  To determine kinetics and the 
selectivity of the individual domains of ACE one needs a more malleable substrate. The Aβ(2-
11) and Aβ(1-16), would hence allow for the study of the physiologically significant N-terminal 
region of Aβ, which as mentioned above is prime “cleavage ground” for ACE. 
The lack of consensus and explanation throughout the literature on the subject of domain 
selectivity and lack of specific cleavage towards Aβ, prompts the further characterisation of 
molecular mechanism that occurs with different ACE constructs in Aβ cleavage.  
Aims and Objectives: 
The overall aim of this chapter is to investigate the cleavage of Aβ peptides by the N- and C-
domain catalytic sites of ACE. 
The objectives used to achieve this aim include: 
1) To express and purify all ACE variants used in this study. 
2) To investigate the mode of hydrolysis, and domain specificity of Aβ(2-11) cleavage by 
the N- and C-domains of ACE using HPLC. 
3) To design fluorogenic Aβ substrates that mimic larger Aβ cleavage sites of ACE 
4) To determine the primary cleavage sites of various Aβ peptides using mass 
spectrometry 
5) Determine the crystal structure of various Aβ peptides bound to the N-domain. 
6) To characterise the cleavage site preference of ACE in the hydrolysis of Aβ peptides 
using truncated and full-length ACE constructs. 
  
Kate Larmuth CHAPTER 2 Characterisation of Aβ cleavage 
38 
2.2 Methods: 
 Enzyme constructs 2.2.1
All construct DNA was prepped in DH5α E.coli and DNA extracted as in appendix section 7.2. 
All upscale preparations for transfection of construct DNA, barring CC-sACE, was performed 
using the Plasmid Midi kit (QIAGEN, USA). 
2.2.1.1 Soluble Truncated Constructs 
2.2.1.1.1 Wild type C-domain (Cdom) 
The wild type tACE construct used throughout this thesis is the fully N-glycosylated tACE∆36NJ 
mutant.  This lacks the transmembrane region, truncated after residue S625, as well as the 
unique 36 amino acid N-terminus (Yu et al., 1997).  This construct is identical to the C-domain 
of sACE and will be referred to as Cdom (Figure 2.2) 
2.2.1.1.2 Wild type N-domain (Ndom) 
A soluble form of the N-domain, consisting of amino acids 1 to 629 (Ndom629D)of somatic 
ACE, in vector pECE was a kind gift from Dr S. Danilov (University of Illinois, Chicago) 
(Balyasnikova et al., 2003; Corradi et al., 2006).  Ndom629D comprises of a signal sequence of 
36 residues (not present in the mature enzyme), targeting the protein for secretion, followed 
by the first 629 residues of sACE.  A soluble form of Ndom629D was created in our lab 
(Redelinghuys, 2006) and is identical to the N-domain of human somatic ACE and will be 
referred to as Ndom (Figure 2.2). 
2.2.1.2 Full-length Constructs: 
2.2.1.2.1  CC-sACE 
CC-sACE was constructed in our group as previously described (Woodman et al., 2005) via an
elaborate cloning strategy.  Essentially, CC-sACE consists of two C-domains joined by the sACE
inter-domain linker region; it also contains the juxtamembrane stalk, transmembrane (TM),
and cytoplasmic regions (Figure 2.2)
2.2.1.2.2 Membrane bound sACE Constructs 
2.2.1.2.2.1 Wild type sACE 
The wild type human sACE genetic sequence encodes the entire ACE coding region including 
the signal sequence, N- and C-terminal catalytic domains, the TM region and the cytoplasmic 
tail (Figure 2.2). This construct, pcDNAsACETM, was created by Kerry Gordon (Gordon, 2011). 
2.2.1.2.2.2 Domain inactivated sACE constructs: C-sACE and N-sACE 
The full-length domain knock outs of sACE, both in pECE, were a kind gift from Vincent Dive 
and were constructed by Wei et al., 1991., through site directed mutagenesis (Taylor et al., 
1985).  For the construction of N-sACE, the His361 (CAT) and His365 (CAT) residues were 
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converted to Lys (AAG and AAA respectively).  Similarly, C-sACE was generated by mutating 
sites His959 (CAC) and His963 (CAC) to Lys (AAA and AAG respectively). 
Both constructs have the complete signal, TM and stalk regions corresponding to full-length 
sACE (Figure 2.2). Each construct was sent for sequencing to confirm the integrity and identity 
of the mutants. This was performed by capillary sequencing and was conducted at the Central 
Analytical Facility (CAF) (Stellenbosch University, South Africa) using internal sACE sequencing 
primers (Appendix A1). 
Figure 2.2 Schematic of ACE constructs used. The wild-type ACE (sACE) contains a signal peptide (left 
black box), the two homologous ectodomains (the N-domain in grey and the C-domain in black) with 
the indicated active site residues necessary for the coordination of Zn. Also indicated is the stalk region 
just prior to the transmembrane domain (right shaded box) and finally the cytoplasmic region (CR) at 
the C terminus. The truncated Ndom contains the signal peptide and the N domain. The truncated 
Cdom is essentially the same as the C-domain in wild type sACE only it lacks the transmembrane region 
and has the added signal peptide. The domain inactivated mutants are identical to sACE except for the 
mutation of the catalytic His residues to Lys (white boxes) in the N-domain (N-sACE) and C-domain (C-
sACE). The CC-sACE construct is a fusion construct, via the linker region, of a C-domain to the N-
terminal C domain (two black domains).  
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Protein expression and purification 2.2.2
The CHO-K1 (Chinese hamster ovary (CHO)) mammalian cell line was used as a model system 
for expression of all ACE variants.  CHO-K1 cells were cultured at 37°C, 5 % CO2 and 80 % 
relative humidity levels in various flasks and dishes.  All tissue culture flasks and dishes were 
supplied by Nunc Ltd. 
2.2.2.1 Mammalian cell expression of ACE enzymes 
Prior to transfection, CHO-K1 cells were grown to 60-80 % confluency in 10 cm dishes. 
Transfection of the ACE constructs was performed according to manufacturers’ instructions 
using the calcium phosphate Profection® Mammalian Transfection System (Promega Corp.). 
This entailed application of fresh serum growth medium, 3-4 hours prior to transfection, to 
the 60 % confluent cells.  Actual transfection of the cells required 15-20 ug of pcDNA construct 
DNA to be precipitated via drop-wise addition to CaCl2. This DNA precipitation mix was 
incubated for 30 min at room temperature before once again being added to the 10 cm dish 
of cultured cells in a drop wise fashion. These cells were incubated for 4 hours, following 
which they underwent glycerol-shock for 2 min to facilitate the uptake of DNA. The cells were 
then washed and normal growth medium was added for 24 hours post transfection. After this, 
they were grown to confluency in growth medium containing 0.8mg/ml geneticin G418 
(Sigma-Aldrich Co.) to select for positive clones.  Cells were grown in the presence of selective 
medium and showed clear negative control plates (no vector DNA added) with G418 resistant 
colonies observed in the transfected plates.  Colonies were picked, seeded into 12 well plates, 
grown to confluency and assayed for ACE activity using benzyloxycarbonyl-Phe-L-His-Leu (Z-
FHL) assay (see section 2.2.3.1). The highest expressing clones were then reseeded into T-
75 cm2 flasks and grown to confluency. 
2.2.2.2 Selection of high expressing cells lines 
Fluorescence-activated cell sorting (FACS) is a specialized form of flow cytometry used to sort 
heterogeneous mixtures of cells based on their cell wall protein profiles. It provides a means 
to physically separate cells more heavily labelled with fluorescent ACE specific antibody, from 
those which have fewer labels and hence lower ACE expression. This technique was applied to 
all sACE TM constructs to aid in the selection of high expressing transfected CHO clones. 
For FACS analysis, transfected and control untransfected cells were lifted from confluent T-75 
cm2 flasks and washed twice in phosphate-buffered saline (PBS).  The cells were then labelled 
via 1 hour incubation with 10 µg/ml mouse antibody 5C5, which is a monoclonal antibody 
specific to the N-domain of ACE. Extensive washing in PBS was performed to remove any 
unbound primary antibody. A secondary antibody was then added to the cells and allowed to 
incubate for an hour in the dark, which was followed again by extensive washing.  This 
secondary antibody is a chicken anti-mouse IgG antibody coupled to a modified fluorescein 
isothiocyanate (FITC) Alexa Fluor® 488 (abcam®).   
FACS was performed, on the labelled cells in PBS suspension, at the Flow Cytometry Core 
Facility (Department of Immunology, UCT, South Africa). The machine used was a FACS 
VantageTM SE cytometer (BD Biosciences, USA).  Cells were gated according to highest 
fluorescence directly into growth medium supplemented with 100 U/ml penicillin and 
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100 µg/ml streptomycin. The sorted cells were grown to confluency in T-75 cm2 flasks under 
selective medium and assayed for ACE activity. Thus, high expressing sACE TM construct cell 
lines were generated; stocks were made and were subsequently flash frozen in liquid 
nitrogen. 
2.2.2.3 Isolation of secreted ACE protein from growth media 
Standard practice of ACE purification within our group is as such: clonal cell lines of CHO-K1 
cells overexpressing soluble forms of ACE were grown in T175 cm flasks with growth medium. 
Once confluent, the medium was replaced with minimal medium (50 % DMEM, 50 % Ham’s 
F12, 20mM HEPES, 2 % FCS (heat-inactivated for a further 15min at 70°C)) and harvested 
every 48-72 hours until ACE protein over expression becomes compromised by the cells 
survival response (routinely until harvest 7 or 8). Harvested media is pooled and, if not 
immediately required, stored at -20°. 
Affinity chromatography was used to purify all constructs. The non-selective ACE inhibitor 
Lisinopril has been coupled, via its P1’ Lys group and linker, to sepharose beads creating an 
ACE specific affinity column (Ehlers et al., 1991). This allows for a convenient one step affinity 
chromatography purification (Bull et al., 1985; El-Dorry et al., 1982) of ACE from harvested 
media.  Columns were equilibrated in wash Buffer (20 mM HEPES, pH 7.5, 0.5 M NaCl), prior 
to loading harvested media, for approximately 30 minutes. The media was then loaded on and 
passed over the column, at a flow rate maximum of 0.5 ml/ min. The column is subsequently 
washed overnight with the same wash Buffer to remove any impurities and non-specific 
protein binding. 
All ACE constructs were eluted on addition of elution buffer (50 mM borate buffer pH 9.5) in 
1.5 ml fractions. These fractions were assayed for ACE activity (section 2.2.3.1). Those with the 
highest activity readings were pooled and dialysed overnight, through SnakeSkin® pleated 
dialysis tubing (Pierce Biotechnology Ltd) at 4°C, in 2 L of dialysis solution [5 mM HEPES, 
pH 7.5, 0.1 mM PMSF (in ethanol)]. A second 6 hour dialysis was then performed in fresh 
dialysis buffer. Post dialysis, protein concentrations were calculated using the BIORAD 
Bradford reagent (BioRad Laboratories Inc.) in the Bradford assay (Bradford, 1976) as per 
manufacturer’s instruction. Proteins were concentrated down using 30 kDa Amicon Ultra-15 
centrifugal filters (Merck Millipore) and buffer exchanged into 50 mM HEPES (pH 7.5). Activity 
of the purified ACE protein was assayed (section 2.2.3.1) and the integrity, size and purity 
were analysed on a 10 % polyacrylamide sodium dodecylsulphate gel following 
electrophoresis (SDS-PAGE) (Laemmli, 1970).  Finally, aliquots of protein were stored at 4 and 
-20°C.  
2.2.2.4 Isolation of transmembrane protein from cell lysis: 
A modified purification procedure was developed to increase the amount of protein 
generated for all TM constructs. Natural secretase induced secretion into the cell growth 
medium was not sufficient, despite FACS selection of high expressing clones. Cells, expressing 
high levels of TM sACE, were grown to confluency in six T-150 cm2 flasks and lysed in 5ml 
triton lysis buffer (0.05 M HEPES, 0.5 M NaCl, 1% triton X-100, 1 mM PMSF) containing 
Protease Inhibitor Cocktail (Set III, Calbiochem, USA - 0.2 mM AEBSF, 0.16 M Aprotinin, 
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0.01 mM Bestatin, 3 µM E-64, 4 µM Leupeptin and 2 µM Pepstatin A). Flasks were left to 
incubate at 0°C for 30 minutes before the whole-cell lysates were scraped from the flasks, 
pooled, centrifuged at 10000 x g for 5 minutes and the supernatant extracted.  
In total, approximately 30 ml of cell lysate was extracted. This was subsequently diluted 1:2 
into Wash Buffer and syringe filtered through a 0.8 µm filter, to ensure no cell debris 
remained prior to loading the affinity column. The lysates were kept on ice at all times and 
sample aliquots were tested for ACE activity, at each step, to ensure that no loss of protein 
occurs prior to purification. Purification of all TM sACE constructs was carried out using the 
same ACE specific lisinopril affinity column chromatography process as previously mentioned 
(Section 2.2.2) (Ehlers et al., 1991).  
Columns were equilibrated in wash buffer, for approximately 30 minutes, prior to loading 
harvested and cleaned lysate. The lysate was, loaded on and passed over the column at a flow 
rate maximum of 0.5 ml/min. The column was then washed with approximately 200 ml of the 
same wash buffer to remove any impurities and non-specific protein binding. Elution 
procedure occurs as above (section 2.2.2.3). However, a slightly longer elution step was 
required if multiple TM constructs are to be purified in one sitting to ensure the column is 
clean. This was performed to avoid cross contamination of  separate constructs. 
 Synthetic ACE substrates  2.2.3
2.2.3.1 Z-FHL ASSAY 
ACE activity can be measured by assaying the fluorescent adduct of the cleaved product His-
Leu (HL), from either ZFHL or hippuryl-L-histidyl-L-leucine (HHL) synthetic substrate. This assay 
was developed by Friedland and Silverstein (1977) and adapted according to Schwager et al. 
(2006). The generation of HL from ZFHL (Bachem, Ltd) was assayed in 96-well plates with 30 µl 
of 1mM ZFHL in phosphate buffer (100 mM KHPO4/KH2PO4 (pH 8.3), 300 mM NaCl, 10 µM 
ZnSO4) and 6 µl of medium or 3 µl of cell lysate (1 in 10 dilution is usually appropriate). 
Samples were incubated at 37°C for 15 (C-and N-domain mutants) or 20 minutes (sACE and 
sACE mutants). The endogenous fluorescence of the sample and assay constituents was 
accounted for by the inclusion of a blank zero time (BZT).  
The reaction is stopped via addition of 125 µl of 0.4 M NaOH. The cleavage product HL is 
converted to a fluorescent adduct on addition of 10 µl of o-phthalaldehyde (24 mg/ml) whilst 
shaking, in the dark, at room temperature for 10 minutes. This reaction is stopped on addition 
of 30 µl of 3 M HCl. The resulting fluorescence was measured on a Cary Eclipse fluorescence 
spectrophotometer (Varian Inc.) at 360 nm excitation wavelength and 485 nm emission 
wavelength. The fluorescence readings, conducted in triplicate for each sample, were 
converted to ACE activity (mU) with the use of an HL standard curve (see appendix 7.5.1).  ACE 
activity (Unit) is defined as the amount of nmols of HL produced per ml of sample, per minute 
(nmols/ml/min).  
  
CHAPTER 2 Characterisation of Aβ cleavage  Kate Larmuth 
43 
2.2.3.2 HL Standard Curve 
For the conversion of fluorescent intensity units to nmols of HL product liberated from a ZFHL 
or HHL reaction, a HL standard curve is required. Construction of this curve was carried out as 
described in (Schwager et al., 2006). Briefly, a 5 mM stock of HL (Sigma-Aldrich Co.) dissolved 
in water was made. A 0.5 mM working stock of this was made up in phosphate buffer. A 
dilution series of this 0.5mM working stock was performed in phosphate buffer in a 96-well 
plate in 30 µl aliquots. From this step onwards, the HL fluorescence assay commenced (see 
section 2.2.3.1) with the addition of 0.4 M NaOH. Linear regression analysis was used to 
correlate the change in fluorescence to the nmols of HL product formed (see appendix 7.5.1) 
 HPLC 2.2.4
HPLC of the Aβ(2-11) substrate was performed using a C18 Jupiter column. To determine 
progress curves for the hydrolysis of Aβ(2-11), 2 nM Ndom and 200nM Cdom (100-fold excess) 
were incubated with 44 µM Aβ(2-11) in IX HEPES assay buffer (50 mM HEPES buffer, 300 mM 
NaCl, 10 µM ZnSO4) for varying periods of time at 37°C. Reactions were stopped on addition of 
50 µl 1.25 % trifluoroacetic acid (TFA). The final reaction volume was 250 µl.  Samples were 
separated by HPLC over a gradient of 4 % to 40 % ACN (in 0.1 % TFA). Absorbance was read at 
λ = 225nm which is the determined absorbance maximum for Aβ(2-11).  
The hydrolysis of Aβ(1-16) was assessed via HPLC chromatography. Reactions had final 
volumes of 50 µl and were performed at 37ºC in IX HEPES assay Buffer. The reactions were 
stopped with the addition of 10 µl of 0.25% TFA. The comparison of cleavage site specificity 
across ACE subtypes, for both 15 minute and 24 hour incubations, were performed with 
enzymes concentrations determined under kinetic assay conditions (See Chapter 4).  Samples 
were analysed on the Agilent 1260 Infinity HPLC at a multiple wavelengths simultaneously, 
however λ=214 nm was adequate for detection of product peaks. The total reaction (60 µl) 
was cleared of contaminants on a spin column (GHP Nanosep® MF Centrifugal Device 0.45 µm 
pore size) prior to being run on the column. Mixtures were separated on a Poroshell 120 EC-
18 column with a 2.7 micron pore size over an isocratic gradient of 40% ACN in 0.1% TFA.  
All sample runs, per peptide, were compared to those with buffer only and substrate only.  
 Mass Spectrometry analysis of Aβ peptides 2.2.5
2.2.5.1 Sample clean up procedure 
Fractions corresponding to product and substrate peaks on the HPLC chromatograms were 
collected, dried down and resuspended in 20 µl of a 60 % ACN, 0.1 %TFA solution prior to 
MALDI-TOF analysis. Whole peptide reactants not collected from HPLC fractions were cleaned 
over a C18- Zip Tip’s (Millipore™) as per manufacturer’s instructions. 
2.2.5.2 Mass Spectrometry 
The Mass spectrometry was analysed at the Centre for Proteomic and Genomic Research 
(CPGR, Cape Town, South Africa). The collected peptides were spotted onto a 10 mg/ml α-
cyano-4-hydroxycinmanic acid matrix (Fluka, USA) in 80% ACN, 0.2% TFA for a final 
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concentration of 5mg/ml matrix in 40% ACN, 0.1% TFA, and 10 mM NH4H2PO4.  Mass 
spectrometry was performed with a 4800 MALDI TOF/TOF (Applied Biosytems) with all 
spectra recorded in positive reflector mode. Spectra were generated with 400 laser 
shots/spectrum at a laser intensity of 3800 (arbitrary units) with a grid voltage of 16kV. 
 X-ray Crystallography 2.2.6
Crystallization of the Ndom with various Aβ peptides was performed by collaborators Prof K. 
Ravi Acharya and Dr G Masuyer (Department of Biology and Biochemistry, University of Bath, 
Bath, United Kingdom). Crystals were generated through co-crystallization with 1 μl of 2.5 mM 
peptide mixture (5-10 mg/ml in 50 mm HEPES, pH 7.5, 0.1 mm PMSF). The peptides Aβ(1-16) 
(Sigma, SCP0052), Aβ(10-16) (Sigma, SCP0031), Aβ(4-10) (GenScript, RP20173), Aβ(35-42) 
(GenScript RP20145), and Aβ(4-10)Y were used. Crystals were grown in an equal volume of 
reservoir solution consisting of 30 % PEG550 MME/PEG20000, 100 mM Tris/Bicine, pH 8.5, 
and 0.06 M divalent cations (Molecular Dimensions) and suspended above the well as a 
hanging drop. Crystals of better quality were obtained after 2-3 cycles of macro-seeding.  
Prof K. Ravi Acharya and Dr G Masuyer also performed all diffraction studies and solved the 
Ndom- Aβ structures. X-ray diffraction data were collected on station IO3 at the Diamond 
Light Source (Oxon, UK). Crystals were kept at constant temperature (100 K) under the liquid 
nitrogen jet during data collection. Images were collected using a PILATUS-6M detector 
(Dectris, Switzerland). Raw data images were processed and scaled with MOSFLM (Leslie and 
Powell, 2007), and SCALA using the CCP4 suite 6.5 (CCP4, 1994). Initial phases for structure 
solution were obtained using the molecular replacement routines of the PHASER program 
(McCoy et al., 2007). The atomic coordinates of N-domain (PDB code 3NXQ (Anthony et al., 
2010) were used as a search model for structure determination. The resultant models were 
refined using REFMAC5 (Murshudov et al., 1997). Manual adjustments of the model were 
carried out using COOT (Emsley et al., 2010).  
Water molecules were added at positions where Fo−Fc Fourier difference electron density 
peaks exceeded 3σ, and potential hydrogen bonds could be made. Validation was conducted 
with the aid of the program MOLPROBITY (Chen et al., 2010). Crystallographic data statistics 
are summarized in Table 2.4. All figures were drawn with PyMOL (Schrödinger, LLC, New 
York). Hydrogen bonds were verified with the program LigPlot+ (Laskowski and Swindells, 
2011). 
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2.3 Results: 
Protein purification of ACE constructs 2.3.1
The human sACE, C-sACE, N-sACE, Ndom, Cdom and CC-sACE variants (Figure 2.2) were 
expressed in mammalian CHO cells and then purified using lisinopril-sepharose affinity 
chromatography. The sACE, C-sACE and N sACE constructs are expressed as membrane-bound 
proteins and undergo poor ectodomain shedding (Kost et al., 2003; Pang et al., 2001; 
Woodman et al., 2006, 2000). Hence, these constructs were purified directly from cell lysates 
of stably transfected cell lines. CC-sACE is also membrane bound, but is shed much more 
efficiently than the other TM constructs and thus was purified from the culture medium. All 
ACE variants were purified to apparent homogeneity as assessed by SDS-PAGE (Figure 2.3).  
The sACE proteins migrated at approximately 170 kDa, while the recombinant glycosylated 
Ndom and Cdom migrated with an apparent molecular mass of 100 kDa and 90 kDa, 
respectively. It is known that CC-sACE is less stable than other sACE constructs, as can be seen 
by a small band at approximately the same size as Cdom (Woodman et al., 2006).  
Figure 2.3 Purified ACE constructs. The affinity-purified preparations of 
recombinant human ACE (approximately 10 µg of protein each) were analysed by 
SDS-PAGE as described in the Materials and methods section. Molecular-mass 
markers (kDa) are indicated mid gel.  
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The hydrolysis of Aβ(2-11)by Ndom and Cdom 2.3.2
2.3.2.1 Analysis of product peaks over time: 
The Ndom was employed to determine what concentration of enzyme was necessary to 
produce sufficient product for further kinetic analysis. On incubation of Aβ(2-11) with 
increasing amounts of Ndom, two product peaks were formed: P22 and P10 at retention times 
22 and 10 minutes, respectively (Figure 2.4). It is likely that P22 is the primary product as with 
higher concentrations of Ndom substrate P22 is further converted to P10 (Figure 2.4 F). 
Sufficient P22 product was measured after 15 minute incubation with 2 nM Ndom. To 
investigate the hydrolysis of Aβ(2-11) by Ndom and Cdom, a time course of Aβ(2-11) 
incubated with Ndom and Cdom was carried out; and the relative increase of product and 
decrease of substrate was compared (Figure 2.5). Notably, 2 nM Ndom produced a substantial 
(13 % of total substrate injected) amount of product (P22), with a peak area of 146 917, after 
5min incubation while zero product was generated by the Cdom at a concentration of 
100 nM.  
Figure 2.4 Sequential break down of Aβ(2-11) by Ndom. Overlaid HPLC traces of 
44µM Aβ(2-11) digested with N-domain for 15 minutes at 37°C to determine 
concentration of enzyme required to generate a product peak (P22) within 10% 
hydrolysis of substrate (S23). A) Substrate Aβ(2-11); incubated with B) 2 nM 
Ndom; C) 10 nM Ndom; D) 22 nM Ndom; E) 28 nM Ndom; F) 100 nM Ndom.  
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With 2nM of Ndom, complete hydrolysis of Aβ(2-11) was achieved in 3 hours; however Cdom 
(125 nM) required 20 hours of incubation. These data show that the Ndom is far more 
efficient at Aβ(2-11) hydrolysis than the Cdom and provided a basis for continuing with the Aβ 
peptide cleavage site analysis. Kinetic analysis of the ACE variants hydrolysis of different Aβ 
peptides is presented in the following Chapters 3 and 4. 
 
 
 
 
  
   
Figure 2.5 Digestion of Aβ(2-11) by the N and C-domain. The integrated peak area of Aβ(2-
11) substrate (S23) digested with: A)The Ndom construct and B) The Cdom construct over 
time. The Aβ(2-11) proving a better substrate for the Ndom as seen by the rapid formation 
of product peaks P22 and P10  
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 ACE cleavage-site analysis of Aβ peptides 2.3.3
2.3.3.1 N-terminal peptide Aβ(2-11). 
The N-domain cleavage site on Aβ(2-11) was ascertained using HPLC of the cleavage products 
(Figure 2.4) followed by MALDI-TOF mass spectrometry. The results indicated that the primary 
cleavage site (P22) under substrate saturating conditions, was between residues Asp7 and 
Ser8, evident from the corresponding m/z fragment detected (Table 2.). This was confirmed 
by MS/MS analysis of the product Aβ(2-7). Thus, ACE has an endopeptidase action on this 
peptide. The P10 peak did not reveal any peptides with a signal above the matrix background. 
It is hence most likely that P10 consists of much smaller peptide degradation products.  
2.3.3.2 Design of small fluorescence resonance energy transfer (FRET) 
Aβ(4-10) mimics of Aβ(2-11). 
Based on the Aβ(2-11) cleavage site, fluorogenic versions of the amyloid beta peptide were 
designed, namely: Aβ(4-10)Q with an N-terminal, o-aminobenzoic acid (Abz) donor group and 
a C-terminal, ethylenediamine 2, 4-dinitrophenyl (EDDnp); and with an alternative 
3-nitrotyrosine quenching group, Aβ(4-10)Y. These fluorogenic substrates are described in the 
following chapters, where they were used to further characterise the cleavage of Aβ by the 
Ndom and Cdom catalytic sites (Chapter 3 and 4). 
 
2.3.3.3 Physiological Aβ(1-16) peptide  
Cleavage of the Aβ(1-16) peptide was investigated using the truncated Ndom variant.  The 
HPLC chromatogram of the hydrolysis of Aβ(1-16) by the Ndom indicated a product peak 
(P5.8) that eluted slightly later than the substrate (S5.6) (Figure 2.5 B). This shift suggests a 
slight increase in hydrophobicity of the product peptide. Substrate and product peaks were 
collected and subjected to mass analysis (Table 2.) which indicated the loss of the last two 
residues of Aβ(1-16) consistent with a slight loss of hydrophilicity. Thus, ACE functions as a 
dicarboxypeptidase towards this substrate, cleaving between residues His14–Gln15 and 
liberating Aβ(1-14) as the P5.8 primary product (Figure 2.6). This product had an observed 
mass corresponding to Aβ(1-14) (Table 2.).  Although Aβ(1-16), like Aβ(2-11), is comprised of 
the N-terminal region of Aβ(1-42), they have different cleavage sites. 
Table 2.1 Primary cleavage sites of Aβ(2-11) and Aβ(1-16). The MALDI-TOF analysis of Aβ(2-11) and 
Aβ(1-16) digested with 2 nM Ndom for 15min. The substrate and cleavage sites corresponds toS23 
and P22 for Aβ(2-11) and S5.6 and P5.8 for Aβ(1-16) respectively. 
 
 
 
Amyloid Peptide Peptide Residues
Calculated 
m/z 
Observed 
m/z
Aβ(2-11) Substrate  Ac-AEFRHDSGYE-NH2 1252.53 1251.55
Product  Ac-AEFRHD 816.37 816.38
Aβ(1-16) Substrate H-DAEFRHDSGYEVHHQK-OH 1954.88 1954.88
Product H-DAEFRHDSGYEVHH 1698.73 1698.58
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Figure 2.6 Ndom hydrolysis of Aβ(1-16). The HPLC chromatogram of  A) The 
substrate Aβ(1-16), incubated for 30  minutes without enzyme. B) Aβ(1-16) 
incubated with 1 nM Ndom for 30 minutes, the substrate peak is indicated as S5.6, 
and the product peak is indicated as P5.8. C) The chromatogram of the buffer 
constituents used in the enzyme reaction.  
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2.3.3.4 Cleavage site specificity of the various forms of ACE  
To determine the bond at which the β-amyloid peptides were cleaved by the different ACE 
variants, each substrate was incubated under the stated assay conditions (see Chapter 3 
and 4) and the resultant peptide products were purified and analysed by MALDI–TOF MS.  The 
FRET peptides constructed from Aβ(2-11) (Table 2.), Aβ(4-10)Q and Aβ(4-10)Y, yielded a 
product with a m/z (Table 2.2) corresponding to the N-terminal Abz-FRHD, on digestion with 
Ndom, N-sACE, C-sACE and sACE. Thus, both FRET Aβ(4-10) peptides were endoproteolytically 
cleaved at the Asp7-Ser8 bond in the same fashion as the non-FRET parent peptide Aβ(2-11) 
(Table 2.2). The Cdom and CC-sACE cleavage sites were not analysed, as hydrolysis of the Aβ 
peptides by these ACE variants under assay conditions was negligible. All four constructs 
cleaved these short synthetic peptides at the same position with no apparent difference in 
specific cleavage preference between the Ndom and Cdom. Hydrolysis of Aβ(1-16) by all the 
ACE variants except Cdom yielded peptides with m/z ratio corresponding to the N-terminal 
peptide Aβ(1-14) (Table 2.2).  This indicates that Aβ(1-16) undergoes dicarboxypeptidase 
cleavage at the His14-Gln15 bond by all five ACE variants and there is no apparent difference 
in cleavage site selectivity between the two functioning domains of ACE under these 
conditions. 
 
To determine if the Aβ(1-16) is further degraded over time by all forms of ACE, 36.5 µM of 
Aβ(1-16) was incubated for 24 hours under assay conditions described in Chapter 4 section 
4.2.5.1. The reaction products were separated by HPLC and analysed via MALDI-TOF (Table 
2.3). Interestingly, the mass of the initial cleavage intermediate, Aβ(1-14), was present across 
all ACE constructs except for N-sACE. However, the Aβ(1-12) peptide was only generated by 
the sACE mutants (expected m/z of 1325.54). The corresponding C-terminal peptide Aβ(12-16) 
was detected in both Cdom and Ndom digests as well as in sACE and C-sACE, but not N-sACE 
or CC-sACE.  Presumably, the Aβ(1-12) product is hydrolysed faster by the Cdom, Ndom and 
wild type sACE. Overall, there appears to be no absolute domain preference towards any 
specific cleavage site, similar to the hydrolysis for 15 minutes. The Aβ(1-7) cleavage site is also 
found across constructs barring N-sACE and CC-sACE. These results indicate that the hydrolysis 
of Aβ(1-16) by both domains of ACE is not limited or specific, and that under certain 
conditions the C-domain does hydrolyse Aβ peptides.  
Table 2.2 Observed [M+H]+ ions of the peptide products generated by endoproteinase and 
exoproteinase action of the various ACE constructs on the Aβ(1-16), Aβ(4-10)Q and Aβ(4-10)Y 
substrates.  
 
Ndom N-sACE sACE C-sACE CC-sACE Cdom
Aβ(1-16) 
Substrate
H-DAEFRHDSGYEVHHQK-OH 1954.88
1954.82 1954.82 1954.82 1954.83 1954.80 1954.83
Product H-DAEFRHDSGYEVHH 1698.73 1698.58 1698.68 1698.76 1698.67 1698.66
Aβ(4-10)Q 
Substrate
Abz-FRHDSG(Q)-EDDnp 1191.49
1191.49 1191.44 1191.45 1191.37 nd nd
Product Abz-FRHD 693.31 693.30 693.31 693.30 693.31
Aβ(4-10)Y 
Substrate
Abz-FRHDSG(Y)-3NO2 1064.43
1064.37 1064.43 1064.39 1064.39 nd nd
Product Abz-FRHD 694.32 694.26 694.29 693.28 694.29
Observed m/z
Calculated 
m/z 
Peptide Residues
Amyloid 
Peptide
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 Crystal Structures of Ndom in Complex with Aβ Peptides  2.3.4
In order to better understand the molecular interactions that occur between Aβ and ACE, 
considering the variation in cleavage position both in this study and in literature, 
crystallization experiments were planned. The peptides chosen for crystallography were based 
on cleavage sites derived from this study as well as from the literature, with focus on the N-
terminal region of the full length Aβ(1-42). Furthermore our lab in collaboration with Prof K. 
Ravi Acharya and Dr G Masuyer (Department of Biology and Biochemistry, University of Bath, 
Bath, United Kingdom) have had success in the crystalisation of larger products like ANGII 
(Masuyer et al., 2012). Ndom was pepared as in section 2.2.2 in this labroratory and sent to 
our collaborators Prof K. Ravi Acharya and Dr G Masuyer for crystallisation, diffraction studies 
and resolution of the structures in this thesis. 
Crystallisation trials were performed initially on the full length Aβ(1-42) and while co-crystals 
with Aβ(1-42) could not be obtained, trials with shorter Aβ fragments, namely Aβ(4-10), 
Aβ(10-16), Aβ(1-16), Aβ(35-42) and Aβ(4-10)Y, were successful.  These fragments we 
specifically chosen as mentioned, based on ACE cleavage sites found along Aβ(1-42). These 
crystals have generated high-resolution (1.5-1.9Å) structural data of the latter co-crystal 
complexes (Table 2.4).  
Overall, the structure of Ndom did not show any major conformational change upon peptide 
binding (Figure 2.7 A). The previously observed hinge motion of the N-terminal helices 
(Anthony et al., 2010), was slightly more pronounced in some of the molecules. This resulted 
in a larger asymmetric unit (a=73, b=102, c=114 Å; α=85, β=86, γ=81°) of four Ndom chains, 
still in space group P1, for the Aβ(4-10), Aβ(10-16), Aβ(1-16) complexes (Table 2.4). The 
structures with Aβ(35-42) and Aβ(4-10)Y were in the same crystallographic cell as previously 
reported for Ndom comprising of 2 chains per asymmetric unit in P1 (a=73, b=77, c=83 Å; 
α=89, β=64, γ=75°) (Table 2.4). The degree of movement however, appeared limited. This lack 
Table 2.3 The cleavage product [M+H]+ ions generated by of the various ACE constructs on the Aβ(1-16) 
substrate over a 24 hour period. 
 
Amyloid 
Peptide
Peptide Residues
Calculated 
m/z 
Ndom N-sACE sACE C-sACE CC-sACE Cdom
Aβ(1-16) H-DAEFRHDSGYEVHHQK-OH 1954.88 1954.75 1954.75 1954.80 1954.79 1954.81 1954.82
N-terminal products:
Aβ(1-14) H-DAEFRHDSGYEVHH 1698.73 1698.68 1698.65 1698.68 1698.64 1698.66
Aβ(1-12) H-DAEFRHDSGYEV 1424.61 1424.53 1424.52 1424.54 1424.57 1424.55 1424.57
Aβ(1-11) H-DAEFRHDSGYE 1325.54 1324.50 1325.52 1325.49
Aβ(1-7) H-DAEFRHD 889.38 889.33 889.35 889.36 889.38
Aβ(1-6) H-DAEFRH 774.35 774.36
Aβ(1-5) H-DAEFR 637.29 637.30 637.27 637.29 637.30 637.29 637.28
C-terminal products:
Aβ(2-16) AEFRHDSGYEVHHQK-OH 1839.85 1839.80
Aβ(4-16) FRHDSGYEVHHQK-OH 1639.77 1639.73
Aβ(12-16) VHHQK-OH 648.36 648.30 648.31 648.30 648.36
Observed m/z
24 hour digestion with:
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of movement could not be correlated to the size of the substrates or bound peptides, but 
visible disorder in the N-terminal region of the Ndom did occur and is highlighted by higher B-
factors (Table 2.4) (Figure 2.7 A).  
In each of the structures, electron density was clearly observed in the S’ side of the Ndom 
catalytic pocket for what correspond to a dipeptide. Electron density maps for the side chains 
of sites P1’ and P2’ of the peptides were interpreted as the products of the prolonged 
reactions of Aβ cleavage by Ndom (Figure 2.7 C). The carboxy-dipeptide residues of Aβ(35-42) 
and Aβ(4-10)Y were visible, Ile41-Ala42 and Gly9-nitroTyr10 respectively. Both Aβ(4-10) and 
Aβ(1-16) presented the Asp7-Ser8 residues.  
The structure of Ndom with Aβ(10-16) was unique in offering two alternative dipeptides, each 
present in two of the chains forming the asymmetric unit, and corresponding to Glu11-Val12 
and Gln15-Lys16. Coincidentally, the Aβ(10-16) structure also showed unusual ion 
coordination in proximity to the binding site. In presence of Glu11-Val12 a cation is 
octahedrally coordinated by Glu262, Asn263 and Asp354 of Ndom along with three water 
molecules, while the same residues are involved in cationic interaction with only two water 
molecules when Gln15-Lys16 is bound (Figure 2.10). The ion coordination was carefully 
analysed in each case using the CMM validation server (Zheng et al., 2014) and interpreted as 
calcium and sodium ions, respectively. Both are present in the crystallisation conditions but 
are unlikely to have any physiological role and have not been observed in any of the other N-
ACE crystal structures.  
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Table 2.4 Crystallographic statistics of the Ndom structures in complex with Aβ fragments. 
 
Aβ(4-10) Aβ(10-16) Aβ(1-16) Aβ(35-42) Aβ(4-10)Y
Resolution (Å) 1.9 1.8 1.8 1.55 1.65
Visible peptide D7-S8 E11-V12 / Q15-K16 D7-S8 I41-A42 G9-(NT)
Space group
Cell dimensions   (Å; 
a, b, c);
73, 102, 114; 73, 102, 114; 73, 102, 114; 73, 77, 83; 73, 76, 83;
angle (°; α,β,γ) 85, 86, 81 85, 86, 82 85, 86, 81 89, 64, 75 89, 64, 76
Molecule/AU 4 4 4 2 2
Total/Unique 
reflections 
384,870/293,455 929,478/291,734 461,830/281,258
324,307/200,
050
520,452/172,
512
Completeness (%) 93 (84)a 97 (95.7)a 94 (82)a 88 (56)a 92 (64)a
R merge 
a, b 7.1 (43.8) 12.0 (76.3) 6.1 (46.0) 4.2 (44.4) 8.1 (70.6)
R pim
 a, c 7.1 (43.8) 7.9 (49.7) 6.0 (45.9) 4.2 (44.4) 5.4 (49.8)
I/σ(I) a 5.8 (1.4) 5.3 (1.4) 6.8 (1.4) 7.5 (1.4) 6.4 (1.3)
CC(1/2) 0.996 (0.816) 0.993 (0.325) 0.998 (0.635) 0.993 (0.565) 0.995 (0.318)
R cryst
d 18.5 19.7 18 15.8 20.8
R free
e 22.4 22.9 21 18.1 24.1
Rmsd in bond 
lengths (Å)
0.016 0.012 0.011 0.014 0.011
Rmsd in bond angles 
(°)
1.34 1.4 1.34 1.4 1.33
Protein all atoms 27.4/24.8/22.2/23.1 29.3/26.3/24.3/27.0 26.5/23.3/21.2/23.4 33.0/37.8 27.9/31.0
Protein main chain 
atoms
26.4/23.7/21.1/22.3 28.4/25.2/23.4/26.2 25.2/22.1/20.0/22.3 30.8/35.4 26.7/29.9
Protein side chain 
atoms 
28.4/25.8/23.2/23.9 30.2/27.3/25.2/27.9 27.7/24.6/22.4/24.5 35.2/40.1 29.1/31.1
Peptide atoms 26.0/23.5/24.6/23.3 27.5/23.5/21.9/28.1 27.4/27.3/23.5/26.3 28.4/28.9 41.7/44.6
Solvent atoms 29.7 31 30.9 44.8 35.3
19.2/19.7
(Na+ 33.5/Ca2+ 35.2)
Favored 98% 98% 98% 98% 98%
Outliers 0.20% 0.20% 0.20% 0.20% 0.20%
PDB code 5am8 5am9 5ama 5amb 5amc
a Values in parentheses refer to the highest resolution shell.
b R merge = ΣΣi |I h  − I hi |/ΣΣi I h , where I h is the mean intensity for reflection h .
c R pim = Σh (1/n h  – 1) Σl |I hl  – (I h ) |/Σh Σl (I h )
d R cryst = Σ‖F o | − |F c ‖/Σ|F o |, where F o  and F c  are measured and calculated structure factors, respectively.
e R free = Σ‖F o | − |F c |/Σ|F o |, calculated from 5% of the reflections selected randomly and omitted during refinement.
Ramachandran statistics (Molprobity)
Ndom complexed with:
Glycosylated/ 
carbohydrate atoms
48.6 54.1 47.7 67.3 58.9
P1
B- factor statistics (Å2 )
Zn2+ / Cl- ions 16.7/16.2 17.5/16.7 25.5/26.9 19.9/21.5
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2.3.4.1  Mode of Peptide Binding in N-domain S’ pockets  
The crystal structures of Ndom in complex with the Aβ fragments present a common 
mechanism of peptide binding within the S’ catalytic pocket (Figure 2.7 B). The Ndom 
essentially recognises the main chain of the peptides through seven hydrogen bonds. The P1’ 
position interacts with the main chain of Ala332, and the side chains of Glu362, His491 and 
His331. The S2’ pocket is composed of Gln259, Lys489 and Tyr498 whose polar side chains 
anchor the carboxy-terminal end of the peptide. Furthermore, a network of water molecules 
was also observed in all structures that further mediates interaction of the peptides’ main 
chain with residues Ala332, Glu362, Tyr501 and Lys489 of Ndom (Figure 2.8). The N-terminal 
groups of the peptides are closely tied up to the zinc ion via two coordinating water 
molecules. Additional and more specific contacts were observed with peptides Asp7-Ser8  
         
Figure 2.7 General properties of the five Aβ peptides crystallised within the Ndom. Overall structure of 
Ndom coloured in a B-factor spectrum (white=low; red=high) to highlight the hinge region of the N-terminal 
domain ‘capping’ the catalytic channel. The bound dipeptide is shown in purple, the catalytic zinc ion as a grey 
sphere. B) Close up view of the catalytic site of the N-domain in complex with a bound dipeptide. The 
dipeptide, modelled as Ala-Ala, reflects the common mechanism of binding observed in all complex structures 
with Aβ fragments. The dipeptide is shown in purple and the N-domain residues involved in binding are 
represented as sticks. The spheres represent the zinc ion (in grey) and water molecules (in red). C) Portions of 
the Fourier electron density map at the site of the bound peptides. The picture was generated using REFMAC5 
(Murshudov et al., 1997) and correspond to the difference weighted 2mFo-DFc density map, contoured at 
1.0σ level, in which the peptide atoms were omitted. 
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where the side chain of Thr358 makes a hydrogen bond with the acidic group of Asp7, and a 
water-mediated bond exist between Gln259 and the Ser8 side chain (Figure 2.8). Interestingly 
the two alternative peptides seen within the structure of Aβ(10-16) show similar contacts at 
the P1’ position with the longer side chain of Glu11 or Gln15 able to make direct contact with 
Ala332 and two water mediated interactions with Gln355 (Figure 2.8). The side chain of 
residues at P2’ may be held in position by the surrounding hydrophobic residues Phe435, 
Tyr501 and Phe505. Additionally, the Lys16 ε-amino group is within distance (5.5Å) of a 
potential cation-π interaction with Phe435. In the case of Aβ(4-10)Y, the larger nitrotyrosine 
fits well within the S2’ pocket. The additional nitro group is within hydrogen-bond distance of 
Gln259 and the hydroxyl group can make water mediated interactions further down the 
catalytic channel with residues Asp393 and Glu431. Electron density was observed to be 
weaker in both molecules of the asymmetric unit for the nitrotyrosine, which may be 
indicative of some flexibility (Figure 2.7 C).  
Figure 2.8 Mechanism of Aβ fragment binding to the N-domain. Schematics of peptide binding to the 
N-domain. Interactions were calculated with LigPlot
+
 (Laskowski and Swindells, 2011). The two
alternative peptides for Aβ(10-16) are included with Glu11-Val12 and Glu15-Lys16 observed in chains A,
D and B, C respectively.
Kate Larmuth CHAPTER 2 Characterisation of Aβ cleavage 
56 
2.4 Discussion: 
The hallmark of AD is the accumulation of Aβ within the brain. This peptide is constitutively 
shed and produced via proteolysis of its precursor APP (see Chapter 1). It is comprised of 39-
43 residues and is renowned for its N- and C-terminal heterogeneity and toxicity. Thus, subtle 
disturbances in metabolism of APP can have severe pathophysiological consequences. The 
production of Aβ by different proteolytic enzymes has been well characterised. However, the 
molecular basis for the hydrolysis of Aβ by ACE is less clear. In this chapter, we investigated 
the mode of binding and hydrolysis of Aβ peptides to ACE, through crystallography and MS, in 
the hope to better understand the role of ACE in AD.  
ACE’s primary catalytic function is as an exopeptidase, known to remove the last two amino 
acids from the C-termini of its substrates. However, ACE also functions as an endopeptidase 
towards some substrates like substance P (cleaved at Phe8-Gly9 and Gly9-Leu10) (Yokosawa 
et al., 1983), gonadotropin-releasing hormone (GnRH) (Ehlers and Riordan, 1991; Skidgel and 
Erdös, 1985) and, of course, Aβ (Hu et al., 2001). It is worthwhile noting that C-terminal 
amidated peptides, like substance P and GnRH, inhibit the exopeptidase ability of ACE (Skidgel 
et al., 1984). The Aβ(2-11) peptide was endoproteolytically cleaved which was not surprising 
considering it has an amidated C-terminus. The Aβ(2-11) cleavage at the Asp7-Ser8 bond is 
consistent with previous studies where varying forms of both full-length cellular and 
truncated synthetic Aβ were used (Hemming and Selkoe, 2005; Hu et al., 2001; Kumar et al., 
2012; Oba et al., 2005) (Table 2.) (Figure 2.1). 
The amidated form of Aβ(1-16), on the other hand did not produce any proteolytic product 
even after prolonged incubation with the Ndom (data not shown). The free acid version, 
however, was effectively cleaved in ACE’s traditional exopeptidase fashion. (Table 2.2) 
Subsequent degradation of the Aβ peptide after the initial cleavage was more rapid with Aβ(2-
11) than Aβ(1-16), presumably due to the secondary structure of the Aβ(1-16) and indicative
of structure dependent cleavage specificity.  If incubation with the different ACE variants is
prolonged, Aβ(1-16) is further broken down from the primary Aβ(1-14) intermediate to other
fragments, including Aβ(1-7) (Table 2.3 and Table 2.4). NEP hydrolyses the N-terminal region
of Aβ(1-42) between residues Gly9-Tyr10 and Gly37-Gly38, liberating the primary
intermediate Aβ(10–37) (Iwata et al., 2000). This then undergoes subsequent degradation in a
similar fashion to ACE cleavage of Aβ(2-11) and Aβ(1-16) found in this study and of Aβ(1-42)
found in other studies.
The production of the Aβ(10-37) intermediate by NEP seems to constitute a rate-limiting step 
in the enzyme’s Aβ(1-42) catabolism (Iwata et al., 2000).  NEP thus removes the N-terminal 
and C-terminal regions of Aβ(1-42) before further breakdown. It is conceivable that this 
removal of the N-terminal region destabilizes the molecule as a whole due to the removal of 
the metal coordinating His-rich Aβ(1-10) region (Curtain et al., 2001; Istrate et al., 2012). ACE 
appears to perform a similar function. The endoproteolytic degradation of the N-terminal 
region of Aβ(1-42) and the removal of the final Aβ(41-42) residues, found in this study and 
others (Zou et al., 2009, 2007), removes Aβ’s metal stacking ability and greatly reduces Aβ’s 
aggregation potential. This is exemplified in the progression of the Aβ(2-11) hydrolysis by the 
Ndom and Cdom construct over time (Figure 2.5). The Aβ(2-11) peptide is cleaved efficiently 
by the truncated Ndom over time. The truncated Cdom, in contrast, cleaved the Aβ(2-11) very 
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inefficiently. These data support the evidence that the single C domain has a very small role, if 
any, to play in the cleavage of the Aβ peptide (Oba et al., 2005; Toropygin et al., 2008; Zou et 
al., 2009). In terms of domain selectivity, the Aβ peptides appear N-selective. As AD is a 
chronic illness, one should not discount the fact that the C-domain does cleave Aβ, confirmed 
by studies done on full-length ACE (Hemming and Selkoe 2005; Sun et al. 2008; Zou et al. 
2009;), for it may only take a very long time to do this. However, the physiological relevance 
of such slow hydrolysis is questionable. The selectivity towards Aβ(1-16) was much the same 
as that of Aβ(2-11) for after 24 hours of incubation multiple degradation products were found 
from all C-domain constructs (C-sACE, CC-sACE and Cdom), both exo- and endoproteolytically. 
(Table 2.4) 
For the first time, we have confirmed the exopeptidase cleavage of Aβ by ACE using X-ray 
crystallography (Figure 2.7). High-resolution structures of six Aβ peptides in complex with the 
truncated N-domain were solved by our collaborator Professor Ravi Acharya. In each of the 
structures presented here, a dipeptide, representing different cleavage sites, was observed 
occupying the active site of Ndom.  In congruence with Zou et al. 2007, the crystal structure 
indicated that the Aβ(35-42) was cleaved between Ile41-Ala42 (Figure 2.9 and Figure 2.10 B). 
Crystallisation experiments of Aβ(4-10) and Aβ(1-16) with Ndom yielded structures with the 
Asp-Ser dipeptide bound in the active site, suggestive of cleavage at the His6-Asp7 bond 
(Figure 2.7 C). This was contrary to results found under kinetic assay conditions wherein the 
Asp7-Ser8 bond in Aβ(4-10) is hydrolysed within 5 minutes (Figure 2.9). However, the 
alternate cleavage, of both Aβ(4-10)and Aβ(1-16), is likely due to the longer incubations under 
slightly different conditions required for the formation of crystals. Supporting this, Aβ(1-16) 
hydrolysis at His6-Asp7 was seen after 24 hour incubation with C-sACE, though no N-domain 
constructs generated this hydrolysis product (Table 2.3). MS analysis of the peptides 
generated by digestion of Aβ(1-16) with Ndom showed that it undergoes extensive 
degradation. This finding was supported by the crystal structures of Ndom in complex with 
Asp7-Ser8, Glu11-Val12 and Gln15-Lys16 alluding to multiple cleavage of the Aβ(1-16) peptide 
(Figure 2.9). Presumably, based on the MS analysis, primary cleavage occurs between residues 
His14 and Gln15 emphasized by the Ndom-Gln15-Lys16 crystal of Aβ(10-16) (Figure 2.10C). 
The presence of the Ndom-Glu11-Val12 crystal could be indicative of secondary exopeptidase 
action removing His13-His14. This peptide correlates well with the cleavage sites found after 
prolonged incubation of Aβ(1-16) with all constructs, both N and C-domain forms (Table 2.3). 
Presumably, the next exopeptidase digestion step, on what would now be left of the 
Aβ(10-16), was found in the Glu11-Val12-Ndom crystal complex (Figure 2.10 D). This 
presented a cleavage site, between Tyr10-Glu11, found in the study by Sun et al. 2008 who 
used the Aβ(4-15) as a substrate, yet was not seen in this study (Figure 2.9). 
Fluorogenic ACE substrates are frequently used to investigate substrate and inhibitor 
mechanisms (Araujo et al., 2000; Jullien et al., 2006; Skirgello et al., 2005). The substrates 
Aβ(4-10)Q and Aβ(4-10)Y used in this thesis were intended for exactly this purpose as well as 
to facilitate kinetic analyses with the different ACE variants. Under kinetic assay conditions 
both fluorogenic peptides (Aβ(4-10)Q and Aβ(4-10)Y) were endoproteolytically cleaved at the 
previously identified Asp7-Ser8 bond (Hemming and Selkoe, 2005; Hu et al., 2001; Kumar et 
al., 2012; Oba et al., 2005). Again, the cleavage site was consistent across all ACE variants. 
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The crystal structure of the Ndom-Aβ(4-10)Y complex found that the Gly9-nitroTyr10 residues 
were occupying the S1’ and S2’ pockets of the Ndom, respectively (Figure 2.8 and Figure 
2.10A). In agreement with this result, previous studies on ACE FRET substrates, indicated that 
a large C-terminal EDDnp group usually occupies the S2’ pocket and cleavage occurs one 
residue away from this acceptor group (Araujo et al., 2000). In contrast to the crystal results, 
MS analysis of products after 30 minutes of ACE digestion revealed that cleavage was 
consistently three residues from the EDDnp and nitrotyrosine groups (Table 2.2). Combined, 
these results provide evidence that the fluorogenic peptide may undergo endoproteolytic or 
classical exoproteolytic activity depending on the experimental conditions used for a single 
substrate.  
Both MS and crystal structure data demonstrate ACE’s ability to cleave peptides of diverse 
length and composition. The high-resolution structures of the Aβ dipeptides in complex with 
Ndom present a common mode of binding in the active site. This principally targets the C-
terminal P2’ position of the substrate to the S2’ pocket and recognises the main chain of the 
P1’ peptide. It is a mechanism reminiscent of Cdom binding to ANGII and the bradykinin 
potentiating peptide b (BPPb) (Masuyer et al., 2012). The residues involved in the binding of 
Aβ within the S’ pockets are conserved in both ACE domains. The apparent Ndom selectivity 
for Aβ could be conferred through interactions upstream of the catalytic channel above 
position S2 (Anthony et al., 2010; Masuyer et al., 2012). Additionally, Ndom should be able to 
accommodate larger substrates through movement of its flexible lid region of N-terminal 
helices. This is evident from the level of disorder of the hinge region in the crystal structures. 
 
Figure 2.9 Diagram of the five peptides crystalized with cleavage sites. Indicated are the cleavage 
sites found in the literature, kinetic studies in this thesis and those based on the dipeptides found in 
the Ndom co-crystallisation. 
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Although the chloride ion is expected to play a role in substrate binding in domains (Yates et 
al., 2014), the structures presented did not provide any further evidence of this.  
Additional interactions, despite the common mode of binding described above, exist as 
evident from the five high-resolution structures. There are two groups of residues, from the 
different fragments, which coordinate well with the S1’ subsite. The first is distinguished by 
peptides with P1’ longer polar side chains (Aβ-Asp7, Glu11 and Gln15) which make hydrogen 
bonds with Ala332 or Thr358 of Ndom. The second includes small hydrophobic residues, such 
as Ile41, at the P1’ position of the substrate, however such residues have also been shown to 
be cleaved effectively by both domains of ACE (Araujo et al., 2000). The unique residues of the 
S2’ pocket offer strong hydrophobic interactions for the P2’ position, as seen with Val12, 
Ala42 and the nitroTyr group of Aβ(4-10)Y (Figure 2.10 A). Furthermore, longer polar side 
 
Figure 2.10 Ndom S1’ and S2’ residues within 5 Å of the Aβ dipeptides. A) The cleavage products 
Gly9-nitroTyr10 (hot pink sticks) of the Aβ(4-10)Y peptide, the pale cyan residues make up the S1’ 
pocket and the green residues the S2’ pocket with the zinc ion in grey. B) The Aβ(35-42) short 
peptides cleavage product Ile41-Ala42 in hot pink, zinc in purple and the S1’ and S2’residues in 
pale cyan and green respectively.  C) The putatively initial cleavage product, Gln15-Lys16 (TV-
green), of the Aβ(10-16) peptide. The pale green residues indicate the active site residues of the 
S1’ pocket, and the blue residues of the S2’ pocket with a large purple Na
2+
 ion deeper in the S2’ 
pocket and the catalytic zinc in grey.  D) The second cleavage product crystallised of Aβ(10-16), 
Glu11-Val12 (in TV green), coordinated to the S1’ active site residues in pale green and the S2’ 
residues in cyan. Again bound deeper in the S2’ pocket is the pale yellow Ca
2+
 ion and in grey the 
catalytic zinc sphere. These images were generated using PyMOL software (v 0.99, DeLano 
Scientific).  
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chain may also be stabilised by electrostatic interactions (e.g. Lys16) deeper into the pocket 
(Figure 2.10 C). Due to the size and possibly the affinity that the N-terminal region of Aβ has 
for zinc, the two different domains of ACE may adjust accordingly to accommodate the 
peptide. The Aβ peptides in all the crystal structures presented only occupy the S1’ and S2’ 
subsites and, thus, one is unable to comment on the molecular basis of their interaction with 
the non-prime subsites of the enzyme. 
Within controlled and set conditions this study has established conserved primary 
intermediate products across four different N-terminal variants of the Aβ(1-42) and multiple 
forms of ACE. Thus, this has established a basis for molecular understanding of the cleavage of 
Aβ by ACE, which will be elaborated on in the following chapters. 
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3 CHAPTER  
What residues are responsible for the lack of activity in the C -domain?  
3.1 Introduction and Aims 
The findings in the previous chapter and in the literature, that the N-domain catalytic site of 
ACE selectively hydrolyses Aβ peptides, provide a rationale to investigate the basis for this 
domain-selectivity. With the increase of three-dimensional structures of ACE in complex with 
domain-specific inhibitors, key active-site residues responsible for domain selectivity have 
been identified (Corradi et al., 2007; Douglas et al., 2014; Georgiadis et al., 2003; Kröger et al., 
2009; Natesh et al., 2003).  Characterising and substituting the unique C-domain active site 
residues for the corresponding N-domain active site residues may indicate which residues in 
the C-domain are impeding the hydrolysis of Aβ and facilitating cleavage by the N-domain. 
Previous studies performed in our lab as well as by others have taken advantage of the 
differences in homology between the N- and C-domains to develop better inhibitors of ACE. 
These differences combined with the multitude of crystal structures, in both bound and 
unbound states, can pinpoint structurally specific interactions between the enzyme and 
ligand. The benchmark for N- and C-domain selective inhibitors is set with the two phosphinic 
peptide analogues RXP407 and RXPA380, respectively. They are currently the most potent C-
and N-selective inhibitors; with 3 orders of magnitude more potent inhibition for the C- and N-
domains, respectively (Dive et al., 1999; Georgiadis et al., 2004). These inhibitors are fantastic 
tools, used to tease out residues within the active sites, which play decisive roles in their 
substrate specificity.  
There are only two residues (Phe391 and Glu403 (tACE numbering)) within the S2 pocket of 
the C-domain that likely contribute to the selectivity of C-domain inhibitors. These residues 
have been implicated due to their hydrophobic interactions with the P2 Phe of RXPA380 seen 
in the co-crystalized structure with the C-domain (Corradi et al., 2007; Natesh et al., 2003). In 
contrast, the RXP407 co-crystal structure with the N-domain shows salt-bridge interactions 
between the S2 Arg381 to the small acidic P2 residue(Anthony et al., 2010). In addition, the N-
domain contains Tyr369, which is substituted by Phe391 in the C-domain, to which RXPA380’s 
phenyl P2 group may concede to steric hindrance within the N-domain as a result. 
Mutagenic studies revealed that the Phe391 residue of the C-domain played a more important 
role in selectivity than Glu403 (Kröger et al., 2009). Furthermore, Phe391 was found to have 
more of a hydrophobic interaction with the C-selective ketomethylene compounds kAW and 
kAF, both P2’ derivatives of the tripeptide ACE inhibitor keto-ACE (Watermeyer et al., 2008). 
Keto-ACE (Bz-Phe-Gly-Pro), was the first ACE inhibitor to exhibit C-domain selectivity, by 26-
34-fold, towards a large array of substrates (Almquist et al., 1980; Deddish et al., 1998). The C-
domain specificity of keto-ACE was further improved via the substitution of the P2’ group with 
larger hydrophobic residues to generate kAF and kAW (Nchinda et al., 2006). The derivatives 
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implicate the C-selectivity of S2-Phe391, S1-Val518 and S2’-Glu376 and Val380 via further 
hydrophobic interactions (Watermeyer et al., 2010). 
These hydrophobic interactions are lost in the N-domain where the Phe391 (S2), Val518 (P1), 
Glu376 (S2’) and Val380 (S2’) residues are replaced by more polar Tyr369, Thr496, Asp435 and 
Thr358 residues, respectively (Watermeyer et al., 2010).  
The C-domain S2’ subsite is physically larger than that of the N-domain. This is due to the 
presence of Ser357 and Thr358 on the border between S1’ and S2’ sites which occlude the 
pocket. Furthermore, the N-domain contains the E431 residue which is replaced in the C-
domain with a much shorter Asp453 adding to the smaller size of the N-domain S’ pockets. 
Overall, the difference in charge, size and hydrophobicity of this subsite is mainly responsible 
for the selectivity of the C-domain. This is exemplified in RXPA380 and Lisinopril-Trp where the 
P2’ Trp drives the C-domain selectivity (Georgiadis et al., 2004; Corradi et al., 2007). 
Interestingly, further potential substituted residues Thr282, Val379, Glu403, Asp453, and 
Ser516 did not individually contribute favourably to the binding of these inhibitors. 
Determinants of N-domain selectivity, however, also implicate the S2’ pocket which contains 
the largest amount of unique amino acids. The implication is largely based on the results from 
the removal of the C-terminal amide of RXP407 (P2’ position). There is a massive loss in N-
selectivity, despite a lack of proximity of RXP407, in the crystal structure to any unique 
residues in the S2’ pocket (Dive et al., 1999). Secondly, the residues in the S2 and S1´ subsites 
are distant from RXP407 in the crystal structure (Anthony et al., 2010).  
Previous literature reports implicate both the S2 and S2´ subsites in N-selective binding and 
processing. Based on the site of cleavage of Aβ(2 11), Aβ(4 10), Aβ(4 10)Q and Aβ(4 10)Y (see 
Chapter 2), the peptides in this study correlate well theoretically to inhibitor studies in that 
their amino acid properties, in the bound cleavage positions, may determine thier selectivity  
(Figure 3.1). Thus, screening was performed on a set of S2’ pocket mutants. The particular 
 
Figure 3.1 Schechter and Berger representation of subsites and putative binding sites of the 
Aβ(4-10)Q peptide within the ACE active site. The active site subsites are indicated by S2, S1 on 
the N-terminus of the scissile bond and S1’ and S2’ subsites on the C-terminus. The corresponding 
peptide residues positions are indicated in green from P2, P1, P1’ and P2’ accordingly  
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mutants screened were chosen for their great shift in domain selectivity from C-domain to N-
domain (Kröger, 2009; Kröger et al., 2009; Watermeyer et al., 2008). 
Aims and Objectives: 
The major aim of this chapter is to identify the determinants for N-domain vs. C-domain 
selective hydrolysis of Aβ peptides using mutagenesis and a kinetic approach.  . 
Objectives designed to achieve this aim were: 
1) To develop optimum conditions for the kinetic analysis of Aβ(4-10)Q hydrolysis
2) To express and purify wild type and active site substitution mutant ACE constructs.
3) To determine the kinetic constants of the hydrolysis of the Aβ(4-10)Q FRET peptide by
the N-domain, C-domain and C-domain active site substitution mutants
4) To investigate the selectivity of, the FRET peptide, Aβ(4-10)Y and the effect of the
capping groups on substrate selectivity.
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3.2  Methods:   
 Enzyme constructs 3.2.1
3.2.1.1 C-domain constructs 
3.2.1.1.1 Wild type C-domain (Cdom) 
The wild type tACE construct used is the fully N-glycosylated tACE∆36NJ mutant. Refer to 
Chapter 2 section 2.2.1.1.1 for more detail 
3.2.1.1.2 C-domain Active Site Substitution Mutants 
Here, key active site C-domain residues were converted to their corresponding N-domain 
counterparts. All substitution mutants were previously generated in our lab (Kröger, 2009). 
Briefly, a pcDNAtACEΔ36NJ template was used to mutate various residues in the S2’ region. 
This region was sub-cloned from the pcDNA-tACE∆36NJ construct into the cloning vector 
pGEM11-Zf(+). This generated a convenient shuttle vector, pGEM-S2’, from which subsequent 
site directed mutagenesis reactions were performed to generate the substitution mutants of 
interest. Positive clones were identified by restriction endonuclease digestion. These newly 
mutated fragments were then cloned back into pcDNAtACEΔ36NJ to create V379S, V380T, 
E378D, D453E, T282S and the VV/ST double mutant (containing both V379S and V380T 
mutations) (Table 3.1). 
The complete substitution of the C-domain S2’ pocket with N-domain residues, was 
performed in a similar fashion. They were created by sequential mutagenesis of the, already 
mutated, template pGEMS2’ constructs. Three multiple mutants were used in this study 
namely: TEVD (T282S, E376D, V380T and D453E), TEVVD (containing the V379S mutation in 
addition to the TEVD substitutions) and S2’F (which contains the F391Y mutation in addition 
to those in the TEVVD construct). The mutants used in this study were selected because of the 
large differences displayed in inhibitor binding studies compared to the N-domain (Kröger, 
2009).  
Table 3.1 Summary of the C-domain active site substitution mutants and corresponding N-domain 
substitution mutants used in this study. 
 
Pocket Mutant
Cdom residues mutated to corresponding N-
domain residues (sACE C-domain numbering)
N-domain residue
E376D Glu 376 (952) Asp 354
D453E Asp 453 Glu 431
T282S Thr 282 (859) Ser 260
V379S Val 379 (955) Ser 357
V380T Val 380 (956) Thr 358
VV/ST Val 379, Val 380 Ser 357, Thr 358
TEVD/SDTE T282, E376,  V380, D453 S260, D354, T358, E431
TEVVD/SDSTE T282, E376, V379, V380, D453 S260, D354,S357, T358, E431
S2'F T282, E376, V379, V380, D453, F391 S260, D354,S357, T358, E431, Y369
Ndom residues mutated to corresponding C-
domain residues
C-domain residue
Ndom: T358V Thr 358 Val 380(956)
Ndom: S357V Ser 357 Val 379 (955)
S2'
S2'
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3.2.1.2 N-domain constructs 
3.2.1.2.1 Wild type N-domain (Ndom) 
A soluble form of the N-domain (Ndom) (see Chapter 2 section 2.2.1.1.2). This construct is 
essentially the N-domain of human somatic ACE 
3.2.1.2.2 N-domain active site substitution mutants 
Those C-domain active site mutants that gave the most dramatic change in selectivity towards 
Aβ were investigated in a reciprocal manner. Here, the N-domain active site residues are 
converted to their corresponding C-domain residues. The two mutants investigated (S357V 
and T358V) were created via site directed mutagenesis (by R.G Douglas) of the shuttle vector 
pBS-D629. Once the mutants were screened and sequence integrity checked, each 
successfully mutated template was doubly digested with EcoRI and XbaI. Each mutant was 
then cloned via the same compatible restriction sites into the mammalian expression vector 
pcDNA3.1(+).  
 Protein expression and purification 3.2.2
The CHO-K1 mammalian cell line was used as the model system for transfection and 
expression of all enzymes as described in Chapter 2 section 2.2.2 
 Mammalian cell expression of ACE enzymes 3.2.3
See Chapter 2 section 2.2.2.1 
 Isolation of secreted C-domain derivatives of sACE 3.2.4
Purification of soluble constructs via affinity chromatography was performed as described in 
Chapter 2 section 2.2.2.3.  Activity of the purified ACE protein was assayed (See Chapter 2 
section 2.2.3.1)and the integrity, size and purity were analysed on a 10% SDS-PAGE (Laemmli, 
1970) (Figure 3.3.).  
 Isolation of secreted N-domain derivatives of sACE 3.2.5
For N-domain constructs, 0.8M NaCl was added to the cell culture medium to increase binding 
to the column, otherwise all harvested medium was processed and stored as described 
Chapter 2 section 2.2.2.3 
 Active site titrations 3.2.6
The kinetic characterization of enzymes requires an accurate quantification of the amount of 
enzyme present in any reaction. Methods often used to quantify amount of enzyme rely solely 
on the amount of protein present; whilst this is often useful, this is not an indication of how 
much active enzyme is actually present. Over time, even in correct storage conditions, 
degradation and or protein instability can lead to a loss of active enzyme (Knight, 1995). As 
with most enzyme inhibitors conditions can be manipulated so that the inhibitor appears to 
be a tight binding inhibitor (Morrison, 1982, 1969). It is best not to assume and rather to use a 
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well-characterised inhibitor with known Ki’s, such as lisinopril to single domain ACE. ACE active 
site concentrations have successfully been determined by assessment of remaining enzyme 
activity (Ehlers et al., 1991). This remaining activity is determined through analysis of the 1:1 
stoichiometric binding of inhibitor to enzyme molecule, across an inhibitor concentration 
range (Binevski et al., 2003; Rice et al., 2004; Skirgello et al., 2005).  
Using a modified ZFHL assay (see section 2.2.3.1), active ACE concentrations were determined 
according to the above mentioned principle. A serial dilution of the tight binding lisinopril was 
incubated with an appropriate amount of enzyme (enough to have a fluorescent emmision 
reading of 200 after 15 minutes at zero inhibitor concentration) in AST-phosphate buffer (100 
mM KHPO4/KH2PO4 pH 8.3, 300 mM NaCl, 10 µM ZnSO4, 1 mg/ml albumin). This reaction was 
incubated for 15 minutes in the dark at room temperature. Of each enzyme-inhibitor reaction 
complex, 20 µl aliquots were plated in triplicate into a 96-well plate. To this substrate (2 mM 
ZFHL in AST-phosphate buffer) was as added and incubated at 37°C for 15 minutes. The 
reaction was then stopped with 125 µl of 0.4 N NaOH. The free HL dipeptides were then 
derivatised and fluorescence read as previously described (see section 2.2.3). The equimolar 
(S:I) inhibitor concentration required to achieve no enzyme activity (0% ) is indicative of the 
amount of active site present in the final reaction (Figure 3.2). This can then be correlated 
back to determine the active enzyme concentration in one’s stock 
. 
Figure 3.2 Representative active site titration curve. Graph of 
the percentage activity remaining after enzyme-inhibitor 
incubation against the ratio of lisinopril concentration over 
Enzyme concentration ([I]/[E]). The equimolar point, SI, is 
indicated on the x-axis. The initial enzyme concentration is 
determined from specific activity determinations. 
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 Fluorescent resonance-energy transfer (FRET) assay 3.2.7
Fluorescence resonance energy transfer peptide assays make use of intermolecular proximity 
of two groups; namely an N-terminal, o-aminobenzoic acid (Abz) donor group and a C-
terminal, ethylenediamine 2, 4-dinitrophenyl (EDDnp) acceptor group. When the substrate of 
interest is intact, the two molecules do not emit a signal as the donor (Abz) signal is quenched 
by the acceptor (EDDnp) group. On proteolytic cleavage, however, the free Abz groups are no 
longer in close proximity to the quenchers and emit a measurable fluorescence. These assays 
have been utilized for years as a high-throughput means to quantify enzyme activity, ACE 
included (Araujo et al., 2000, 1999; Dive et al., 1999; Wang et al., 1993). 
3.2.7.1 Standard Curve 
A simplified molecule of product only, a free donor Abz group coupled to a Gly, Abz-Gly 
(Bachem Ltd.), was used to quantify the product yielded. A standard curve was set up with 
Abz-Gly to correlate fluorescence intensity to amount of free donor group. A serial dilution of 
a 2 µM stock of Abz-Gly was carried out in HEPES buffer (50 mM HEPES (pH 7.5), 100 mM 
NaCl, 10 µM ZnSO4, 10 µM ZnCl ), to a final concentration range of 0-600 pmols. Aliquots of 
300 µl volumes of this range were pipetted, in triplicate, into a 96-well plate. The fluorescence 
intensities were then determined using excitation and emission wavelengths at 320 nm and 
420 nm respectively in a Cary Eclipse spectrofluorimeter (Varian Inc.). A linear regression 
analysis was performed on the subsequent fluorescent output and a standard curve 
generated (v 4.01, GraphPad Prism4®) (Figure 7.1). 
3.2.7.2 The inner filter effect and the Correction Curve 
The principle of the FRET peptide assay is based on the proximity of the donor group (in this 
study Abz) to the acceptor (EDDnp and 3-nitrotyrosine [(Y)3NO2]) used in this study). In a 
confined volume, however, the increasing concentrations of substrate (necessary for a kinetic 
curve) proceed to quench any signal generated by means of acceptor group substrate 
inhibition. Simply put, there is no space between the uncleaved substrate and Abz-product 
molecules, resulting in fluorescent quenching and an overall decrease in the signal at higher 
concentrations. This effect is known as the inner filter effect (IFE) (Liu et al., 1999). This effect 
is problematic in the accurate characterization and determination of enzyme kinetic 
parameters. IFE can be overcome by means of correction through empirical method. 
Liu et al. 1999, developed a simple 96-well plate assay to empirically correct for IFE. Briefly, a 
baseline of fluorescence of a concentration range of 0-45 µM of Abz-FRKG-E(DDnp) at a 
volume of 296 µl in HEPES assay buffer was measured as above mentioned (Section 3.2.7.1). 
To this, 4 µl of 38 µM Abz-Gly was added (final concentration of 0.5 µM), mixed thoroughly 
and reread as above. The change in fluorescence with increasing substrate concentration was 
compared to zero substrate concentration to determine a ratio. This generated a non-linear 
equation, fit to the substrate concentration range known as a correction curve (Figure 3.4). 
The values of each substrate concentration were then used to correct all further kinetic 
experiments. As all donor groups in this study were Abz, and both acceptor groups have 
similar mechanism and structure this correction is applicable to all. 
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  Kinetic analysis of amyloid FRET peptides 3.2.8
3.2.8.1 Aβ(4-10)Q 
Hydrolysis of the fluorogenic peptide Abz FRHDSG(Q)-EDDnp (Aβ(410)Q), a kind gift from A. 
Carmona, Universidade Federal de São Paulo) by ACE was performed in HEPES buffer (50 mM 
HEPES (pH 7.5), 100 mM NaCl, 10 µM ZnSO4 buffer) with 150 µl enzyme (at a concentration 
within 10% hydrolysis) and equal volume of substrate ranging from 0 to 35 µM.  The assay is a 
modified form of the continuous assay (Araujo et al., 2000) where the assay is set up, on ice, 
in triplicate in a 96 well plate. The baseline fluorescence was taken at time zero and then 
incubated at 37ºC and fluorescence read at a 45 min time point on a Cary Eclipse 
spectrofluorimeter (Varian Inc.) at λex= 320 nm and λem= 420 nm.  Again, kinetic constants 
were calculated using the Michaelis-Menten method with GraphPad Prism software (v 4.01, 
GraphPad Prism®). The detected fluorescence was converted to pmol product formed through 
the slope of a calibration curve of Abz-Gly. A correction curve was also applied to correct the 
data for the inner filter effect (Liu et al., 1999) 
3.2.8.2 Aβ(4-10)Y 
An alternate fluorogenic peptide, Abz-FRHDSG-(Y)3NO2 (BIOPEP ™South Africa) (Aβ(4-10)Y) 
was assayed as above in 96 well plates. The only exception being that the samples were read 
at a 5 min time point on a Cary Eclipse spectrofluorimeter (Varian Inc.) with λex= 320 nm and 
λem= 420 nm.  Kinetic constants, inner filter effect and standard curves were calculated as 
above. 
 Peptide integrity and cleavage site analysis 3.2.9
3.2.9.1 Mass spectrometry 
The Mass spectrometry was analysed at the Centre for Proteomic and Genomic Research 
(CPGR, Cape Town, South Africa). As further elaborated in Chapter 2 section 2.2.5    
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3.3 Results: 
Protein expression and Purification: 3.3.1
The constructs of human recombinant Ndom, Cdom and active site mutants (Table 3.1) were 
expressed in mammalian cells and then purified. All constructs are soluble and secreted into 
the cell medium.  The constructs were purified from conditioned medium by aﬃnity 
chromatography on a lisinopril-sepharose aﬃnity resin as previously described in (Ehlers et al. 
1996). All preparations were purified to apparent homogeneity as assessed by SDS-PAGE 
(Figure 3.3). Recombinant Ndom and N-domain mutants T358V and S357V migrated as a 
single band with an apparent molecular mass of 90 kDa. The Cdom and single and multiple S2’ 
mutants (T282S, E376D V380T, V379S, D453E, VV/ST, TEVD, TEVVD and S2’F) migrated with an 
apparent molecular mass of 80 kDa (Figure 3.3). 
Figure 3.3 Representative SDS-PAGE gels of approximately 10 µg of all the constructs used. From left to 
right: Indicated are the N-domain active site residues converted to their corresponding C-domain residues 
next to the N-domain or D629 construct. Followed by the C-domain and the indicated active site 
substitution mutations. The mass ladders are as indicated on the far right and in the centre of the gels.  
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Correction Curve for the Inner Filter Effect 3.3.2
The incubation of increasing concentrations of substrate with a fixed concentration of the free 
donor results in a non-linear decrease in fluorescence intensity. This result is in congruence 
with the theory of the inner filter effect. The correction values were determined as described 
(in section 3.2.7.2). From these values a polynomial trend line can be derived which allows for 
the correction of substrate quenching from concentrations ranging from 0 to 50 µM (Figure 
3.4). 
 Kinetics of the hydrolysis of the fluorogenic Aβ(4-10)Q peptide. 3.3.3
In order to assess the N-domain selectivity towards Aβ cleavage, the contribution of unique 
residues in the C- and N-domain active sites were interrogated. Specifically a panel of C-
domain S2’ substitution mutants were characterised using the FRET peptide Aβ(4-10)Q .  
The Aβ(4-10)Q peptide was hydrolysed very slowly (kcat 0.220 ± 0.020 s
-1) yet selectively by the 
Ndom, as the Cdom did not produce measurable levels of activity, even after prolonged 
incubation times (Table 3.2). Mutation of the C-domain’s S2’ pocket residues E376D, D453E, 
T282S did little to improve the catalysis or affinity (Table 3.2 and Figure 3.5 A). However, the 
conversion of the C-domain V379 to the N-domain Ser residue induced a 7-fold increase in 
catalytic efficiency (kcat/Km 1.580 ± 0.01 x 10
5 M-1.s-1) compared to that of the Ndom and was 
the most efficient construct screened. The substitution of the adjacent Val380 for a Thr 
residue led to an increase in Aβ(4-10)Q hydrolysis, but the catalytic efficiency (kcat/Km 0.065 ± 
0.04 x 105 M-1.s-1) was still 3-fold less than the Ndom. Surprisingly, for the double valine 
mutant the overall efficiency (kcat/Km 0.007 ± 0.001 x 10
5 M-1.s-1) dropped 9-fold below that of 
the individual V380T mutant.  
Figure 3.4 Correction curve and derived polynomial equation, used to 
determine the necessary adjustments for the correction of the inner filter 
effect. 
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Subsequent sequential conversion of more C-domain to N-domain residues in the S2’ active 
site did little to improve the efficiency of the Cdom (Figure 3.5 A).  This is evident since the 
TEVD mutant, which contains all but the V379S mutation, only has a catalytic efficiency of 
0.003 ± 0.0002x 105 M-1.s-1, while TEVVD containing both valine substitutions has a kcat/Km of 
0.009 ± 0.001 x 105 M-1.s-1. These are 80 and 26-fold lower than that of the Ndom, 
respectively. The complete S2’ C-domain substitution (TEVVD) and the S2 F391Y mutation 
(S2’F) had an efficiency equal to the Ndom. However, the turnover rate was 3-fold lower than 
the Ndom (kcat 0.163 ± 0.008 s
-1 and kcat 0.220 ± 0.020 s
-1, respectively), their efficiencies are 
only equal as the Km  of the S2’F mutant also increased 3-fold (7.62 ± 1.07 µM) (Figure 3.5 B). 
The affinity of the other multiple mutants are all similar (TEVVD Km 24.22 ± 4.15 µM; TEVD Km 
17.54 ± 4.18 µM) to the Ndom; yet their turnover rates are abysmal (Figure 3.5 B and C). The 
same holds for the two Val residues whose increase in efficiency is largely related to the 
increase in catalytic rate and not a change in affinity towards Aβ(4-10)Q. Most notable, is the 
dramatic increase in the kcat of V379S (1.462 ± 0.084 s
-1), being 3-fold higher than the Ndom, 
yet its Km is only half the Ndom’s. 
 
In order to ascertain whether the two valine residues could cause a reciprocal decrease in the 
activity of the N-domain towards Aβ(4-10)Q, we characterised the N-domain mutants S357V 
and T358V (N-domain numbering). Overall, there was no drastic change in the mutants’ 
catalytic rates compared to wild type Ndom. The affinity for S357V is just less than 2-fold 
higher (Km 35.14 ± 2.19 µM) and its turnover rate (kcat 0.485 ± 0.015 s
-1) is equal to the Ndom, 
which in effect brings down the efficiency making it equal to the Ndom (Figure 3.5). 
Surprisingly, the T358V mutant was equivalent to the Ndom across all constants kcat (0.528 ± 
0.061 s-1) Km (22.06 ± 2.86 µM). 
 
  
Table 3.2 Aβ(4-10)Q (Abz-FRHDSG(Q)-EDDnp) kinetic parameters. Determined by the hydrolysis of 
different active site substitution mutations of the N and C-domain of ACE. 
 
Enzyme k cat /KM   (M
-1
. s
-1
)(x10
5
) k cat  (s
-1
) KM  (µM)
Ndom: T358V 0.240 ± 0.003 0.528 ± 0.061 22.06 ± 2.86
Ndom: S357V 0.138 ± 0.007 0.485 ± 0.015 35.14 ± 2.19
Ndom 0.220 ± 0.020 0.480 ± 0.039 22.24 ± 3.23
S2'F 0.223 ± 0.024 0.163 ± 0.008 7.62 ± 1.07
TEVVD/SDSTE 0.009 ± 0.001 0.020 ± 0.002 24.22 ± 4.15
TEVD/SDTE 0.003 ± 0.000 0.005 ± 0.001 17.54 ± 4.18
VV/ST 0.007 ± 0.001 0.007 ± 0.002 10.44 ± 6.06
V380T 0.065 ± 0.040 0.080 ± 0.007 12.32 ± 0.88
V379S 1.580 ± 0.010 1.462 ± 0.084 9.25 ± 0.49
T282S nd nd nd
D453E nd nd nd
E376D nd nd nd
Cdom nd nd nd
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Figure 3.5 Graphic representation of the kinetic parameters determined for the hydrolysis of the FRET 
Aβ(4-10)Q (Abz-FRHDSG(Q)-EDDnp). A) The overall catalytic efficiency ratio of all the mutants 
screened: kcat/KM (s
-1
. M
-1
)(x10
5
).  B) Turnover rate for all the mutants screened represented as kcat (s
-1
). 
C) The binding affinity of Aβ(410)Q towards each enzyme determined as Km (µM).  
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 Confirmation of V397S trend and N-domain selectivity of ACE 3.3.4
with the use of an alternate FRET peptide Aβ(4-10)Y. 
To investigate the role that the large end group EDDnp and the attached Gln, might have on 
the selectivity of the FRET peptide, we used an alternate FRET peptide Aβ(4-10)Y in the kinetic 
analysis of Ndom, Cdom and V397S. 
This peptide contains the wild type sequence FRHDSGY of the Aβ(4-10). The Tyr residue forms 
part of the acceptor group, however, the donor remains the same: Abz-FRHDSG-(Y)3NO2. 
There is increased catalytic efficiency of Cdom Aβ(4-10)Y compared to Aβ(4-10)Q; however, 
Aβ(4-10)Y is still N-domain selective. The increased activity of the C-domain is further 
elaborated on in the following chapter (Chapter 4). Overall Aβ(4-10)Y is a much better 
substrate than Aβ(4-10)Q (Figure 3.6 A and B) (Table 3.3).  This is evident from the kcat values 
of the Ndom constructs, where the turnover rate of Aβ(4-10)Y substrate was two orders of 
magnitude faster than that of Aβ(4-10)Q.  
 It is also quite clear from the turnover rates of V397S that Aβ(4-10)Y is a better substrate as 
the Aβ(4-10)Y kcat for V397S was 24-fold greater than the Aβ(4-10)Q peptide (Table 3.3). In 
terms of catalytic efficiency, the V397S mutant still hydrolyses the Aβ(4-10)Y 2-fold better 
than the Ndom.  This increase in efficiency is due to V397S’s increased catalytic ability (kcat 
36.26 ± 2.75 s-1), the affinity being equivalent to the Ndom and similar to that of Aβ(4-10)Q 
(Figure 3.6 C). The Cdom gained activity (kcat 6.26 ± 2.75 s
-1) with the Aβ(4-10)Y peptide and its 
efficiency was approximately 6-fold lower than that of the Ndom. Thus, this substrate is still 
N-domain selective. The general trend of the results remains the same (Figure 3.6).  
 
Table 3.3 The comparative kinetic parameters of the N-domain, C-domain and V379S mutant to Aβ(4-
10)Y. The Aβ(4-10)Y (Abz-FRHDSG-(Y)3NO2) substrate is highlighted in green and Aβ(4-10)Q 
(Abz-FRHDSG(Q)-EDDnp) in yellow. 
 
 
Substrate Enzyme k cat /KM   (M
-1
. s
-1
)(x10
5
) k cat  (s
-1
) KM  (µM)
Ndom 9.22 ± 0.41 21.72 ± 1.19 23.56 ± 0.24
Cdom 1.67 ± 0.10 6.39 ± 0.71 38.08 ± 3.45
V379S 16.83 ± 2.08 36.26 ± 2.75 22.72 ± 3.87
Ndom 0.220 ± 0.020 0.480 ± 0.039 22.24 ± 3.23
Cdom nd nd nd
V379S 1.58 ± 0.01 1.46 ± 0.08 9.25 ± 0.49
Aβ(4­10)Y
Aβ(4­10)Q
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Figure 3.6 A graphic illustration of the mean kinetic parameters determined for 
the N-domain, C-domain and V397S C-domain active site mutant on two FRET 
substrates with different acceptor groups. Aβ(4-10)Y (Abz-FRHDSG-(Y)3NO2) 
kinetic parameters are represented in green and Aβ(4-10)Q (Abz-FRHDSG(Q)-
EDDnp) are represented in yellow. A) The mean comparison of the enzymes 
hydrolytic efficiency represented by: kcat/KM (s
-1
. M
-1
)(x10
5
). B) The mean turnover
rate represented as kcat (s
-1
). C) The binding affinity of the substrates towards each
enzyme, determined by Km (µM).  
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3.4 Discussion: 
The two domains of ACE are responsible for the enzyme’s diverse functions. The substrates of 
ACE and the resulting products are key to many physiological mechanisms besides blood 
pressure regulation including haematopoiesis, reproduction, immune response and of course 
neurological behaviour (Acharya et al., 2003; Ferrington et al., 2012; Gräff et al., 2012; 
Riordan, 2003). These physiological functions emphasise the importance of determining the 
exact requirements for domain selectivity and functionality, in order to develop better 
treatment for complex disease states like AD.  
The use of spectrophotometric tools to interrogate ligand–protein interactions is pivotal to 
many fields of study, structural biology, biotechnology, and drug discovery being but a few 
examples (Hovius et al., 2000). Advances in peptide synthetic chemistry has made the 
incorporation of non-coded amino acids into polypeptide chains possible (Nilsson et al., 2005). 
FRET peptides are an example of modern spectrophotometric tools for protein analysis, which 
are useful in that they have high assay sensitivity and allow continual reaction monitoring. 
This is key in the determination of enzyme kinetics and subsequent mechanistic 
characterization. This study emphasises, and reiterates the truncated N-domain selectivity of 
Aβ found in Chapter 2 and the literature using the FRET peptides Aβ(4-10)Q and Aβ(4-10)Y.  
The S2’ pocket active site mutants were screened to identify which residues were 
determinants of Aβ selectivity, inducing a switch from the C-domain to N-domain-like activity 
towards Aβ(4-10)Q.  This substrate has an Abz fluorescent group and EDDnp quencher group 
(attached via the substitution of Tyr10 for Gln10). The donor-acceptor pair have an excellent 
energy overlap, and a fluorescence quenching which is not affected by pH (De Souza et al., 
2000). As previously, mentioned (Chapter 2) the large C-terminal EDDnp group usually 
occupies the S2’ pocket, thus cleavage ensues one residue away (Araujo et al., 2000). 
However, under the assays conditions in this study, both fluorogenic peptides were cleaved at 
Asp7-Ser8 as previously described for the non-FRET Aβ peptides. With regards to the 
substrate, this cleavage site shifts the large EDDnp group into the P3’ position. The greater the 
hydrophobicity of the P1’ residues of a substrate, the less domain-selective it is and the better 
it is cleaved by both domains (Araujo et al., 2000). It is conceivable that the two smaller Ser8 
and Gly9 residues occupy the S1’ pocket and, as they are rather neutral and hydrophobic, 
respectively, this would facilitate binding to both N-and C-domain (Figure 3.7). However, the 
substituted Gln10 residue would then occupy the S2’ pocket generating N-selectivity, as 
interactions with similar large charged residues have previously been shown to drive 
selectivity (Douglas et al., 2014).  Electrostatic and chloride mediated interactions with the 
unique charged residues could then shift the acceptor groups into S3’ pocket (Yates et al., 
2014). 
Substitution of Val379 and Val380 with the N-domain Thr and Ser, respectively, induced the 
most significant gain in activity. This suggests that the two valines in the S2’ pocket of the C-
domain are largely responsible its lack of enzyme activity on Aβ(4-10)Q. All other unique 
individual mutations failed to generate N-domain activity towards Aβ(4-10)Q in the C-domain. 
Of the two mutations, the V380T indicated only a moderate increase in overall catalytic 
efficiency compared to the Ndom. This moderate effect has been seen before on this mutant 
with the C-selective Abz-LFK(Dnp)-OH FRET substrate (Kröger, 2009). However, in terms of C-
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selective binding to inhibitors such as RXPA380, kAW and kAF, this single residue mutation 
caused the greatest decrease in affinity.  This residue is found on the border of the S2’ and S1’ 
pockets in the C-domain and it is unlikely that the slight change in hydrophobicity of this large 
S1’ pocket would affect the affinity towards the P1’ Ser8 and Gly9 residues. However, the C-
selective inhibitors’ P1’ residues were much bulkier and the effect of this mutation is thus 
understandable in their case (see review Acharya et al., 2003). 
Replacement of Val379 with a serine results in a C-domain gain in affinity and improved 
catalysis compared to the other S2’ substitutions. The presence of the Ser residue in the S2’ 
pocket induces a 3-fold increase in catalytic activity over the Ndom, along with a large 7-fold 
enhancement in efficiency. The decrease in hydrophobicity of the Cdom S2’ pocket induced 
more favourable interactions towards the large, charged, Gln10 residue of Aβ(4-10)Q.  A 
similar effect was found on this mutant towards N-selective inhibitor RXP407’s affinity (Kröger 
et al., 2009). Stabilisation of the S2’ interactions overcame any lack of interaction in the other 
pockets towards Aβ(4-10)Q. However, the presence of the Ser in V379S, is only beneficial if all 
the residues within the C-domain S2’ pocket remain, otherwise possible inhibitory 
associations and conformations could occur between the residues in S1’ and S2’ pocket 
(Watermeyer et al., 2008).  It is likely that without ligand-mediated stabilising interactions 
within the S1 and S2 pockets, the presence of more charged residues within the C-domain’s 
S2’ pocket disrupt it fundamentally, tipping the balanced charge state as it also contains other 
conserved hydrophobic residues . Hence introducing more N-domain residues together into 
the C-domain does not produce an overall enhancement of substrate hydrolysis. 
This gain of Aβ(4-10)Q hydrolysing ability by the V379S mutant was substantiated through the 
hydrolysis of the Aβ(4-10)Y FRET substrate with a wild type P2’ nitrotyrosine (assuming the S1’ 
occupancy of Ser8 and Gly9). This peptide was a far better substrate for both domains of ACE 
and reflected the same trend in selectivity and activation of the C-domain in the V379S 
mutant.  Tyrosine is a mildly hydrophilic residue due to the presence of the hydroxyl group on 
its hydrophobic aromatic ring.  Thus, it would most likely be a non-selective P2’ residue as it is 
  
Figure 3.7 Schechter and Berger representation of subsites and comparison of putative binding sites 
of the Aβ(4-10)Q, Aβ(4-10)Y and the wild type Aβ(4-10) sequence. The ACE active site subsites are 
indicated by S2, S1 on the N-terminus of the scissile bond and S1’ and S2’ subsites on the C-terminus.  
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neither, large and hydrophobic, nor highly charged, placing greater emphasis on the substrate 
interactions with pockets other than the S2’.  That said, the addition of the 3-NO2 group to the 
benzene ring of Tyr, makes the Y3NO2 group 10 000-fold more acidic (De Filippis et al., 2006). 
The only possible caveat with this quencher group is that its absorption properties are 
strongly pH-dependent, unlike the EDDnp group. The Y3NO2 side chain length, being 30 Å 
larger than the natural Tyr, and its electron-withdrawing NO2 group make the hydroxyl group 
more acidic with a pKa of 6.8 (Sokolovsky et al., 1966). Thus, at lower pH the molecule 
becomes more hydrophobic, and possibly more C-selective, and at neutral to higher pH’s 
more acidic. Our assays were performed at physiological pH and thus this group remains 
acidic. However, this acidity did not affect Cdom hydrolysis of the Aβ(4-10)Y substrate and, 
most notably, improved the interaction with the mutant Ser residue.  This is possibly due to 
the electron sharing of the hydroxyl group with the NO2 group, as they approach the S2’ 
pocket entrance. Interactions with the N-domain would most likely occur between the Ser357 
or Thr358 and Glu431 through hydrogen bonding to either hydroxyl or NO2 group of the 
molecule.  In the C-domain this opening is gated via the two Val379 and Val380 residues and 
the Glu431 is replaced by Asp453 (Figure 3.8). Thus, the NO2 or the hydroxyl group could still 
make hydrogen bonding to the Asp453 residue inducing a gain in C-domain hydrolysis. This 
interaction would not be possible with the Aβ(4-10)Q as the hydrophobicity of the two valines 
would repel the large polar Gln10 as well as its bulky charged EDDnp group.  
Given that V379S was the only single mutation to induce N-domain-like binding, with better 
catalysis of Aβ(4-10)Q, and that this was reproducible with another FRET substrate, and one 
may speculate that this residue is very important for N-domain selectivity towards Aβ. With 
this in mind, the converse mutation of the N-domain’s Ser357 to the corresponding C-domain 
valine (S357V) reduced the catalytic efficiency of the N-domain 2-fold. Mutation of N-
domain’s Thr358 to Val380 (T358V) had no effect. Notably, S357V catalysis was comparable to 
the N-domain but substrate affinity was weakened. The S357V loss of efficiency may be 
attributed to disruption of the backbone hydrogen bonding at the opening of the S2’ pocket 
caused by the inclusion of a valine residue at this position. Hydrogen bonding occurs via 
Ser357 to Glu431, its disruption allows the helix 17 of the N-domain, on which the Glu431 
residue and other S2’ pocket residues exist, to drop and open (Figure 3.8 and Figure 3.9).  This 
could allow for easier access of the Gln10-EDDnp groups, as is seen by the higher KM and thus 
weaker affinity. Movement of this helix is thought to occur based on comparison of the similar 
N-domain bound crystal structure to that of the open ACE2 structure (ACE2 is structurally very
similar to the N-domain with 40% homology) (Guy et al., 2003; Towler et al., 2004).
The more N domain-like the C-domain S2’ pocket became the less benefit was conferred from 
the individual V379S and V380T changes. This is evident from the double VV/ST mutant, for 
which an additive beneficial effect was expected via the overall reduction of hydrophobicity at 
the S2’ pocket opening.  On the contrary, the double mutant had very poor catalytic activity, 
despite very similar binding to V379S.   Similarly, with the TEVD mutant, the binding reverted 
to N-domain-like affinity, yet the catalysis remained dismal.  With the added mutation of 
V379S, to complete the conversion of the C-domain S2’ pocket to that of the N-domain, the 
KM surpassed that of the N-domain, reducing the affinity of the interaction but did little to 
restore enzyme activity.   
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The inhibitor studies and crystal structures (Acharya et al., 2003; Anthony et al., 2012; Corradi 
et al., 2007, 2006; Kröger et al., 2009; Watermeyer et al., 2009, 2008) indicate that there 
should have been an additive effect of these multiple mutants towards a switch in selectivity.  
It is likely that additional intermolecular electrostatic interactions occurred between the 
newly introduced amino acid residues within the more rigid C-domain prime pockets, 
changing the overall conformation of the molecule (Kröger et al., 2009). 
It is also likely that the affinity of Aβ towards these mutants was stronger on the prime side of 
the molecule.  It is possible that there were little or no interactions in the C-domain non-prime 
end to the peptide. Thus, it simply does not bind to the non-prime side and positioning for 
catalysis to occur is weak. This is supported in the complete S2’ mutant combined with the S2 
pocket F391Y mutation (S2’F).  With the S2’F enzyme the affinity of Aβ(4-10)Q improved 3-
fold towards this mutant, catalysis was restored  and the efficiency equalled the Ndom.  The 
single Phe391 residue appeared essential for the C-selectivity of RXPA380 (Kröger et al., 2009) 
for, once mutated to the Tyr, a 36-fold decrease in Ki resulted.  The increased KM towards 
Aβ(4-10)Q in the combination mutations (TEVD and TEVVD) could be a reflection of the lack of 
any S2 interactions and strong S2’ affinities, which together produce rather average affinity 
and a decreased catalytic rate compared to the individual valine mutants. 
The His6 residue, of both FRET peptides, in the P2 position forms part of the Aβ peptide’s 
natural Zn2+chelating region (which includes Glu11, His13 and His14) (Zirah et al., 2006). The 
available crystal structures combined with the kinetics determined in this study compared to 
N-domain inhibitors, allow for speculation as to the interactions driving selectivity from the
non-prime side. It is quite possible that the His6 residue interacts with the H388 conserved
residue in the S2 pocket as well as with the two Zn2+-coordinating H361 and H365 residues via
Figure 3.8 Structural overlay of the Cdom (grey) open structure, with that of the Ndom (cyan) bound 
to the dipeptide Aβ(10-16) cleavage product. Indicated is the 4.206 Å bond between the Ndom Ser357 
and Glu431 residues creating the S2’ gate.  The Ndom S2’ residues are indicated in purple and the Zn
2=
coordinating His residues in cyan.  All Cdom residues are in grey.  
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stacked π-bonds. An example of such an interaction can be found in the binding mode of the 
tetrazole residue of the RXP407-based inhibitor 33RE (Douglas et al., 2014). These π-stacking 
interactions could shift the peptide further along into the S’ subsites and the cleavage site 
towards the non-prime side (as found in the kinetic studies), thus placing more emphasis on 
the S2’ pocket’s water mediated-hydrogen bonding network and the charged residues, all of 
which would interact with the charged Gln10 and Y3NO2 groups. When the S2 Phe391 of the 
C-domain is converted to the N-domain Tyr369, hydrogen bonding could occur to the π-
bonded Aβ His6 residue strengthening the affinity. One further observation from the Aβ(1-16) 
crystal structure with its Gln15 and Lys16 dipeptide is that R381 is outwards facing (Figure 
3.9).The R381 residue on the S2 pocket may well swing round, as it does with RXP407 where it 
forms a salt bridge to the P2 acetylated aspartate residue (Kröger et al., 2009). This 
interaction is lost in the 33RE N-domain crystal structure (Douglas et al., 2014) and from the 
current crystal structures of Aβ fragments this R381 also faces away as in 33RE (PDB number 
4BXK ) (Figure 3.9). 
 
 
 
Figure 3.9 The crystal structure of the Ndom active site (cyan ribbons) with the Aβ Gln15 and Lys16 
(gold sticks) dipeptide product bound to the S2’ pocket. The S2’ pocket residues are in purple with the 
Ser357,Glu431 and water mediated gate interactions indicated. Helix 17 is closed as a result. The Zn
2=
is 
indicated in grey, coordinated to the two cyan H365 and H361. The S2 pocket residues of interest are 
indicated in green, with the Arg381 turned away from the active site.  
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This balance of enzyme-inhibitor interactions in the different active site binding pockets is 
currently being investigated in our lab on the N-selective inhibitor 33RE (Douglas et al., 2014) 
using molecular dynamics. The S2’ interactions are identical in both 33RE and RXP407, with 
the unique N-domain S2’ residues quite distant from the inhibitors, indicating direct 
interactions to conserved residues only, like many of the Aβ-crystals indicated. Mutation of 
these unique residues did little to reduce RXP407 affinity towards the N-domain (Kröger et al., 
2009), yet removal of the P2’ amide of RXP407 abolished selectivity (Dive et al., 1999). 
Similarly, we did not see a gain in activity towards Aβ(4-10)Q with the complete conversion of 
unique C-domain S2’ residues to their N-domain counterparts. It appears that N-selective 
substrates require interations to occur through N-domain specific residues and indirectly 
through a water network. This suggests that the P2 (small acidic reisdues) and P2’ (larger 
charged residues) groups of the substrate synergistically govern N-selectivity, in a similar 
fashion to that of N-selective inhibitors, like RXP407, where selectivity is driven by less 
obvious interactions.  Also, the amyloid substrates used all appear to have the requirements 
of an N-domain selective substrate, namely a small acidic P2 residue (His6) and charged P2’ 
group (Douglas et al., 2014; Kröger et al., 2009; Vazeux et al., 2001) like Gln10 and Y3NO2 in 
the case of Aβ(4-10)Q and Aβ(4-10)Y, respectively. 
The lack of C-selectivity towards Aβ is likely dependent on what fragment of the full-length 
sequence the active site is exposed to at a time. The identification of various Aβ cleavage sites 
in this study strongly suggests that ACE does not have a preference for specific residues in the 
P1 and P1’ position with regard to Aβ, being targeted to conserved residues only. However, 
within the N-terminal region of Aβ its large charged groups in the P2’ or P3’ position combined 
with acidic P2 groups make it a preference of the N-domain active site. These ligand 
characteristics, be they substrates or inhibitors, form part of the molecular basis for N-domain 
specificity. As Aβ appears to fit these requirements, the results in these studies have 
implications towards the development of domain selective ACEi for the treatment of 
hypertension and or AD. Specifically these results are in support of the development of C-
selective inhibitors that may provide both cognitive and anti-hypertensive beneficial effects. 
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4 CHAPTER  
Kinetic characterisation of the interactions between the two domains of sACE on the hydrolysis 
of N-terminal Aβ peptides  
4.1 Introduction and aims 
The most well-known toxic form of the Aβ is 42 residues long, although Aβ also occurs in 
many truncated variants and in more soluble forms (Kummer and Heneka, 2014) (see Chapter 
1 section 1.2.1). These more soluble oligomers and protofibrils are strongly correlated with 
increased toxicity compared to the more structured fibrils (Mc Donald et al., 2010; McLean et 
al., 1999; Tomic et al., 2009; Woltjer et al., 2009). The Aβ(1-16) amyloid variant is formed via 
both amyloidogenic and non-amyloidogenic secretion pathways, however it has a 
controversial role in AD and its toxicity is unclear (see Chapter 1 section 1.2.1.2).  
The level of ACE’s substrate promiscuity has a lot to do with its physiological two-domain sACE 
form. There is conflicting evidence regarding N- and C-domain-selectivity of Aβ cleavage by 
ACE and the enzyme’s P1 and P1’ preference (see Chapter 2). The general trend of results 
indicates that the N-domain alone is more effective at Aβ cleavage than the C-domain (Oba et 
al., 2005; Toropygin et al., 2008; Zou et al., 2009) (See Chapter 3). However, in sACE the C-
domain appears to have equivalent selectivity to the N-domain (Hemming and Selkoe, 2005; 
Sun et al., 2008a). To date, the mechanism of interaction between the N- and C-domains of 
ACE is not fully understood. It is, however, evident that there is a degree of cooperativity 
between the two domains with certain substrates and inhibitors (Andújar-Sánchez et al., 
2007; Binevski et al., 2003; Ehlers et al., 1991; Jaspard et al., 1993; Junot et al., 2001; Wei et 
al., 1991). Cooperativity refers to the synergistic effect that ligands or substrates have on 
enzymes where binding to one site influences the binding and catalysis of the other.  The N- 
and C-domains of ACE have been shown to display negative cooperativity in substrate 
hydrolysis (Binevski et al., 2003; Rice et al., 2004; Skirgello et al., 2005). While this was 
observed with many synthetic and naturally occurring peptides, not all substrates displayed 
such an effect (Rice et al., 2004). 
As established within this thesis, the truncated domains of ACE are N-selective towards both 
short FRET peptides, Aβ(4-10)Q and Aβ(4-10)Y, supporting the results from the literature on 
various forms of amyloid (Chapter 1 section 1.6.1). Characterisation of the cleavage site of 
Aβ(1-16) suggested that the N-domain was selective for this substrate (Chapter 2). This 
peptide contains the metal binding region of Aβ(1-42) and also undergoes multiple PTMs 
following aging and AD states, which enhance its aggregation and that of the longer Aβ(1-X) 
peptides (reviewed in Chapter 1 section 1.2.1.1). This emphasises the need to further evaluate 
the kinetic analysis of its hydrolysis by ACE. As selectivity occurs within the truncated 
domains, it is important to understand whether this selectivity is conserved within the two-
domain form of ACE. 
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Aims and Objectives: 
The main aim of this chapter is to analyse the soluble species of Aβ, the possibly toxic Aβ(1-
16) (Du et al., 2011; Kozin et al., 2011; Portelius et al., 2006; Ramteke et al., 2014) and two 
fluorogenic peptides of the N-terminal region of Aβ to investigate the kinetics of processing, 
the degree of domain substrate specificity and potential co-operative effect the two domains 
of ACE have on hydrolysis.   
Objectives: 
1) To kinetically characterise and assess the truncated N-and C-domains, full-length 
sACE, and its domain knock-out forms as well as the double C-domain sACE construct 
towards Aβ(1-16) . 
2) To examine and compare, kinetically, the FRET substrates (Aβ(4-10)Q and Aβ(4-10)Y) 
in terms of hydrolysis by the truncated and full-length ACE variants.  
Kate Larmuth  CHAPTER 4 Domain cooperativity towards Aβ 
83 
4.2 Methods: 
 Enzyme constructs 4.2.1
For expression of protein in CHO cells, the relevant genes were cloned into the mammalian 
expression vectors. For the construction of full-length, human, recombinant sACE constructs 
see Chapter 2 section 2.2.1.2. This includes the construction of sACE, CC-sACE, N-sACE and C-
sACE (Figure 2.2). Briefly, sACE consists of wild type membrane bound human sACE. CC-sACE 
consists of sACE, in which the N-domain has been substituted for a second C-domain. For the 
full-length domain knockouts of sACE, both constructs have the complete signal, TM and stalk 
region corresponding to full-length sACE with their N and C-domain active sites inactivated (C-
sACE and N-sACE respectively). For the soluble, truncated, human Cdom and Ndom 
constructs, see Chapter 2 section 2.2.1.1. 
 Protein expression and purification 4.2.2
Transfection and expression of all enzymes as described in Chapter 2 
4.2.2.1 Mammalian cell expression of ACE enzymes. 
For the cellular expression of ACE proteins See Chapter 2 section 2.2.2.1 
4.2.2.2 Selection of high expressing cells lines. 
The FACS technique was applied to all sACE TM constructs, barring CC-sACE, which is shed in 
high amounts and can be purified directly from all growth media, see Chapter 2 
section 2.2.2.2. 
4.2.2.1 Isolation of secreted ACE protein from growth media. 
For purification of soluble constructs (Ndom, Cdom and CC-sACE) affinity chromatography was 
used as described in Chapter 2 section 2.2.2.3.  
4.2.2.2 Isolation of transmembrane protein from cell lysis. 
For the purification of the membrane bound sACE, N-sACE and C-sACE a modified procedure 
of affinity chromatography (Ehlers et al., 1991) was used, as described in Chapter 2 
section 2.2.2.4. 
 Determination of ACE activity 4.2.3
Cell lysate, medium or purified protein was assayed for ACE activity using the synthetic 
peptide ZFHL see Chapter 2 section 2.2.3.1. 
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 Specific activity/active site titrations 4.2.4
In addition to active site titrations, specific activities were also performed and used to 
determine enzyme concentration for all kinetics performed in this chapter. This technique was 
implemented as inhibitor binding to two domain molecules induces cooperativity and one 
mole of sACE is equivalent to one mole of non-selective inhibitor (Lisinopril) (Andújar-Sánchez 
et al., 2007). Thus, active site titrations in sACE are not ideal, as the total amount of potential 
Aβ degrading actives sites could not be determined. In order to determine loss of enzymatic 
activity due to storage, specific activities were calculated immediately after purification. It was 
assumed that the enzyme, which is eluted off the lisinopril column, must be active in order to 
bind the ligand. Specific activities were then re-determined prior to kinetic analysis and 
protein concentrations adjusted accordingly towards two active sites (Rice et al., 2004). 
 Amyloid kinetics 4.2.5
4.2.5.1 The unmodified Aβ(1-16) substrate. 
The Aβ(1-16) (H-DAEFRHDSGYEVHHQK-OH) (Bachem AG) ACE hydrolysis assays were 
performed in reaction tubes and transferred to HPLC vials for analysis using the Agilent 1260 
Infinity HPLC. 
4.2.5.1.1 Determination of Aβ(1-16) kinetic parameters. 
4.2.5.1.1.1 HPLC based assay on the unmodified Aβ(1-16). 
Enzyme reactions were initiated on the addition of 25 µl enzyme (at a concentration within 
10% hydrolysis of substrate of 0.25 nM Ndom, 1 nM N sACE, 2.4 nM sACE, 35 nM C-sACE, 290 
nM CC-sACE and 300 nM Cdom) to 25 µl Aβ(1-16) in 1X HEPES buffer, ranging in concentration 
from 0 to 45 µM. The reaction was incubated for 15 min at 37ºC and stopped with the 
addition of 10 µl 0.25% TFA. The total reactions (60 µl) were cleared of contaminants on a spin 
column (GHP Nanosep® MF Centrifugal Device 0.45 µm pore size) prior to loading on the 
HPLC. All reactions were performed in duplicate and 50 µl injections were used to analyse 
samples, via HPLC (Agilent technologies), across a gradient of 0.1% TFA and 2% ACN in water 
to 0.1% TFA, 95% ACN. Importantly the substrates and products eluted at an isocratic step of 
40% of the high ACN solution. The initial rates of reactions were generated via plotting the 
resultant peak product area, and converting it to pmols Aβ(1-14) product formed by means of 
a calibration curve (see below). This was then used to assess enzyme activity. The kinetic 
constants, for each enzyme, were calculated using the Michaelis-Menten method using Graph 
Pad Prism software (v 4.01, GraphPad Prism®). 
4.2.5.1.1.2 Calibration Curve of Aβ(1-16). 
In quantitative HPLC, the height and peak area are proportional to the concentration of the 
corresponding specific compound. A calibration curve was set up to convert product peak 
area to pmols product formed, through the complete hydrolysis of the substrate with the 
Ndom. Simply put, the curve allows for the determination of the amount of Aβ(1-14) 
produced from a specific concentration of Aβ(1-16). Initial reaction rates, generated by 
converting and plotting the resultant product (Aβ(1-14)) peak area, enables the assessment of 
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enzyme activity (See appendix 7.5.3). For the generation of calibration curves, reaction 
mixtures were separated on a Poroshell 120 EC-18 column with a 2.7 micron pore size. The 
reaction consists of 25 µl aliquots of Aβ(1-16) in 1X HEPES buffer, over the concentration 
range 0 to 40 µM, incubated with 25 µl 1 nM Ndom for 2 hours at 37ºC for complete 
digestion. The reactions were stopped with the addition of 10 µl of 0.25 % TFA. The total 
reaction (60 µl) was cleared of contaminants on a spin column (GHP Nanosep® MF Centrifugal 
Device 0.45 µm pore size) and run on the HPLC (Agilent technologies). Linear regression 
analysis was used to correlate the change in peak area to pmols of Aβ(1-14) product formed, 
with GraphPad Prism software (v 4.01, GraphPad Prism®). 
4.2.5.2 Fluorogenic Amyloid Substrates. 
Fluorogenic substrates designed around the established N-terminal Asp7-Ser8 cleavage site of 
the Aβ(2-11) were used as for a more high-throughput assessment of kinetic characteristics. 
There are two variations of FRET peptides, the first Aβ(4-10)Q, (Abz-FRHDSG(Q)-EDDnp) has 
an N-terminal o-aminobenzoyl (Abz) donor and a C-terminal ethylenediamine 2, 4-
dinitrophenyl (EDDnp) quencher group, which is attached to an additional Gln10 substitution 
residue . The second peptide has a different quencher molecule, a 3-nitrotyrosine, a 
modification, which occurs in amyloid plaques, to the naturally occurring Tyr10 residue, Aβ(4-
10)Y (Abz-FRHDSG-(Y)3NO2). 
4.2.5.2.1 Determination of the Fluorogenic amyloid Substrate kinetic 
parameters. 
4.2.5.2.1.1 Fluorogenic Aβ(4-10)Q Substrate. 
Hydrolysis of Abz-FRHDSG(Q)-EDDnp (Aβ(4-10)Q), a kind gift from A. Carmona, Universidade 
Federal de São Paulo) was performed in 1X HEPES buffer with 150 µl enzyme (at a 
concentrations of 5 nM Ndom, 30 nM N-sACE, 5 nM sACE, 5 nM C-sACE, 20 nM CC-sACE, 
20 nM Cdom, within 10% hydrolysis) and an equal volume of substrate ranging from 0 to 
30 µM.  The assay is a modified form of the continuous assay (Araujo et al., 2000) performed 
in 96 well plates. Again, kinetic constants were calculated using the Michaelis-Menten method 
with GraphPad Prism software (v 4.01, GraphPad Prism®). The detected fluorescence was 
converted to pmol product via a Abz-Gly standard curve and data was corrected for IFE (Liu et 
al., 1999).  Also see Chapter 3 section 3.2.7. 
4.2.5.2.1.2 Flourogenic Aβ(4-10)Y Substrate. 
An alternate fluorogenic peptide, Abz-FRHDSG(Y)3NO2 (BIOPEP ™South Africa) (Aβ(4-10)Y) 
being more physiological apart from its Abz-group, was assayed, as above, in 96 well plates. 
They had a final volume of 200 µl (final enzyme concentrations, within 10% hydrolysis of 1 nM 
Ndom, 0.6 nM N-sACE, 0.2 nM sACE, 1.3 nM C-sACE, 0.3 nM CC-sACE and 4.2 nM Cdom once 
more within 10 % hydrolysis). The samples were read at a 5 min time point on a Cary Eclipse 
spectrofluorimeter (Varian Inc.) at excitation wavelength of 320 nm and emission wavelength 
of 420 nm. Kinetic constants, IFE and standard curves were calculated as above. Also, see 
Chapter 3 section 3.2.7.  
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 Peptide integrity and cleavage site analysis 4.2.6
4.2.6.1 Mass Spectrometry 
The Mass spectrometry was performed at the Centre for Proteomic and Genomic Research 
(CPGR, Cape Town, South Africa), as further elaborated in Chapter 2 
 Statistical Analysis 4.2.7
Statistical analysis of the data was determined by Student’s t-test. Differences with p < 0.05 
were considered statistically significant. 
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4.3 Results: 
 Kinetics of hydrolysis β-amyloid peptides by ACE 4.3.1
Kinetic constants were determined for the hydrolysis of various Aβ peptides by the two 
separate domains of ACE (Ndom and Cdom) and full-length sACE variants in order to further 
delineate domain selectivity and probe cooperative effects of the two domains. The human 
sACE, C-sACE, N-sACE, Ndom, Cdom and CC-sACE variants were purified to apparent 
homogeneity as assessed by SDS-PAGE (Chapter 2 Figure 2.3). For all average Michaelis-
Menten curves see section 7.6. 
4.3.1.1 The Aβ(1-16) substrate:  
The Aβ(1-16) peptide was cleaved most efficiently by the truncated Ndom (kcat/Km 17.70 x 
105 M-1.s-1), but was not hydrolysed by the truncated Cdom even after prolonged incubation 
times (Figure 4.1.1 A) (Table 4.1). A similar trend was found with the full-length sACE 
constructs. The sACE with a catalytically inactive N-domain (C-sACE) was approximately 
18-fold less efficient than N-sACE. The efficiencies of N-sACE and wild type sACE, however, are 
comparable with kcat/Km’s of 3.21 ± 0.22 and 2.36 ± 0.03 x 10
5 M-1.s-1, respectively. The varying 
catalytic efficiencies between N-sACE and C-sACE are due to an 16-fold difference in kcat as the 
Km’s for sACE, N-sACE and C-sACE are almost equivalent (Figure 4.1.1 B and C respectively). 
It is important to note that the kcat/Km for N-sACE and sACE was approximately 6-fold lower (p 
< 0.05) than that of the truncated N-domain (Ndom) (Figure 4.1.1 A).  This is attributed to the 
relatively low affinity (Km 22.85 ± 0.21 µM) and the high catalytic activity (kcat 39.30 ± 1.99.s
 -1) 
of the Ndom (Figure 4.1.1 C and B respectively) (Table 4.1). The CC-sACE construct was 
investigated to see if there was any structural or physical effect on the C-domain of sACE 
through the presence of another protein other than the N-domain. Similarly to the Cdom, 
CC-sACE processed Aβ(1-16) poorly compared to C-sACE. Although CC-sACE did process Aβ (1-
16), the rate was too slow to generate accurate kinetic constants (Table 4.1). 
 
Table 4.1 Kinetic parameters of Aβ(1-16) (H-DAEFRHDSGYEVHHQK-OH) hydrolysis by different ACE 
variants/molecules. Turnover rates were normalised to activity per unit active site for enzymes containing 
two functional domains (sACE and CC-sACE). (Error is represented as standard error of the mean (± SEM) 
 
Enzyme k ca t/KM (µM
-1. sec-1) k ca t (sec
-1) KM (µM) Vmax  R
2
Ndom 17.70 ± 0.70 39.30 ± 1.99 22.85 ± 0.21 0.49 ± 0.02 0.9566
N-sACE 3.21 ± 0.22 11.03 ± 1.62 34.20 ± 5.90 0.55 ± 0.08 0.9230
sACE 2.36 ± 0.03 8.37 ± 1.54 35.63 ± 6.23 1.00 ± 0.19 0.9497
C-sACE 0.17 ± 0.02 0.67 ± 0.08 42.36 ± 9.57 1.15 ± 0.14 0.9355
CC-sACE ND ND ND ND ND
C-Dom ND ND ND ND ND
*ND, not determined
  
8
8
 
    
Figure 4.1 The hydrolysis of 1: Aβ(1-16)  2: Aβ(4-10)Q  3: Aβ(4-10)Y by ACE.  Bar graph diagrams illustrating A) The overall catalytic efficiency (kcat/Km), B) the turnover 
rates (kcat)and C) the relative affinity (Km ) of the Aβ(1-16) hydrolysis by both truncated and full-length constructs of ACE, including wild type sACE. 
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4.3.1.2 The FRET Aβ(4-10) Substrates: 
Following Aβ(1-16), I examined theability of different ACE constructs to hydrolyse the 
fluorogenic Aβ(4-10) peptides with different quencher groups.  
4.3.1.2.1 The Aβ(4-10)Q substrate. 
The Aβ(4-10)Q peptide was hydrolysed very inefficiently by both Ndom and N-sACE (kcat/Km 
0.22 x 105 and 0.09 x 105 M-1.s-1, respectively) (Figure 4.1.2 A) (Table 4.2). However, the trend 
of the full-length and truncated ACE constructs was similar to the physiological Aβ(1-16), 
being more selective for the truncated Ndom.  
Compared to N-sACE, Ndom’s greater selectivity for the Aβ(4-10)Q peptide was due to a 
tighter affinity alone (Figure 4.1.2 C), as the catalytic rate of N-sACE (0.36 ± 0.02 s-1) was 
roughly equal to the Ndom (0.48 ± 0.04 s-1) (Figure 4.1.2 B).  By comparison, the C-sACE has 
very poor catalytic ability (kcat 0.08 ±0.01.s
-1) and tight affinity, with Km half that of the Ndom 
(Figure 4.1.2 B and C), creating an equivalent efficiency to N-sACE.  
The efficiency of sACE was very poor compared to Ndom, due to its approximately 8-fold 
lower kcat; its affinity was equal to the Ndom (22.90 ± 3.45.s
-1). Overall, the efficiency of sACE 
was 3-fold lower in comparison to the mutants with only a functional C- or N-terminal active 
site. This is indicative of a synergistic effect between the two active domains. The two domain 
CC-sACE cleaved Aβ(4-10)Q very slowly and accurate kinetic constants could not be calculated
(Table 4.2).
Table 4.2 Aβ(4-10)Q (Abz-AβFRHDSG(Q)-EDDnp) kinetic parameters by hydrolysis of different ACE 
variants/molecules. Error is represented as standard error of the mean (± SEM). 
Enzyme kcat /KM (s
-1. M-1)(x105) kcat  (s
-1) KM (µM) Vmax  R
2
Ndom 0.22 ± 0.02 0.48 ± 0.04 22.20 ± 3.23 0.28 ± 0.02 0.9500
N-sACE 0.09 ± 0.01 0.36 ± 0.02 42.43 ± 3.92 3.230 ± 0.20 0.9797
sACE 0.03 ± 0.01 0.06 ± 0.01 22.90 ± 3.45 0.09 ± 0.01 0.9002
C-sACE 0.08 ± 0.01 0.08 ± 0.01 11.50 ± 3.03 0.12 ± 0.01 0.9181
CC-sACE ND ND ND ND ND
Cdom ND ND ND ND ND
*ND, not determined
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4.3.1.2.2 The Aβ(4-10)Y substrate. 
The more physiological fluorogenic peptide, Aβ(4-10)Y, was a far better substrate than 
Aβ(4-10)Q. When comparing the truncated constructs, Aβ(4-10)Y was more N-domain-
specific. It was cleaved with half the catalytic efficiency of Aβ(1-16) by Ndom (9.2 vs. 13.0 
x 105 M-1.s-1) yet there was a gain of function with Cdom (Figure 4.1.3 A) (Table 4.3). 
Contrary to the results of Aβ(1-16), sACE hydrolysed Aβ(4-10)Y more efficiently than Ndom, 
this difference is due to the larger Km value of the Ndom, as their catalytic rates are equivalent 
(Figure 4.1.3). Most surprisingly, the catalytic efficiency of sACE towards Aβ(4-10)Y was 
equivalent to the Ndom Aβ(1-16) catalytic efficiency. Notably, there was a general gain in C-
domain activity with Aβ(4-10)Y. This is evident in the comparable efficiencies between, Cdom 
and C-sACE, and, N-sACE and CC-sACE (Figure 4.1.3 A) (Table 4.3). The C-sACE Km is, however, 
2-fold larger than its active N-domain counterpart (Figure 4.1.3 C) accounting for C-sACE’s
lower catalytic efficiency (Figure 4.1.3 B).
Interestingly, the CC-sACE construct cleaved the Aβ(4-10)Y with a higher kcat/Km than N-sACE, 
but a lower efficiency than the truncated Ndom.  The overall turnover rate for CC-sACE was 
double that of the Cdom and much greater than C-sACE for Aβ(4-10)Y. 
Table 4.3 . Aβ(4-10)Y (Abz-FRHDSG-(Y)3NO2) kinetic parameters on hydrolysis with different ACE 
variants/molecules. Error is represented as standard error of the mean (± SEM). 
Enzyme kcat /KM (s
-1. M-1)(x105) kcat  (s
-1) KM (µM) Vmax R
2
Ndom 9.22 ± 0.41 21.72 ± 1.19 23.56 ± 0.24 4.62 ± 0.14 0.9662
N-sACE 3.88 ± 0.11 4.45 ± 0.45 11.52 ± 1.49 0.44 ± 0.01 0.9413
sACE 17.35 ± 1.48 24.30 ± 3.55 13.15 ± 2.66 0.90 ± 0.18 0.9798
C-sACE 1.67 ± 0.10 6.39 ± 0.71 38.08 ± 3.45 1.57 ± 0.09 0.9826
CC-sACE 5.51 ± 1.21 9.92 ± 0.58 18.67 ± 3.06 0.90 ± 0.08 0.9462
Cdom 2.18 ± 0.70 6.33 ± 1.81 35.38 ± 19.65 4.45 ± 0.63 0.9065
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4.4 Discussion: 
In order to understand the potential differences between the two domains of ACE and their 
synergy in full-length sACE we have investigated the metabolism of the Aβ peptide by single 
and double domain ACE forms. Previous studies have noted potential discrepancies in kinetic 
data and a lack of substrate specificity based on different sources and forms of ACE (Marcic et 
al., 2000; Rice et al., 2004). Thus, all of the constructs were purified from one cell line of CHO 
cells and assay conditions were as physiological as possible for the assessment of Aβ.  With 
regard to this, the cleavage of Aβ under kinetic assay conditions was examined extensively in 
chapter 2 and the Aβ(1-16) peptide was cleaved at the penultimate His14-Gln15 bond by all 
the ACE constructs, typical of ACE’s exopeptidase action. The fluorogenic ACE substrates, Aβ(4 
10)Q and Aβ(4 10)Y, were both endoproteolytically cleaved at the anticipated Asp7-Ser8 
bond. Again, the cleavage site was consistent across all ACE variants (Chapter 2). Thus, it is 
unlikely that any differences, across ACE variants, in selectivity and cooperativity would be 
attributed to variations of cleavage specificity of these peptides within this assay. 
The only kinetic constants, available for ACE and Aβ, in the literature were characterised using 
an ELISA assay, which is not the most reliable and accurate technique (Zou et al. 2007). 
Furthermore, only sACE was used and there was no deeper investigation into selectivity or 
cooperativity. Comparatively, the Aβ(1-16) is a better substrate of ACE than Aβ(1-42) with a 
faster catalytic rate. The soluble Ndom had a much higher catalytic turnover for Aβ(1-16) than 
either sACE or N-sACE. Furthermore Aβ(1-16) was a better Ndom substrate than the smaller 
Aβ(4-10) substrates (Figure 4.1.1, 4.1.2 and 4.1.3 B).  
Interestingly, N-domain selectivity is affected in the full-length form of ACE across all 
substrates. Thus, sACE with an inactivated C-domain (N-sACE) has lower kcat values for both 
Aβ(1-16) and Aβ(4-10)Y than the truncated Ndom. This decrease in turnover rate substantially 
reduces the N-domain selectivity of the full-length knockouts. For example, the kcat for 
Aβ(4-10)Y is similar for the N- and C- sACE constructs (Figure 4.1.3 B), even though the Km of 
the C-sACE is greater than that of N-sACE (Km of 38.08 ± 3.45 and 11.52 ± 1.49 µM 
respectively) (Table 4.3). On the other hand, the truncated Ndom and Cdom have large 
differences in their kcat’s and similar Km’s and thus are highly N-domain selective. The sACE 
form appears to improve the interaction of the Aβ(4-10)Y within the N-domain of N-sACE and 
slow the turnover rate. The opposite is true for Aβ(4-10)Q. 
Despite a general decrease in selectivity of N-sACE compared to the Ndom, our results 
indicate amyloid is far more N-domain selective in the current optimal C-domain conditions 
(higher NaCl concentrations, which are critical to C-domain activity). The two active sites 
within human and bovine sACE have been shown to exhibit negative cooperativity with 
synthetic tripeptide substrates (Binevski et al. 2003; Skirgello et al. 2005; Woodman et al. 
2005). In addition, a study using physiological substrates and human ACE enzymes showed a 
similar result for ANGI and ANG(1-7), but not ANG(1-9) (Rice et al. 2004). This implies that 
different substrates result in varying synergistic effects of the two domains (Rice et al. 2004). 
Similar to other kinetic observations with physiological substrates such as ANG(1-9) and BK, 
the degree of cooperativity between domains, with regard to Aβ(1-16) and Aβ(4-10)Q and 
sACE constructs, is considerably less than that observed with synthetic peptides (Jaspard et al. 
1993; Rice et al. 2004).  
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Given the discrepancy between the magnitude of selectivity of the truncated domains and the 
sACE forms, there are most certainly cooperative effects taking place with regard to the Aβ 
substrates analysed. The equivalent affinity, of the truncated and full-length constructs, to 
Aβ(1-16) and the largely varying turnover rates suggests a close interaction between the two 
domains (Figure 4.1.2 A and B). Thus, the binding and hydrolysis of their individual active sites 
appear to be affected by the domain proximity.  The cooperative effects of the two domains 
towards Aβ(1-16), overall, are negative (Figure 4.1.2  B). Due to the C-domains poorer 
hydrolysis of Aβ we can infer that the C-domain appears to negatively regulate the N-domain 
in sACE.  This is also true for the Aβ(4 10)Q substrate, although to a lesser extent.   
There is a large shift in both level of cooperativity and type of cooperativity when comparing 
the truncated domains to the full-length knockouts. For instance, with Aβ(1-16) the 
magnitude of the negative cooperativity with the full-length constructs is much smaller than 
that derived from the truncated domains. However, Aβ(4-10)Q has no shift in cooperativity. 
The positive effect of the N-domain on Aβ hydrolysis is evident with the C-sACE variant.  
C-sACE exhibited improved activity when compared to the truncated Cdom for all Aβ 
substrates, suggesting that the N-domain plays an auxiliary role. This notion is further 
supported by the poor activity of CC-sACE and its interaction with Aβ(1-16). This confirms that 
the mere presence of another domain does not improve the C-domain hydrolysis of Aβ 
peptides and that the interaction is N-C-specific. Our laboratory has previously shown that the 
presence of the N-domain has regulatory effects on the post-translational shedding of ACE 
and hydrolysis of substrates ZFHL and (Abz)-LFK(Dnp)-OH (Woodman et al. 2005). In contrast 
to these substrates, sACE CC-domain enzyme possessed a catalytic ability per active site 
similar to the individual domains, indicating an additive effect between the two C-domains 
with Aβ(4-10)Y substrate. Taken together, these data suggest that the type of substrate could 
influence the effects caused by domain interactions.  
With this in mind, the cooperativity in the two-domain sACE variants was drastically altered by 
the presence of Aβ capping groups. The FRET substrates, considering only the truncated 
domains (Ndom and Cdom), induce a negative cooperative effect on the activity of sACE 
(Figure 4.1.3 B and to a much smaller extent Figure 4.1.4 B). On examination of the N-sACE 
and C-sACE constructs, a positive form of cooperativity is now found towards the Aβ(4-10)Y 
peptide. The binding and hydrolysis of the two catalytic sites is thus affected by both the 
structural arrangement of the two domains as well as the substrate-binding site interactions. 
The different cooperative effects of Aβ(4-10)Q and Aβ(4-10)Y could be ascribed to their 
distinct quencher groups. Specifically, the Aβ(4-10)Y contains a nitrotyrosine, instead of the 
Gln-EDDnp group, and the linker to the quencher also differs, resulting in cooperativity 
contrary to what was observed with FRET Aβ(4-10)Q  and  Aβ(1-16).  
Oba et al. (2005) discovered that the larger Aβ(1-40) substrate did not out-compete smaller 
substrates like HHL within the truncated C-domain. They advocated that the C-domain was 
not conducive to the binding of large Aβ peptides, as Aβ did not inhibit the C-domain. This 
observation is supported by the architecture of the central cavity found in the tACE crystal 
structure and the chloride-dependent substrate interactions (Natesh et al. 2003; Yates et al. 
2013). The Oba et al. (2005) study was performed on recombinant truncated domains only, 
resulting in a large N-domain preference for Aβ hydrolysis. This is supported by the results on 
truncated domains found in this study. The full-length C-sACE, however, gains activity towards 
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both the longer Aβ(1-16) and the shorter FRET substrates. This suggests that physiologically 
the role of the C-domain in Aβ cleavage cannot be excluded. Based on the results of this study 
and the synergistic effect that the C-domain exerts on the N-domain, it is likely to be 
important in vivo.  
Smaller Aβ molecules, like Aβ(1-16), may have better access to the C-domain. Indeed, the C-
domain of sACE most certainly has some Aβ affinity, as is evident in the Aβ(1-16) and the FRET 
Aβ(4-10)Q and Aβ(4-10)Y peptides. One might speculate that the structure of the C-domain in 
sACE may be more open due to the physical, and specific, presence of the N-domain.  The N-
domain, possibly, stretches out the flexible lid of helices α1-α3 in the C-domain, giving it more 
efficient substrate access (Corradi et al. 2006).  Fluorogenic peptides may not necessarily be 
the best at indicating selectivity. This is so as the addition of, or derivativisation with, artificial 
groups may bias domain specificity due to their size, charge and the additional amino acids 
required to attach them (Araujo et al. 2000; Narawane et al. 2014). It is also possible for these 
groups to stabilise an interaction that would not necessarily take place (Narawane et al. 
2014).  Nevertheless, it is interesting to note the shifting selectivity within the FRET systems 
themselves, particularly towards Aβ(4-10)Y, as it contains a naturally occurring nitrotyrosine 
(Kummer et al., 2011; Radi, 2004). This modification may make targeting and proteolysis by 
the C-domain of ACE easier, especially since the Abz groups are shared between FRET 
peptides implicating the final residue position as crucial. Thus, extrapolating in theory, C-
domain hydrolysis of peptides bearing this PTM could enhance the plaque clearing abilities of 
sACE within the human brain with its induced positive cooperativity. 
In this study, we have assessed the domain selectivity and cooperativity of Aβ peptide 
hydrolysis. This further emphasises the dynamic roles of the two domains of sACE in substrate 
processing. This dynamism is not conserved across all ACE substrates, but rather appears 
dependent on the nature of the substrate itself. Together these data could assist in providing 
a perspective towards the relative domain orientation in sACE, with regard to substrate and 
inhibitor binding as well as kinetic cooperativity. Resolution of the sACE crystal structure 
combined with the already existing EM structure (Chen et al., 2010) will undoubtedly assist in 
providing further mechanistic insight into these observations. These considerations are 
important for the future design of N- and C-domain selective ACE inhibitors especially in 
consideration of hypertensive AD patients. 
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5 CHAPTER 
The effects of the Aβ substrate on ACE signalling. 
5.1 Introduction and Aims 
ACE is a membrane bound molecule and has a short cytoplasmic domain, a transmembrane 
region and a large ectodomain - all of which are necessary components of receptors. 
Receptors can make use of phosphorylation to propagate negative and positive feedback to 
stimuli. It is thus intuitive that the one tyrosine and five serine residues, found in ACE’s 
cytoplasmic tail, could act as potential phosphorylation sites for cell signal transduction. These 
observations prompted the investigation of the potential signalling mechanism of ACE 
(Kohlstedt et al., 2004). Kohlstedt et al., found that upon inhibitor binding, dimerization of 
membrane bound sACE and CK2 mediated phosphorylation of Ser1270 occurred. This 
phosphorylation, a result of an ACE outside-in signal response, was found to induce 
recruitment and activation of the JNK through the MKK7 pathway, which ultimately results in 
AP-1 mediated transcription of the Ace gene (Kohlstedt et al., 2006a, 2006b, 2004, 2002) (see 
Chapter 1.4.3). Aside from inhibitors, interactions of ACE substrates ANGI, BK, AcSDKP and the 
product ANGII were shown to trigger sACE signalling along the same pathway (Sun et al., 
2010). 
During the pathogenesis of AD, accumulation of Aβ in the ECM and blood vessels in the brain, 
combined with ACE’s ability to degrade Aβ, may induce ACE signalling. The expression of ACE 
was upregulated in post-mortem studies on the brains of AD patients, specifically the 
temporal cortex which is a region severely affected in AD (Barnes et al., 1991). More recently, 
an elegant and comprehensive study on ACE10/10 mice by Bernstein et al., indicated that AD 
mice over-expressing ACE within monocytes had decreased plaque and inflammatory burden.  
In addition to this, they also regained their cognitive abilities (Bernstein et al., 2014). Chronic 
ACE inhibition in transgenic mice models of AD has been shown to induce enhanced 
deposition of Aβ (Hemming et al., 2007). These results, along with ACE’s ability to hydrolyse 
Aβ, suggest an important and possibly protective role of ACE activity in the diseased brain. 
The specific role of ACE inhibition on amyloid, however, is still somewhat controversial as 
some studies found no effect of ACE inhibition on Aβ load (Eckman et al., 2006) (See Chapter 1 
section 1.6). Nevertheless, an increasing number of studies, some involving mouse and 
epidemiological work, have indicated that ACE inhibitors improve memory function and have 
a protective role against the development and progression of AD (Chapter 1 section 1.6).  
Another factor which may further increase the amount of ACE present is substrate binding. 
Sun et al., (2010) reported activation of the mouse ACE signalling cascade upon binding of a 
number of ACE substrates including ANGI, AcSDKP and BK (Sun et al., 2010).  ANGII, an 
important inflammatory mediator in AD, also resulted in elevated JNK activity upon binding to 
ACE. Importantly, in contrast to mouse sACE and the results from the Sun et al study, the 
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Kohlstedt group reported that while binding to the C-domain of human endothelial sACE 
induced a signalling response, N-domain binding did not (Kohlstedt et al., 2006b; Sun et al., 
2010).  Previous work from our and other laboratories has shown that Aβ is N-domain 
selective. It is thus important to confirm the selectivity of human sACE signalling towards Aβ in 
different cellular systems.  These are important questions to answer, as there is the concern 
that N-domain inhibition would prevent its degradation of Aβ.  The ACE signalling pathway 
also cannot directly account for the beneficial effects of ACE inhibitors. Therefore, if Aβ does 
not induce signalling, other mechanisms are likely to influence ACE expression and may thus 
have an effect on the role that ACE inhibitors play in AD. 
Phosphorylation is one of the most commonly occurring PTM of proteins and peptides. They 
arise via protein kinase transfer of phosphate groups, which induce conformational changes, 
affecting the activity and function of the target. Phosphorylation is crucial to regulation of a 
broad range of cell functions from cell-cycle, metabolism, cell differentiation and 
neurotransmission, to name a few (Hunter, 2000). While some phosphorylation is perpetual, 
other residues are only transiently phosphorylated. This transience is essential to the rate of 
signal transduction of any pathway. Thus, phosphoprotein abundance is generally very low, 
being between 1-2 % of total whole cell protein levels. Techniques commonly employed to 
interrogate levels of phosphorylation include radiometric and flourometeric kinase assays 
(Johnson and Hunter, 2005); phospho-specific antibody based straightforward techniques like 
Western blotting; immunoprecipitation and immunofluorescence microscopy (Delom and 
Chevet, 2006; Johnson and Hunter, 2005; Sefton and Shenolikar, 2001). Technically the 
detection of phosphorylation levels still remains challenging as most of the classic methods 
are not without limitation (Arnott et al., 2003). 
Mass spectrometry has consequently developed into a robust and extremely sensitive method 
for the characterization of protein phosphorylation sites (Sickmann and Meyer, 2001). It has 
become the method of choice for the analysis of protein phosphorylation as a result (Delom 
and Chevet, 2006; Hunter, 2000; Piersma et al., 2015; Sickmann and Meyer, 2001). In order to 
study the signalling mediated by Aβ, high-resolution and accurate mass (HR/AM) analysis on 
the Q-Exactive mass spectrometer can be used to quantify possible Ser1270 phosphorylation 
of ACE. This instrument has a unique configuration in that it consists of a quadrupole mass 
filter as the front-end (for precursor ion mass selection) attached to an orbitrap mass analyser 
(Michalski et al., 2011). This enables quantitative methods based on HR/AM measurements, 
including targeted analysis in MS mode (otherwise known as single ion monitoring (SIM)) and 
in MS/MS mode (parallel reaction monitoring (PRM)) (Gallien et al., 2012) as depicted in the 
work flow (Figure 5.1). The dynamic range limitation of in-line quadrupole trapping devices is 
overcome by the ability of the quadrupole to select a restricted m/z range. This, combined 
with the MS/MS mode, provides an additional stage of selectivity. Targeted MS of complex 
mixtures with this machine yields better performance in terms of selectivity, dynamic range, 
and sensitivity - ideal for detection of low abundance phosphorylated peptides (Gallien et al., 
2012; Kelstrup et al., 2011; Michalski et al., 2011). 
CHAPTER 5 Effects of Aβ on ACE signalling  Kate Larmuth 
96  
The observation that the BRAAS in general is upregulated in AD and that ACE levels correlate 
well with Aβ load begs the question, does Aβ induce a signalling response via ACE? There is 
sufficient evidence throughout the literature and within this study that indicates that Aβ is a 
substrate for ACE, albeit catalysis is poor in comparison to ANGI for instance. However, the 
interactions between ACE and Aβ may have ramifications towards the consideration of ACE 
inhibitors in the treatment of AD and or hypertension. 
Aims and Objectives: 
The overall objective of this chapter is to investigate whether binding of Aβ and lisinopril to 
sACE affects ACE phosphorylation and cellular signal transduction. This aim was achieved 
through the following objectives: 
The objectives used to achieve this aim include: 
1) To investigate the association of ACE, JNK and pJNK upon treatment with lisinopril, 
Aβ(1-16) or Aβ(1-42) via immunoprecipitation and Western blotting. 
2) To determine if increased ACE expression and JNK phosphorylation occurs after 
induced signalling. 
3) To determine if ACE expression is affected by treatment with lisinopril or Aβ(1-42) and 
if this induces an increase in Ser1270 phosphorylation using a targeted mass 
spectrometry approach. 
  
   
Figure 5.1 Schematic of Q-Exactive PRM workflow. For the detection of Ser1270 phosphorylation in 
complex mixtures two label-free sample preparation techniques will be used, in-solution digest and in-gel 
digestion. The spectrum of peptides will be separated via high performance liquid chromatography and then 
selected based on predefined precursor ion masses. Following this parent precursor ions are fragmented 
into product daughter ions, detected in the Orbitrap, generating simultaneous MS/MS spectra. Simplified 
diagram based on the study by Gallien et al., 2012.  
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5.2 Methods: 
 Membrane bound Enzyme constructs. 5.2.1
5.2.1.1 Wild type sACE. 
See Chapter 2 section 2.2.1.2.2.1 
5.2.1.2 sACE S1270A signalling mutant. 
5.2.1.2.1 Site Directed mutagenesis. 
To create a signalling null mutant, conversion of the Ser1270 on the cytoplasmic tail of ACE to 
an Ala residue, was carried out by Vinasha Ramasamy using polymerase chain reaction (PCR)-
based site directed mutagenesis and KAPA HiFi™ DNA polymerase (KapaBiosystems, South 
Africa) (method adapted from (Andreou, 2013). Briefly, complimentary primers were designed 
to introduce the Ser1270 to Ala mutation and a NarI site (for screening), into pBSK-sACETM 
(See appendix 7.2.3.1). Parent DNA was digested overnight with DpnI restriction endonuclease 
(Fermentas, USA) (see appendix 7.2.1 ); the digest products were amplified via replication of 
DH5α competent cells grown under 150mg/ml ampicillin selection. Single colonies were 
picked and grown) and plasmid DNA extracted (see appendix 7.2.5). Crude DNA from selected 
colonies was screened with NarI endonuclease digestion (NEB, UK) (see appendix 7.2).  DNA 
integrity and incorporation of the mutation was confirmed through sequencing, using primers 
flanking the multiple cloning sites as well as internal primers for sACE (see appendix 7.2.3). 
Sequencing was performed as in Chapter 2 Section 2.2.1. The sACE S1270A gene was then 
sub-cloned into the mammalian expression vector pcDNA3.1(-) to create pcDNA.S1270A, 
referred to as S1270A for simplicity from hereon in. DNA was prepared for transfection using 
the Plasmid Midi Kit (QIAGEN, USA). 
 Mammalian cell expression of sACE and S1270A enzymes. 5.2.2
The CHO-K1 mammalian cell line was used as the model system for transfection and 
expression of all enzymes as described in Chapter 2 section 2.2.2. CHO cells are an ideal 
system to investigate ACE signalling responses, as they do not express ACE, ACE receptors, nor 
Bradykinin receptors. 
For the activity assessment of both cell lysate and growth medium sACE protein, see Chapter 
2 section 2.2.3.1 
5.2.2.1 Determination of ACE shedding. 
Cells expressing sACE and S1270A were grown until confluency in 6 well plates in growth 
medium.  Confluent cells were then serum starved and synchronised in minimal medium for 
18 hours (Cooper, 2003). Medium was harvested, the cells lysed in triton lysis buffer and 
assayed (refer to Chapter 2 section 2.2.3.1) for ACE activity. The amount of shedding was 
calculated as a ratio of the total ACE activity from the medium to the sum of the total ACE 
activity in the medium and cell lysate.  
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5.2.2.2 Substrate or inhibitor treatment of CHO cells. 
For the treatment of CHO cells with Aβ or the non-selective ACE inhibitor Lisinopril, cells were 
seeded into 6 well plates or 10 cm dishes, depending on the experiment, and grown to 60% 
confluency in growth medium (See appendix 7.1.1.1).  Cell growth and division was 
synchronised under serum starvation conditions (2 %FCS for 17 hours and then in Opti-MEM 
(Invitrogen, USA) for 1 hour) prior to performing any experiment (Cooper, 2003). Cells were 
washed in PBS prior to adding 1 ml (for experiments in 6 well plates) or 5 ml (for experiments 
in 10 cm dishes) of inhibitor or substrate in Opti-MEM and vehicle in Opti-MEM to the cells.  
Thereafter, the plates were incubated for the periods detailed in Results section 5.3.  
 Immunoblotting and Immunoprecipitation. 5.2.3
ACE monoclonal antibodies, 9B9 used for immunoprecipitation and 4G6 for immunodetection, 
were made by our collaborator (Balyasnikova et al., 2005, 2002).  All other antibodies were 
purchased from Cell Signalling Technologies and are specific towards GAPDH, pJNK and JNK.  
Cells were lysed immediately after removal of substrate, inhibitor or vehicle, in 150-200 µl (for 
6 well plates) or 500 µl (for 10 cm dishes) of triton lysate buffer containing the protease 
cocktail mix and phosphatase inhibitors (PhosSTOP Roche Life Sciences) (see appendix 
7.3.1.5). Lysis was performed on ice, for 20 minutes. All cell lysates were spun down at 
14000rpm for 20 minutes at -4°C and the whole cell supernatant extracted for either 
immediate immunoprecipitation or immunodetection. Where necessary, whole cell 
supernatant was frozen at -80°C for later Western blot analysis.  All samples were 
electrophoresed in sodium dodecyl sulphate polyacrylamide gel using standard lab protocol 
(appendix 7.7.1.5). 
5.2.3.1 Immunoblotting. 
For Western blot analysis the wells were scraped and lysed as mentioned above. Samples 
were normalised to the lowest amount of ACE activity and 25 µl of total cell lysate was then 
separated by SDS-PAGE (Laemmli, 1970). Following electrophoresis, proteins were transferred 
from the gel to a Hybond-ECL, nitrocellulose membrane (Amersham, Buckinghamshire, UK) in 
cold transfer buffer (0.5 M Tris, 1.44% (w/v) glycine, and 0.2% (v/v) methanol) at a constant 
300 mA for 1 hour. Membranes were then incubated in blocking buffer (5% (w/v) skim milk, 
0.1% (v/v) Tween-20, 0.2 M NaCl, 0.05 M Tris (pH7.4)) for 30 minutes prior to addition of 
primary antibody, in blocking buffer, which was then incubated overnight at 4°C. Membranes 
were washed 3 times for 5 minutes with Tris-buffered saline containing 0.1 % (v/v) Tween-20 
(TBS-T)(0.1% (v/v) Tween-20, 0.2 M NaCl, 0.05 M Tris (pH7.4)) prior to 4 hour incubation with 
relevant secondary antibody (1/2000 dilution in blocking buffer). For the detection of ACE, a 
1/250 dilution of primary rat 46G antibody specific to the linear epitope of the N-domain, was 
used (Balyasnikova et al., 2005, 2003). To detect GAPDH, pJNK and JNK, specific primary 
antibodies were diluted 1/1000 in blocking buffer. The membrane was then washed with TBS-
T 3 times for 5 minutes to remove any residual unbound antibody. Detection was carried out 
using the ClarityTM Western ECL Substrate (BioRad, (Hercules, CA, USA)) as per manufacturer’s 
instructions. Resulting chemiluminescence was visualized on a G:Box iChemi™ 
chemiluminescence imager (Syngene, Cambridge, UK) and signal quantification determined 
using ImageJ software (http://rsbweb.nih.gov/ij). 
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5.2.3.2 Immunoprecipitation. 
Cells were lysed as above (see section 5.2.3) and immunoprecipitations were performed with 
Protein-G+ Agarose beads (Merck Millipore, Germany) on whole cell lysate supernatant. All 
samples were precleared with 10–30 µl of 50% bead slurry (protein G coupled agarose beads) 
per 200 µl cell lysate prior to immunoprecipitation. Proteins were precipitated from 200 µl 
whole cell lysates (1 mg/ml) with 1/100 dilution of their respective primary antibodies (as 
detailed under Results section 5.3.) and incubated at 4°C overnight with rotation. Following 
antibody binding to protein, 10–30 µl of 50% bead slurry was added and the samples 
incubated at 4°C for 4 hours with rotation. The beads were pelleted by centrifugation at 
2000 rpm at 4°C. The supernatant was discarded and the beads washed 5 times with 500 µl of 
triton lysis buffer. The samples were kept on ice between washes. Antigen and antibody were 
then eluted from the beads by boiling in 50 µl of Laemmli buffer for 5 minutes. Co-
immunoprecipitated proteins were subsequently detected by Western blotting as detailed 
above (section 5.2.3.2) 
 Targeted Mass Spectrometry. 5.2.4
All sACE and S1270A expressing cell lines were lysed in RIPA buffer (150 mM NaCl, 50 mM 
triethylammonium bicarbonate, 1 % SDS, 0.5 % deoxycholate, (pH 8)), containing protease 
inhibitor and phosphatase inhibitor cocktails, for mass spectrometry analysis. 
5.2.4.1 Protein precipitation. 
For the total protein precipitation, 400 µl whole cell lysate supernatant, was mixed vigorously 
with 400 µl of methanol and 300 µl of chloroform in a glass tube. The mixture was centrifuged 
in order to precipitate the protein in the interphase between the chloroform and methanol. 
Excess chloroform was removed (top layer) and the methanol and protein phases were mixed 
once more with 300 µl extra methanol. This was then centrifuged again at 13 000 rpm for 10 
min, the supernatant was discarded and the remaining protein pellet air dried for 
resuspention in the appropriate buffer. 
5.2.4.2 In-solution Tryptic Digestion. 
For in-solution trypsin digestion 50 µg of total protein was reduced with 1 mM DTT for 1 hour 
with agitation and then alkylated in 5.5 mM IAA for 1 hour in the dark. Proteins were pre-
digested with Lysyl Endopeptidase LysC (Waco, Neuss, Germany) at room temperature for 
3 hours and diluted 4 times with ammonium bicarbonate (ABC) before adding sequencing 
grade modified trypsin (Promega, Madison, USA) (1:100 w/w). Proteolysis was carried out at 
25°C for 18 hours with agitation at 30 rpm. This digestion was stopped by the addition of TFA 
(Sigma Aldrich, St Louis, USA). 
5.2.4.3 In Gel Tryptic Digestion. 
Proteins from cell lysates normalised to total protein were separated by SDS-PAGE (see 
appendix section 7.7.1.5) and visualized using Coomassie staining. Bands in the size region of 
sACE were excised, cut into 1 mm pieces and destained with 200 mM NH4CO3: acetonitrile 
(ACN) (50:50) until clear. The gel slices were dehydrated with 100 % ACN and dried on a 
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Savant SpeedyVac (ThermoScientific, USA).  Slices were further reduced with 10 mM 
dithiothreitol (DTT) (Sigma, USA) in 25 mM NH4CO3 for 30 minutes at room temperature in the 
dark. Any excess DTT was removed and the gel slices dehydrated once again. Cysteine 
protection by carbamidomethylation with 55 mM iodoacetamide (IAA) (Sigma, USA) in 25 mM 
NH4CO3 was performed for 30 minutes at room temperature in the dark. The gel slices were 
finally dehydrated and washed with 25 mM NH4CO3. Digestion of these slices was performed 
with sequencing-grade modified trypsin (Promega, Madison, 162 USA) at a concentration of 
trypsin: estimated protein of 1:100 (w/w) overnight at 37°C. 
5.2.4.4 Sample Desalting. 
Desalting of digested peptides was performed over homemade C18 (Empore Octadecyl C18 
solid-phase extraction disk (Supelco)) stage tips (Rappsilber et al., 2003) They were activated 
and equilibrated with 3 rinses of 80% ACN followed by 3 washes with 2 % ACN, both buffers 
contained 0.1 % Formic acid (Sigma Aldrich, St 179 Louis, USA). Peptides were loaded onto the 
C18 disk and centrifuged. Desalting was performed with 3 washes of 2 % ACN in 0.1 % formic 
acid and desalted peptides were eluted with 3 rounds of 100 µL of 60 % ACN in 0.1% formic 
acid. All desalting steps were carried out using 5min centrifugation intervals of 3000 rpm. 
Solvent was evaporated by vacuum centrifugation at room temperature and peptides were 
resuspended in 2 % ACN, 0.1 % formic acid at 250 ng/µl. 
5.2.4.5 MS of potential Lisinopril induced phosphorylation of Ser1270. 
5.2.4.5.1 High performance liquid chromatography. 
Liquid chromatographic (LC) separation of, duplicate, in-gel extracted samples was performed 
using an Proxeon Easy n-LC II (Proxeon Biosystems, Odense, Denmark) system. Coupled to the 
Easy n-LC II, were two columns, the first was a home packed precolumn (100 µm ID X 20 mm) 
connected to the second, an analytical column of Luna 5 µm C18 100 Å-beads (75 µm X 
500 mm) (phenomenex 04A-5452). In the initial mobile phase of 5 % ACN and 0.1 % formic 
acid, 1 µl (50 ng/µl) of resuspended ACE peptides were loaded onto the column. Peptides 
were eluted over a gradient of 5 % ACN to 50 % ACN for 35 minutes, with a 5 minute isocratic 
of 50 % ACN, then up to 90 % ACN over 35 minutes and back down to starting conditions over 
5 minutes. The flow rate was held constant at 450 ml/min. 
5.2.4.5.2 TSQ-Vantage™ triple quadrupole mass spectrometer parameters. 
Mass spectra were acquired in positive mode on the Thermo TSQ-Vantage (Thermo Fisher, 
San Jose, CA, USA). Protein dilutions to 50 ng were applied to the EASY LC system. Transfer 
capillary temperature was set to 250 °C with a sheath gas pressure of 10. The ESI spray voltage 
was 1 kV and current discharge was set at 4. A 90 minute unscheduled multiple reaction 
monitoring (MRM) assay was conducted on the in-gel digested samples. 185 transitions were 
monitored (see appendix 7.8.2), with predicted collision energies based on the default skyline 
equation. Chrom filter peak width and declustering voltage were not used. Collision gas 
pressure was set to 1 mTorr. The Q1 and Q3 peak widths were set to 0.7 full width at half 
maximum (FWHM) and the calibration tuned, S-Lens value was used for all transitions. A Cycle 
time of 5 seconds was used, which translates to 27 milliseconds per transition, not accounting 
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for quadrupole switching delay. A product ion signal threshold trigger of 1 was used for all 
transitions.  
5.2.4.6 MS of potential Aβ induced phosphorylation of Ser1270. 
5.2.4.6.1 Ultra High Performance Liquid Chromatography. 
Prior to mass spectrometry, re-suspended lyophilized samples were diluted to 50 ng/μl using 
HPLC grade water containing 0.1 % (v/v) formic acid. Nanoflow high performance liquid 
chromatography (ultra-LC) was carried out in-line on a Dionex UltiMate® 3500 RSnano UPLC 
system (Thermo Fisher, San Jose, CA, USA) using a reverse phase precolumn trap 
(100 μm×5 cm; 5 μm; 100Å; C-18) and analytic column (75 μm×50 cm; 5 μm; 100 Å; C-18). 
Gradient chromatography was carried out at 23:C with a flow rate of 300 nL/min and peptides 
were eluted with a 3-80 % gradient of water-acetonitrile from 0-140 minutes. The binary 
mobile phase system consisted of buffer A, 0.1 % formic acid and water, while buffer B 
contained 0.1 % formic acid and ACN. The gradient used to elute peptides was 3 % B from 12-
68 minutes, then increasing to 80 % B over 5 minutes, remaining isocratic at 80 % for 
15 minutes, then a drop from 80 % to 2 % B over 2 minutes following another isocratic step of 
2% B for 15 minutes before proceeding to wash conditions. Washes and equilibrations were 
included at the end of each run; they consisted of an increase of B from 2-50 % over 
15 minutes, followed by a 1-minute transition back to starting conditions (1 % B). 
5.2.4.6.2 Q-Exactive™ quadrupole-Orbitrap mass spectrometer PRM 
parameters. 
Sample analysis was carried out on a Q-Exactive™ Hybrid Quadrupole-Orbitrap Mass 
Spectrometer (Thermo Fisher, San Jose, CA, USA). Analysis settings to samples introduced 
from the in-line ultra-HPLC system were: the resolution was set to 70 000, at a maximum 
injection time of 250 milliseconds or an automatic gain control (AGC) target value of 5 x 106. 
However, this AGC was set at the maximum so that the injection time is consistent across 
chromatographic elution for reproducible quantification. The programed target ion masses 
were selected by the quadrupole during initial scan with an isolation window of 4.0 m/z. 
These targeted peptides were then further subjected to fragmentation via high-energy 
collision dissociation (HCD). Peptide fragmentation was performed at HCD with a normalized 
collision energy (NCE) of 25. The abundance threshold for targeted ion selection was 1.7 x 104 
with a charge exclusion of z=1 and z>5 ions. 
 Statistical analysis. 5.2.5
Data was analysed using built-in statistical software in GraphPad PRISM 4.0 (GraphPad 
software Inc, USA).  Un-paired, nonparametric, student t-tests were used to analyse samples, 
which are represented as ratios of treated vs. untreated or phosphorylated vs. un-
phosphorylated. Results were viewed as statistically significant when p < 0.05.  Statistically 
significant data in figures throughout are indicated as follows: * p < 0.05; ** p < 0.01; 
*** p < 0.001. 
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5.3 Results: 
Mutagenesis and Expression of Phosphorylation Mutant S1270A. 5.3.1
Mutagenesis in sACE of Ser1270 to an alanine (S1270A) was successful as can be seen from 
the sequence data determined after mutagenesis (Figure 5.2 A). No other spurious mutations 
were detected and the exchanged amino acid did not induce a frame shift (Figure 5.2 B).  
On comparison of the activity present in the medium to the total activity (lysate and medium 
combined) a 20-fold increase in S1270A activity was observed (Figure 5.3). As indicated by the 
literature, the expression of S1270A induced an increase in endogenous shedding of S1270A 
from the membrane of CHO cells. Thus, phosphorylation of this Ser residue either plays a role 
in the membrane retention of sACE or the S1270A mutation results in increased affinity for 
the ACE sheddase.  
Figure 5.2 Sequence confirmation of S1270A mutation in sACE 
cytoplasmic tail. The aligned sequences of S1270A mutant and wild 
type sACE are indicated, and the mutation is highlighted in the peach 
square. A) DNA sequence alignment of S1270A and sACE with the 
cytoplasmic tail section of nucleotides highlighted in bold. B) An 
alignment of the amino acid sequences of S1270A and sACE 
indicating the presence of the introduced Ala residue.  
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 Lisinopril induced sACE signalling response. 5.3.2
5.3.2.1 Lisinopril induces sACE signalling via Ser1270 phosphorylation. 
Cells expressing sACE were incubated for 0, 5 and 7 minute periods with 200 NM lisinopril. 
The samples were normalised to total protein and separated via SDS-PAGE. The Coomassie 
stained bands, corresponding to the size of sACE, were excised and an in-gel tryptic digestion 
of each sample was performed (as in section 5.2.4.3). The peptide pool was desalted and 
cleared over a C18 column (as in section 5.2.4.4) so that targeted MS/MS could be performed 
on the corresponding peptide digest. A targeted method was developed to specifically detect 
MS1 and subsequent MS2 ions that correspond to the phosphorylated cytoplasmic tail of ACE 
(HSHGPQFGSEVELR (870.35 m/z), HSHGPQFGSEVELR (830.36 m/z)) as well as to the non-
phosphorylated sequence (HSHGPQFGSEVELR, (790.38 m/z)). This method was applied to the 
samples that were analysed on a Thermo TSQ-Vantage (Thermo Fisher, San Jose, CA, USA) 
mass spectrometer. The resultant chromatograms of parent to product ion transitions were 
analysed using Skyline (MacLean et al., 2010) and the corresponding peak area data extracted 
and plotted accordingly (Figure 5.4). The levels of phosphorylation of Ser1270 increased with 
exposure to lisinopril. The maximum increase with 7 minutes treatment was 8-fold greater 
than that with 0 minutes (Figure 5.4). Comparison of the parent peptide masses (total product 
ion sum) to that of the specific product ion y6 (SEVELR with a single m/z of 812,36), which 
corresponds to the shortest peptide that contains the S1270 residue, gave a similar trend 
increasing 2-fold with 7 minutes treatment (Figure 5.4). It should be noted that the 
quantification of the specific product ion could not be deduced due to low signal (See 
appendix section 7.8.2 for representative chromatograms for the phosphorylated and non-
phosphorylated peptides from this experiment). 
 
 
 
    
Figure 5.3 Basal shedding of wild-type sACE and sACE1270A. Shedding was determined as a 
percentage of total ACE activity in the growth medium over total activity in the cell lysate and 
medium. Results are the mean ±SEM of two experiments performed in triplicate with the 
significance indicated as *** p < 0.001  
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5.3.2.2 Co-immunoprecipitation of ACE and pJNK. 
To investigate if the ACE outside-in signalling cascade does occur with treatment of sACE with 
200 nM lisinopril, co-immunoprecipitations were performed with antibodies against sACE, JNK 
and pJNK. The cell lysates were normalised to the samples with lowest total protein 
concentrations prior to immunoprecipitation. The signal-induced associations were detected 
using Western blotting against sACE and pJNK (Figure 5.5). It is evident that there is activation 
of JNK through an increase in the amount of sACE co-immunoprecipitated with the activated 
pJNK in comparison to JNK. Furthermore, activated pJNK co-immunoprecipitated with sACE 
suggesting that an association with sACE at the cytoplasmic domain. Overall, the signal 
intensity of sACE-corresponding bands was detected in the proportions expected from the 
induced signal cascade (Figure 5.5). Phosphorylated JNK was thereby enriched in lisinopril 
treated cells from 6 well plates.  
        
Figure 5.4 MS analysis on the TSQ-Vantage of Ser1270 phosphorylation on Lisinopril treatment. 
Comparison of parent ion (HSHGPQFGSEVELR) and y6 (SEVELR) ion, normalized to total ion count, of 
phosphorylated Ser1270 over non-phosphorylated. Parent ion ratios of phosphorylated over non-
phosphorylated cytoplasmic tail over different incubation periods of lisinopril (LIS)  To account for 
peptide extraction differences across samples, the peak areas for all parent peptides were normalized 
to total pool of potential Ser1270 phosphorylation site peak areas prior to comparison.  
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5.3.2.3 Determination of the effect of Aβ(1-16) on ACE signal 
transduction. 
Due to the relatively low dose toxicity of Aβ and in an attempt to keep levels physiological, 
sACE-expressing cells were treated with a relatively high to low concentration range of Aβ(1-
16) and vehicle control for 7 minutes. To determine if any dose effect takes place, samples
were immunoprecipitated using an antibody specific to JNK and Western blotting was
employed to probe for total JNK and induced pJNK levels.  Overall no dose effect was
observed, the induction of JNK phosphorylation on treatment occurred at 50 nM Aβ(1-16) as
all other concentrations, up to 6 µM, did not induce an increase in the ratio of pJNK/JNK
above that of the control to any statistical significance (Figure 5.6).
Figure 5.5 Co-Immunoprecipitation of sACE, JNK and pJNK after treatment with lisinopril. 
A representative Western blot (WB) of the immunoprecipitation of sACE expressing CHO cell lysis 
after a 7 minute treatment with lisinopril  The bands corresponding to the correct size of sACE were 
found at 170 kDa and bands indicating pJNK were found at 54 kDa on detection with sACE and pJNK 
specific antibodies respectively. The antibodies used in the immunoprecipitation (IP) are found 
above the lanes corresponding to their elution products.  
Figure 5.6 The pJNK response to increased dosage of Aβ(1-16). Immunoprecipitations, after 
treatment with various concentrations of Aβ(1-16) for 7 min, with JNK specific antibody. 
Results were determined by Western blotting with both pJNK and JNK. Data is representative 
of ±SEM of two experiments in duplicate and significance is indicated by* p < 0.05.  
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Determination of Lisinopril and Aβ(1-16) induced up-regulation5.3.3
of sACE expression. 
To determine if sACE expression increases after the initial signal burst of 7 minutes on 
treatment with either lisinopril or Aβ(1-16), cell lysate of samples was normalised to total 
protein content prior to analysis using Western blotting.  As this study uses only one cell line, 
CHO cells, densitometry of sACE expression was normalised to the expression of an internal 
housekeeping protein GAPDH. The results from 8, 12 and 24 hour incubations, with both 
Aβ(1-16) (Figure 5.7 A) and lisinopril (Figure 5.7 B), yielded no significant increase in sACE 
expression barring 8 hours post lisinopril treatment. This time point generated the only 
significant increase above vehicle control levels (Figure 5.7 B). Neither lisinopril nor Aβ(1-16) 
appear to upregulate ACE expression post initial 7 minute treatment. 
Figure 5.7 Induced expression of ACE, post treatment, by Aβ(1-16) and lisinopril. 
Densitrometery of Western blots performed in duplicate of A) CHO cells treated with 50 nM 
Aβ(1-16) over 7 minutes; and B) CHO cells treated with 200 nM of lisinopril for 7 minutes. 
Controls represent cells treated with the corresponding vehicles for 7 min. Data is representative 
of ±SEM of duplicates. The significance is indicated by* p < 0.05  
Kate Larmuth  CHAPTER 5 Effects of Aβ on ACE signalling 
107 
 Aβ(1-42) Induction of ACE signalling 5.3.4
5.3.4.1 Incubation with Aβ(1-42) induces the association of pJNK with 
sACE. 
Previously, we indicated that ACE hydrolyses Aβ’s N-terminal region as well as the C-terminus 
removing the last two amino acids of the full-length Aβ(1-42) peptide.  In order to determine 
if treatment with Aβ(1-42) induces the outside-in ACE signal cascade, immunoprecipitations 
were performed against sACE and JNK. The co-immunoprecipitates were then probed for sACE 
and pJNK levels through Western blotting analysis. As observed with Aβ(1-16), pJNK signals 
were enriched by their association with sACE (Figure 5.8), suggesting that Aβ(1-42) does 
induce an ACE signal response. 
5.3.4.2 Immuno-quantitation of Aβ(1-42) and Lisinopril Induction of ACE 
Signalling. 
In order to assess if the full-length Aβ(1-42) induces the same association with sACE and 
activation of JNK, that lisinopril and Aβ(1-16) stimulate, immunoprecipitations with sACE 
specific monoclonal antibody 9B9 were performed on cells expressing either sACE or S1270A. 
Interestingly, sACE levels were 2-fold higher on treatment of Aβ(1-42) compared to the 
lisinopril treated cells (Figure 5.9 A and B). Furthermore, treatment with both lisinopril and 
Aβ(1-42) yielded significant increases in sACE expression (0.5- and 2.5-fold, respectively) over 
their vehicle controls and the S1270A mutant, after treatment for 7 minutes (Figure 5.9 A 
and B). Similarly, both lisinopril and Aβ(1-42) induced significant JNK activation over S1270A 
and that of their respective controls (Figure 5.9 C). Despite having a greater sACE 
precipitation, the amount of activated JNK (pJNK) after treatment with Aβ(1-42) was 1.5-fold 
lower than that of the lisinopril treated precipitants (Figure 5.9 C and D).  This suggests that 
Aβ(1-42)-induced signal through sACE may be weaker than that of the signal induced by 
lisinopril. It should be noted however, that the beads used to bind 9B9 and perform the 
precipitations underwent some degradation and the pJNK bands were fairly smeared as a 
result. These co-immunoprecipitants were performed in duplicate, however, and the analysis 
by Western blot in triplicate lending greater power to the densitometry despite smearing. 
 
 
   
Figure 5.8 Aβ(1-42) induced association of pJNK and JNK with sACE.  Co-immunoprecipitation of 
pJNK with sACE and JNK after treatment for 7 minutes with Aβ(1-42)  
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Figure 5.9 Co-immunoprecipitation of pJNK with sACE on treatment with lisinopril and Aβ(1-42). 
Lysates from cells expressing sACE and S1270A were immunoprecipitated with 9B9 after exposed to 
200 nM lisinopril and 200 nM Aβ(1-42) and their corresponding vehicle controls for 7 minutes. 
A) Densitrometry analysis of ACE expression as a % of treated over untreated.  B) Representative
Western blot of sACE on the treated immunopreciptants.  C) Densitrometry results on pJNK, as a
percentage of treated over untreated samples. D) Representative Western blot on the co-
immunoprecipitation of pJNK with sACE on treated cells. Data is representative of ±SEM of two
immunoprecipitation experiments per sample blotted n=3 each. The significance is indicated by
* p < 0.05; ** p < 0.01; *** p < 0.001.
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5.3.4.3 Aβ(1-42) induced up-regulation of sACE expression and activation. 
To investigate if the initial signal induction of 7 minutes produces an increase in sACE 
expression Western blot analysis was performed on cell lysate sACE. Cells were treated with 
either Aβ(1-42) or vehicle for 7 minutes, followed by extensive washing with PBS and medium 
exchange, before being left to grow for 24-48 hours. No change in either activity or expression 
of sACE was seen 24 hours post Aβ(1-42) treatment (Figure 5.10) However, the sACE activity 
increased by 20 % after 48 hours compared to the control (Figure 5.10 B) with a concomitant 
increase of 50 % in expression of sACE 48 hours post Aβ(1-42) (Figure 5.10 C). 
 
 
 
  
   
Figure 5.10 Increased expression and activity of sACE post Aβ(1-42) treatment. Cells were treated with 
200nM Aβ(1-42) for 7 minutes before extensive washing and changing of medium, then incubated for 
24-48 hours before lysing. A) A representative Western blot of sACE and GAPDH, B) Cell lysate sACE 
activity as a percentage of vehicle treated samples and C) Densitrometry of the Western blot analysis of 
both 24 hour and 48 hour time lapses post treatment. The data represent the ±SEM of 4 experiments 
performed in duplicate.  
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5.3.4.4 MS-Quantification of Ser1270 phosphorylation on treatment with 
Aβ(1-42).  
A direct indication of sACE’s ability to induce a signal cascade requires analysis of 
phosphorylation of the signalling-specific Ser1270 site.  In a series of PRM-MS experiments we 
attempted to optimise the detection of the modified variants of sACE’s cytoplasmic tail (Figure 
5.11) from in-solution tryptic digests of whole cell lysate. As the peptide of interest is already 
present in low amounts, we targeted all possible modifications of it including the other serine 
phosphorylation site and all histidine oxidation. Histidine oxidation modifications may occur 
due to sample processing steps prior to MS (Bridgewater et al., 2007). It was apparent that 
the peptides with modified histidines gave the highest signal, and thus, accepted the most 
charge (with signal intensity three orders of magnitude greater) (Figure 7.12) by comparison 
to the unmodified when scanning for M+H++ masses. The phosphorylation of Ser1270 also 
appears to consistently induce a shift in retention time from 26 to 25.7 minutes (see appendix 
7.8.2.2). This can be seen in the optimisation experiments with lisinopril at a resolution of 
17 000 on the nano-LC column (Figure 7.12). However, when the samples were run on the 
ultra-LC with only one set of targets at a higher resolution, 70 000 on the Q-Exactive, these 
low abundant masses could not outcompete other peptides for charge and thus the signal for 
the phosphorylated Ser1270 was too low to quantify.  
As a result, separation of whole cell supernatant was required in an attempt to enrich for the 
low abundance phos-Ser1270 sACE peptide. Cell lysate proteins were resolved using SDS-
PAGE separation and an in-gel digestion was carried out on bands that had a similar mobility 
to sACE. For Aβ(1-42) treated samples good replicates of the unmodified peptide 
(HSHGPQFGSEVELR) were detected with very good transitions (intensity well discernable from 
the background) at 70 000 resolution (Figure 5.12 A). However, the Ser1270 phosphorylated 
peptide (HSHGPQFGSEVELR) had very low signal and did not have very good transitions (very 
few ions had intensity above background) (Figure 5.12 B). These data indicate that further 
enrichment is required to enable accurate quantification since this signal is not as strongly 
induced as it is for lisinopril.  
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Figure 5.11 Initial target groups for PRM of sACE Ser1270 phosphorylation. The Ser1270 residue is 
highlighted and underlined in red, the other Ser1263 is highlighted in bold. The different combinations 
of His oxidation modifications that were accounted for are highlighted in blue (His1262) and green 
(His1264)  
Figure 5.12 Mass spectra chromatograms from Aβ(1-42) 7 minute treatment of sACE expressing cells.  
A) Representative chromatogram of the unmodified HSHGPQFGSEVELR, peptide with y and b product
ion keys indicated.  B) A representative chromatogram indicating the poor signal of the Ser1270
phosphorylated HSHGPQFGSEVELR peptide with the highest signal generated by the b2 ion. The
replicate, transition ion, bar graphs are indicated to the right of both chromatograms.
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5.4  Discussion: 
The dysregulation of the RAAS leads to very complex detrimental signalling processes, a 
number of them overlapping with aberrant signalling that occurs in AD. ACE has been shown 
to induce a signalling cascade, via phosphorylation of its Ser1270, in a receptor-like 
mechanism upon binding to inhibitors, hydrolysis products and substrates (Barauna et al., 
2011; Guimarães et al., 2011; Kohlstedt et al., 2013, 2011, 2006a, 2006b, 2005, 2004, 2002; 
Sun et al., 2008b, 2010). The general up-regulation of the RAAS in AD may be a direct result of 
Aβ binding to and hydrolysis by ACE as ACE has been shown to behave like a receptor towards 
inhibitor binding, substrate binding and shear stress - all of which affect ACE transcription 
(Barauna et al., 2011; Kohlstedt et al., 2013, 2006a; Sun et al., 2010). Higher ACE levels lead to 
more ANGII production and possibly more inflammation. However, ACE also hydrolyses the 
pathological Aβ peptide and thus may be beneficial with regard to AD as discussed previously.  
In an attempt to provide more quantitative data on the degree of phosphorylation of Ser1270 
and the ACE signalling response upon treatment with lisinopril and Aβ, we carried out MS 
analysis on two different mass spectrometers. The TSQ-Vantage could detect the parent ions 
corresponding to the cytoplasmic tail of sACE that contains the phosphorylated Ser1270 
(pSer1270), after lisinopril treatment, although detection was poor compared to its 
unmodified form. No absolute quantification could thus be generated on the amount of 
pSer1270 induced by lisinopril. Relative quantification was however possible on analysis of the 
pool of parent ions and comparisons were made between treated and untreated as well as to 
the level of phosphorylation in an analysis comparable to Western blotting (Figure 5.4). 
Moreover, the involvement of the pSer1270 was confirmed, as the trend of the 
phosphorylation of Ser1270 on the y6 ion and the significant increase in was reassuringly 
similar to that of the parent pSer1270 levels.  It was not identical, however, in that this ion 
could not always be detected on all the samples from the TSQ-Vantage mass spectrometer. 
The level of Ser1270 phosphorylation increased 1.5-fold at 7 minutes (Figure 5.4) exposure to 
lisinopril. This is similar to the  1.3-fold increase that ramipril had in human endothelial cells 
(Kohlstedt et al., 2004).  This is further confirmation that lisinopril induces phosphorylation on 
the Ser1270 residue of sACE.  
Lisinopril, a non-selective inhibitor of ACE, induced the ACE signalling cascade triggered by 
pSer1270 as indicated by the immunoprecipitation of ACE, association of pJNK (Figure 5.5) and 
vice versa. Similarly, Aβ(1-16) associated with pJNK and levels were increased in an inverse 
dose-dependent manner, with the low concentration of 50 nM inducing a significant increase 
in pJNK/total JNK compared to controls.  However, no significant up-regulation of sACE 
occurred post 7 minute exposure to Aβ(1-16), unlike lisinopril, which induced a small but 
significant increase in sACE expression after 8 hours.  Aβ(1-42) however, caused a significant 
increase in ACE levels and activity 48 hours post treatment (Figure 5.10). This result was 
interesting in that it appears the activation of pJNK by Aβ(1-42) via ACE signalling was muted 
in comparison to lisinopril (Figure 5.9), thus the levels of ACE upregulation were anticipated to 
be lower or undetectable.  This muted signal is not unprecedented, as Aβ is an N-domain 
selective substrate, and these N-selective substrates have been shown to have a weaker signal 
induction through mouse ACE in CHO cells (Sun et al., 2010). Human sACE N-domain did not 
induce a signalling response in porcine endothelial cell models while the C-domain did 
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(Kohlstedt et al., 2006a). This may be a cell specific interaction as the cell line transfected with 
sACE in this study is the same cell line used in the mouse ACE study where the N-domain had 
some signalling function.  
As Aβ(1-42) induced such a marked change in ACE expression and activity, an attempt was 
made to quantify the level of pSer1270, possibly induced by Aβ(1-42), to investigate if ACE 
expression is directly linked to the up regulation of pJNK. Since the MS results from the 
lisinopril treatment indicated poor detection of the phosphorylated target peptides and it was 
apparent from the immunoprecipitation experiments (Figure 5.9) that Aβ(1-42) signalling is 
weaker through ACE, HR/AM spectrometry was employed to interrogate pSer1270. The 
characterisation of signal induction is a challenging analytical task, as phosphorylated peptides 
are low in abundance and phosphorylation is typically stoichiometric. Despite the historical 
prominence of triple quadrupole mass spectrometers (like the TSQ) in targeted analyses 
(Stergachis et al., 2011), the Q-Exactive was used to overcome the aforementioned 
challenges. The Q-Exactive combined with ultra-LC provided HR/AM for better sensitivity and 
higher resolution. The use of HCD in the Q-Exactive orbitrap provides greater and more 
extensive fragmentation from its higher energy of collisions, generating deeper scans and 
more informative data, compared to the collision induced dissociation (CID) of the TSQ 
machine (Olsen et al., 2007). CID is not appropriate for phosphorylation analysis due to the 
low energy of collision causing phosphate losses off of the peptide backbone (Palumbo and 
Reid, 2008). The ideal fragmentation type would be ETD (electron transfer dissociation) 
(McAlister et al., 2008) which was unavailable. HCD of the Q-Exactive however, is more 
appropriate for phosphoproteomic analysis as the higher fragmentation energy produces 
fewer phosphorylation site rearrangements making specific phosphorylation site detection 
accurate (Kelstrup et al., 2011).  
Optimisation on the Q-Exactive was performed with lisinopril as a positive control. Groups of 
various histidine modification and phosphorylation target combinations (Figure 5.11) were 
probed at their corresponding resolutions. The higher the resolution settings, the less targets 
and multiplexing capabilities the Q-Exactive has; however the pSer1270-carrying parent 
peptide generated a far better signal than on the TSQ-Vantage. Whole-cell lysate tryptic 
digests increase the chance that two ions of a similar mass and retention will compete for 
charge and those in abundance will always win. The low abundance of the pSer1270-
containing peptides and the parent peptide make quantification difficult without prior 
fractionation or enriching.  Hence, final analysis on Aβ(1-42) treated samples that were 
fractionated via gel filtration, had good transitions (y and b ions) for the unmodified peptide 
HSHGPQFGSEVELR but poor transitions for the pSer1270 HSHGPQFGSEVELR variants (Figure 
5.12) - even when considering the phosphate loss. It is possible that gel fractionation and 
tryptic digestion caused further depletion of the already low abundant peptide as peptide 
extraction can be a variable process.  
The approach used in this study was hypothesis driven, initiating the experiments through the 
theoretical knowledge that the cytoplasmic tail of ACE is phosphorylated, without prior MS-
detection of this specific peptide. As we have successfully detected the peptide of interest in 
this manner but have been unable to quantify it accurately, a different approach is necessary - 
that of evidence based discovery with subsequent PRM analysis. Simply put this is a data-
independent strategy (Masselon et al., 2000), detecting the peptide of interest within the 
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cellular peptide milieu, before targeting it for more accurate quantification. This would 
overcome many issues; from the low abundance of the pSer1270 peptide to the multiple 
modifications which limit pure PRM. Futhermore, where simple statistically significant 
increases and decreases of one molecule or phosphorylation site do not determine absolute 
biological significance, an evidence based discovery approach would provide better biological 
significance to the ACE signalling cascade.  
Aβ(1-42) affects ACE, inducing sACE expression and the activation of the ACE outside-in 
signalling, however, this still requires pSer1270-specific accurate quantification. Especially as 
the Aβ(1-42) response appears to be weaker than inhibitor-based signalling and there could 
be other more effective ways, apart from ACE signalling, in which Aβ upregulates ACE 
expression. An upregulation of RAAS aggravates hypoxic and cell metabolism disturbances 
which upregulate, and may also be triggered by, Aβ (Auerbach and Vinters, 2006; Bell and 
Zlokovic, 2009; Bloch et al., 2015; Iadecola, 2004). This then induces large cytoplasmic 
rearrangements with subsequent microtubule hyperphosphorylation, neurofibrillary tangles 
and finally cell death (Mattson, 2004). ACE signalling is intrinsically linked to shedding and 
cytoskeletal alterations. This is borne out by the increase in shedding observed on mutation of 
the signal-inducing Ser1270 to an Ala (Figure 5.3) (Kohlstedt et al., 2002). CK2 modulates ACE 
retention in vasculature and the activity of CK2 is 3-8-fold higher in the brain than the 
peripheral nervous system and non-neural tissues (Blanquet, 2000; Kohlstedt et al., 2002). 
CK2 is activated to phosphorylate ACE and induce the ACE signalling cascade (Figure 5.13). In 
neuronal cell lines it is activated by the brain-derived neurotrophic factor (BDNF) and 
neurotrophin-4 (NT-4) (Blanquet, 2000, 1998). Both these factors are involved in 
synaptoplastic protective mechanisms against stress induced by metabolic dysregulation as in 
hyperglycaemia, Aβ or ischemia (Inoue et al., 2014; Klumpp et al., 2004). During metabolic 
stress, BDNF has been shown in septal neurons to enhance bone morphogenetic protein-7 
(BMP7)-induced Smad phosphorylation and nuclear translocation to prevent apoptosis in a 
CK2-dependent manner (Hilgard et al., 2004). Although the cell line used in this study is not 
neuronal, CK2 is not only upregulated in neuronal tissue but in other human, rat and mouse 
tissue, in response to a number of stressors.  
The expression of ACE may initially be mediated by Aβ-induced metabolic stress in AD brain 
tissue since CK2 levels are low in late AD. Furthermore, it appears that neurotrophin-induced 
activation of CK2 is dependent on PKC-induced intracellular calcium (Blanquet, 1998) with 
ANG II regulating PKC via AT1R receptor and calcium signalling through ACE (Chan and Chan, 
2013; Murasawa et al., 1998; Villard, 1998).  In addition, many of the neurotrophic factor 
receptors are cholinergic, thus up-regulation of ACE may have a modulating function as ANGII 
inhibits acetylcholine release (Barnes et al., 1990; Blanquet, 2000; Savaskan et al., 2001). 
Thus, positive feedback loops of ACE expression and activity could be a protective mechanism, 
being induced by either dysregulation or, Aβ-induced, hypoxic and metabolic disturbances in 
cells. 
Aβ could also affect ACE expression via AMPK. AMPK is a cellular metabolic sensor in many 
ways and responds to levels of insulin and glucose, both of which are affected by the RAAS 
and AD (Cai et al., 2012; Greco et al., 2011; Kohlstedt et al., 2013, 2011; Mairet-Coello and 
Polleux, 2014; Thornton et al., 2011). This enzyme down-regulates ACE expression in the 
endothelium upon stimulation by shear stress and activates p53 via phosphorylation of Ser15.  
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This promotes cell survival, as opposed to p53’s usual apoptotic role, by post-transcriptionally 
upregulating miR143/145 and reducing ACE expression (Kohlstedt et al., 2013, 2011) (Figure 
5.13). As Aβ in AD induces severe cellular dysfunction which in many ways is related to AMPK 
dysregulation (Cai et al., 2012), it is possible that this induces ACE transcription and expression 
disturbances which lead to greater ACE and consequential RAAS upregulation. 
Overall, the inhibition of ACE appears to have cell-mediated interactions that could prove 
either beneficial or detrimental. In the absence of a complete understanding of ACE inhibitor 
and amyloid-mediated signalling, C-selective inhibitors that do not cross the BBB could confer 
added benefits in the treatment of hypertension. It is plausible that treatment with these 
inhibitors would not only maintain the natural up-regulation of ACE in the brain to reduce the 
Aβ burden, but also maintain the possible ACE inhibitor-induced up-regulation via ACE 
signalling in peripheral monocytes. ANGII production would be slowed and the overall 
inflammatory distress it causes lowered, this would help maintain the BBB, and slow the 
transport of Aβ into the brain via RAGE (induced by ANGII) (Ihara et al., 2007).  
As hypertension and glucose regulation are strongly interlinked and affect one another via 
signalling mechanisms, reducing high BP has added benefits towards cell metabolism 
 
Figure 5.13 Possible mechanisms for Aβ-induced upregulation of ACE expression. ACE expression can be 
activated via the outside-in signalling response as with ACE inhibitors and other substrates. Alternatively 
dysregulation of CK2 (becoming over activated), or AMPK (via a reduction of activity) could induce 
increased up-regulation of ACE expression in neuronal tissue. Whether Monocytes alter their expression 
of ACE in response to inflammatory or stress indications has yet to be tested. This poses another possible 
means by which increased ACE expression may form part of a protective response to AD pathology.  
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(Kohlstedt et al., 2009; McFarlane et al., 2003). A peripheral C-selective ACE inhibitor would 
allow for the lowering of blood pressure and its related increase in ROS induced by multiple 
ANGII mechanisms (See Chapter 1 section 1.4.3.1 and section 1.6.2). Less ANGII improves cell 
energy metabolism and reduces insulin desensitization (Fogari et al., 1998; Marrero et al., 
2004; Olivares-Reyes et al., 2009; Ongali et al., 2014). These responses would, in-turn, remedy 
cytoskeletal derangements through GSK-3β (Agarwal et al., 2013) and lower cell death 
induced by Aβ accumulation (Zhu et al., 2011). Further investigation around ACE signalling 
would be helpful in assessing any further effects that ACE inhibitors have, be they detrimental 
or beneficial. 
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6 CONCLUSIONS AND FUTURE 
DIRECTIONS 
In the light of the debate surrounding the role of ACE in Alzheimer’s and, more specifically, 
the clearance of the plaque-forming Aβ peptide, this study investigated the molecular and 
kinetic mechanisms of Aβ hydrolysis by ACE. The domain selectivity of amyloid cleavage was 
interrogated by kinetic and mass spectrometry approaches and a comparative model system, 
using the physiological Aβ(1-16) as well as two FRET peptides derived from the metal binding 
N-terminal region of Aβ(1-42), was developed. Furthermore, ACE mediated signalling
responses to Aβ and the ACE inhibitor lisinopril were investigated using immunoprecipitation
and HR/AM MS.
In Chapter 2 the preference for ACE to cleave different Aβ peptides at specific peptide bonds 
was examined. The successful expression and purification of six full-length and truncated ACE 
variants (Ndom, N-sACE, sACE, C-sACE, CC-sACE and Cdom) and several active site mutants, 
combined with consistent primary cleavage intermediates that they generated, provided a 
robust model system for analysis. This is important, as throughout the literature there is 
variation in the types of construct and source of ACE used to assess the domain-selectivity of 
Aβ. Furthermore, there has been a lack of Aβ cleavage site specificity and little explanation of 
enzyme-Aβ interactions at a molecular level (see Chapter 2 section 2.1). The model system 
used in this study enables the determination of: domain selectivity, the specific differences 
within the individual domains that may drive selectivity, what cooperative interactions occur 
affecting selectivity, and the rates of hydrolysis of the N-terminal region of Aβ(1-42). In order 
to further understand the mechanism of Aβ hydrolysis, a number of Aβ peptides were 
crystallised with the Ndom and high-resolution structures were solved.  
ACE’s adaptability towards various substrates is exemplified in its endoproteolytic and 
exoproteolytic activity towards peptides derived from the N-terminus of full-length Aβ(1-42). 
The cleavage site and domain specificity of Aβ(2-11) by the N- and C-domains of ACE was 
successfully determined using HPLC. The Aβ(2-11) was endoproteolytically cleaved at the 
Asp7-Ser8 bond as previously described (Hemming and Selkoe, 2005; Hu et al., 2001; Kumar et 
al., 2012; Oba et al., 2005). This knowledge enabled the development of shorter fluorogenic 
FRET-Aβ substrates, Aβ(4-10)Q and Aβ(4-10)Y, which harbour cleavage sites of the larger Aβ 
peptides. These FRET peptides maintained the Asp7-Ser8 cleavage site under kinetic assay 
conditions. The physiological Aβ(1-16) underwent dicarboxypeptidase cleavage by all variants 
of ACE, generating an Aβ(1-14) primary intermediate, again, under kinetic assay conditions. 
This cleavage site has not been documented before but was consistently found using the 
different truncated and full-length ACE variants. The kinetic trend of Aβ(1-16) domain 
selectivity was similar to that of the shorter zinc binding Aβ(2-11). Overall, based on the 
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hydrolysis progress curves, the N-domain variant hydrolysed the Aβ peptides more efficiently 
than the other ACE forms. However, there was no difference in cleavage site specificity 
between N- and C-domains. Notably, truncated C-domain hydrolysis of Aβ does occur, but it is 
likely that it is not physiologically significant.  
To examine the interactions of Aβ peptides with the ACE obligatory binding site, six high-
resolution crystal structures of N-domain in complex with fragments of five Aβ peptides (Aβ(4-
10), Aβ(4-10)Y, Aβ(1-16), Aβ(10-16) and Aβ(35-42)) were solved.  The crystal structures 
provided further evidence of ACE’s endopeptidase activity. However, as crystallisation 
conditions require long incubations with a large amount of substrate, it is likely that these 
cleavage products are the result of both primary and secondary cleavage.  Thus, for Aβ(10-16) 
and Aβ(1-16) the crystal structures indicated a cleavage site between residues His14 and 
Gln15; however, the Aβ- Asp7-Ser8 dipeptide was crystalized from more than one substrate. 
This presence of the Aβ- Asp7-Ser8 dipeptide was surprising as it was the major cleavage site 
found under kinetic assay conditions and it indicates cleavage at His6-Asp7 and Ser8-Gly9. 
These variances are likely attributed to different experimental conditions but, corroborate 
previous findings regarding ACE’s ability to accommodate a variety of P1 and P1’ residues.  
A general mode of binding to the Aβ binding to the Ndom was proposed from the six crystal 
structures.  Interestingly, the general dipeptide S’ binding mechanism appears to be 
conserved, as it is similar to that of the Cdom binding of ANGII and BPPb (Masuyer et al., 
2012). Furthermore, any overlapping interactions occur mostly with conserved residues. N-
domain selectivity based on these structures may occur through a number of additional 
interactions with residues unique to the N-domain. More specifically, the larger polar chains 
of Aβ form hydrogen bonds with Thr389 and, through a network of water mediated 
interactions, the unique residues of the S2’ pocket. Furthermore, there were direct 
hydrophobic interactions between N-specific S2’ residues and the Aβ -Val12, Ala42 and 
nitroTyr10.  
Besides direct interactions, there are other mechanisms by which either domain of ACE may 
better hydrolyse Aβ and affect selectivity. The Aβ(1-42) is one of the largest substrates known 
to be hydrolysed by both ACE and NEP.  ACE and NEP were thought to be structurally similar 
since they share common substrates and ACE inhibitors inhibit NEP to some degree (Kukkola 
et al., 1995). Thus, as NEP and IDE have hinge bending mechanisms, allowing for a larger 
variety of substrates to access their active sites, it is conceivable that ACE functions in this way 
too (Holland et al., 1995; Malito et al., 2008). Based on crystallographic structures, the large 
Aβ substrate might have difficulty in accessing the small active site pockets. There is also an N-
terminal lid on the C domain which consists of three charged α helices that may further 
restrict the access of large substrates (Natesh et al., 2003). The C-domain has high homology 
to two other metallopeptidases neurolysin and thermolysin (Natesh et al., 2003; 
Roychaudhuri et al., 2012). Thermolysin has an open conformation if a substrate is not 
present, and undergoes a five degree rotation of its two ends towards each other in its closed 
conformation (Hausrath and Matthews, 2002). Such a mechanism was previously proposed 
for the C-domain of ACE with six hinge regions identified (Watermeyer et al., 2006). 
Furthermore, ACE2, a close homolog of ACE (40% homology), is known to undergo hinging 
about the active site cleft (Towler et al., 2004). ACE2 has been crystallized in both the open 
and closed conformations (PDB ID: 2R42 and 2R4L, respectively) (Towler et al., 2004). This 
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hinging of ACE2 was inhibitor-dependent and could be extrapolated towards substrates as it 
brings residues important to catalysis into position for optimal enzyme activity. The N-domain, 
which is structurally homologous to the ACE2 closed crystal structure, is likely to undergo a 
large amount of movement and hinging about its catalytic subdomains (Guy et al., 2003). As 
the N- and C-domains share a high degree of structural homology, it is likely that they share 
this potential hinging ability. Thus, the hinging mechanism may allow either domain to 
interact with a large substrate like Aβ-peptide or conformational changes may be activated 
allowing access, prior to substrate binding, by chloride on which C-domain catalysis is highly 
dependent (Wei et al.,1991; 1992).  
In this study, the Aβ dipeptide crystals did not induce major conformational shifts in the 
structure of the Ndom (Figure 2.7 A). However, hinging motion of the Ndom lid helices 
(Anthony et al., 2010), was observed in some of the molecules, evident from the higher b-
factors found in these regions. With this in mind, this study sought to determine which unique 
N-domain active site residues might induce Aβ-hydrolysis within the truncated C-domain. As
the S’ subsite has been implicated as a determinant of N-selectivity towards substrates and
inhibitors alike (Araujo et al., 2000; Dive et al., 1999; Michaud et al., 1999), and contains a
large number of domain-specific active site residues, its role in Aβ selectivity was
interrogated.
In this study the FRET peptides Aβ(4-10)Q and Aβ(4-10)Y showed clear N-domain selectivity. 
Interestingly, the kinetic assay cleavage site results positioned the Gln10 residue within the 
S2’ pocket, and the EDDnp quencher in the S3’ pocket.  This positioning could drive the N-
selectivity of Aβ(4-10)Q as the Aβ(4-10)Y peptide has a nitrotyrosine in this same position and, 
although still N-selective, had moderate C-domain activity. The increased C-domain selectivity 
of Aβ(4-10)Y is likely to be the result of the conserved S2’ hydrophobic interactions indicated 
by the crystal structure.  
The two active site residues within the C-domain that generated the greatest increase in Aβ 
hydrolysis once mutated, were also determinants of C-selective inhibition (RXPA380, kAW and 
kAF) (Kröger et al., 2009; Watermeyer et al., 2010, 2008). The V380 and V379 residues are 
found on the border of the S2’ and S1’ pockets in the C-domain. Thus, it is unlikely that a slight 
change in hydrophobicity of this large S1’ pocket would affect the affinity towards the P1’ Ser8 
and Gly9 residues that theoretically occupy it jointly. Considering this, most of the effects 
caused by these mutants are probably due to increased polar S2’ interactions with the 
hydrophilic Gln10 and Y3NO2 groups of Aβ(4-10)Q and Aβ(4-10)Y, respectively.  The most 
significant increase in activity was derived from V379S Cdom mutant, which had a similar KM 
to the V380T mutant, but a much higher kcat towards Aβ(4-10)Q. Furthermore, its catalytic 
rate far exceeded that of the Ndom towards Aβ(4-10)Q. This mutants selectivity was not 
specific to the large EDDnp quencher of Aβ(4-10)Q, as similar trends were found towards 
Aβ(4-10)Y. To understand this better, the corresponding N-domain mutant S357V was 
analysed. Here there was a loss in substrate affinity but equivalent catalysis to the Ndom.  
Overall the efficiency of S357V was reduced, indicating that this residue does play a significant 
role in the selectivity of Aβ(4-10)Q. Theoretically, the position of the Ser357 residue forms a 
hydrogen bond mediated tightening of the S2’ interactions by bringing helix 17, on which the 
residues are positioned, into closer contact with the substrate. This interaction helps drive 
overall N-domain conformational selectivity. Further combinations of N- to C-domain active 
CHAPTER 6 Conclusions and Future Work Kate Larmuth 
120 
site mutations within Ndom could be examined with the two FRET substrates to further 
elucidate possible unique interactions in the Ndom that make Aβ so selective. 
As physiological ACE does not occur abundantly as truncated N- and C-domains, it is important 
to establish whether the catalytic sites in full-length sACE display similar selectivity.  As 
current clinical ACE inhibitors inhibit both domains of ACE, maintaining Aβ-hydrolytic function 
may be of significance towards patients at risk of AD. Furthermore, understanding how the Aβ 
substrate interacts with the full-length sACE, compared to the truncated domains, could 
better predict how ACE inhibitors may induce beneficial or non-beneficial effects. Four 
additional ACE constructs were employed to determine absolute selectivity and any co-
operative interactions that may occur between the two domains of ACE in Aβ(1-16), and FRET 
Aβ hydrolysis. 
Interestingly, the magnitude of N-domain selectivity is reduced in the full-length form of ACE 
across all substrates.  This is due to an overall decrease in catalytic rate with little influence 
from substrate affinity. The cooperative effects, like many ACE substrates (Binevski et al. 
2003; Skirgello et al. 2005; Woodman et al. 2005), were negative towards the physiological 
Aβ(1-16) and the Aβ(4-10)Q. Surprisingly the Aβ(4-10)Y generated a large positive cooperative 
effect. This positive cooperativity between the two domains was maintained when comparing 
sACE to either truncated or full-length N- and C-constructs. Unlike Aβ(4-10)Q where the sum 
of the full-length constructs indicated only slight negative cooperativity yet remaining large 
between truncated constructs. This positive domain interaction with Aβ(4-10)Y may be of 
significance as the nitrotyrosine is a common PTM of the wild type Tyr10 in Aβ plaques. 
Interestingly ANG(1-7), inversely associated with increasing tau hyperphosphorylation in AD 
(Jiang et al., 2015), has also been shown to have a positive cooperative effect between the 
two domains of ACE (Rice et al., 2004). On catalytic rate alone, the Aβ(1-16) and Aβ(4-10)Q 
have similar trends, where the truncated Ndom is most selective, and the individual active site 
knockouts are also N-selective, with a C-domain mediated negative cooperativity in sACE. In 
both these substrates, the C-sACE construct gained a small amount of activity, indicating an 
importance to the physical and specific presence of the N-domain. This was corroborated by 
the domain-substitution mutant where the N-domain of sACE was replaced with a second C-
domain that exhibited poor Aβ hydrolysis. The same is true towards the Aβ(4-10)Y substrate; 
however, unlike the other substrates the C-domain selectivity was increased and measurable.  
In Chapter 5, the putative signalling of Aβ via membrane-anchored ACE in CHO cells was 
examined. Aβ(1-16), Aβ (1-42) and lisinopril elicited JNK association and activation with ACE’s 
cytoplasmic tail. Only Aβ(1-42) however induced a significant (doubling) increase in ACE 
expression and activity 48 hours post treatment. Targeted mass spectrometry was used to 
quantify changes in Ser1270 phosphorylation as an indication of ACE signalling. For numerous 
reasons this proved difficult to do using hypothesis driven conditions. The phosphopeptide of 
interest could be detected, but the signal was to poor for quantification with the added 
complication of additional PTMs. Thus, an evidence based discovery approach, where the 
native pSer1270 containing peptide could be identified and then targeted using PRM, would 
provide a way forward for absolute quantification of the signalling response. This is otherwise 
known as a data independent acquisition (DIA) approach, which involves tandem MS scans 
collected independently of precursor ion information that is then probed through a targeted 
search for known ACE pSer1270 peptides (Parker et al., 2015). This can be performed as a 
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label-free quantification–based DIA (LFQ-DIA) which has proven to be robust and reproducible
technique for the quantification of signalling responses across many samples (Masselon et al., 
2000; Parker et al., 2015). This approach requires added sample preparation, that of phospho-
enrichment via titanium dioxide (TiO2) chromatography (Delom and Chevet, 2006). This is a 
highly efficient method for purification of phosphopeptides and is suited to the 
characterization of phosphoproteins from both in vitro and in vivo studies. It is possible to 
characterise entire signalling pathways using this technique on the Q-Exactive. One would 
glean a global image of the signalling processes on an MS/MS level, achieved upon ACE 
inhibition or substrate binding, through data independent full scan analysis (Gallien et al., 
2012; McAlister et al., 2008; Parker et al., 2015; Stergachis et al., 2011).  Identifying entire 
pathways may aid in explaining benefits of ACE inhibitors beyond their ability to reduce 
enzyme activity 
Despite a general decrease in selectivity of the N-sACE compared to the Ndom, our results 
indicate amyloid is far more N-domain selective in the current optimal C-domain conditions 
(higher NaCl concentrations, which are critical to C-domain activity). This decrease in 
selectivity may have implications to the relevance of domain selective inhibitors towards the 
treatment of hypertension and AD. Furthermore, it would be of great value to know the 
precise signalling pathway Aβ utilizes to induce increased ACE expression and whether this is a 
cell-specific function. It is especially relevant considering the N-domain has Aβ degrading 
ability and immune-response capabilities forming part of the MHC antigen recognition system 
in macrophages (Bernstein et al., 2014; Shen et al., 2011), to see if Aβ-ACE signalling is 
induced here. Mouse models of AD and ACE over-expression in monocytic cell lines have been 
shown to reverse AD- pathologies (Bernstein et al., 2014). With regard to immune response, 
ex vivo macrophages from fat cells elicit an ACE dependent activation and reduction of pro-
inflammatory cytokines in response to lipids (Kohlstedt et al., 2011). This response is similar to 
NSAID treatment against Aβ-induced macrophage activation (Combs et al., 2000).  
In the absence of a complete physiological understanding of ACE’s biochemical effects in AD, a 
cautionary approach towards ACEi may be warranted. With the treatment of hypertension, 
current ACE inhibitors block both the N- and the C-domains (Anthony et al., 2012). This leads 
to numerous side effects, like the development of angioedema, due to the accumulation of 
bradykinin and substance P (Hecker et al. 1994; Hecker et al. 1997; Erdös et al. 1999).  This 
study has added kinetic and structural mechanistic data indicating that the N-domain is 
selective towards Aβ hydrolysis in all forms of ACE. It provides further rationale for the 
development of C-domain-selective inhibitors that could be efficacious in the treatment of AD 
and hypertension while presenting an improved side effect profile (Acharya et al., 2003; 
Georgiadis et al., 2003). This thesis paves the way for future in vivo studies towards a 
complete understanding of the functional significance of ACE in an upregulated BRAAS and 
RAAS and its role in AD.  
APPENDICES  7 Kate Larmuth 
122 
7 APPENDICES 
7.1 Cell Culture 
7.1.1.1 Growth Medium 
50% Dulbecco’s Modified Eagle Medium (DMEM) (Sigma, USA), 50% HAMS-F12 (Sigma, USA) 
supplemented with 10% foetal calf serum (FCS) (Sigma, USA) and 20M HEPES buffer] 
7.1.1.2 Minimal Medium 
50 % DMEM, 50 % Ham’s F12, 20mM HEPES, 2 % FCS (heat-inactivated for a further 15min at 
70°C 
7.1.1.3 PBS 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, KH2PO4, pH 7.5. 
7.2 DNA and Restriction enzyme digests 
 TENS Mini-Plasmid DNA isolation 7.2.1
Spin 2 ml bacterial overnight culture for 1 min at 6-7000 rpm. Discard supernatant and 
resuspended pellet in 300 µl TENS solution for less than 10 min. Add 150 µl of cold 3 M NaOAc 
to the TENS suspension and then vortex and put on ice. Centrifuge for 10 min at 13000 rpm at 
4°C which should precipitate all protein. Remove 400 µ of the supernatant and transfer to a 
new eppindorf. Add 800µl of 100% EthOH incubate at -20 °C for +/- 15 min to precipitate the 
DNA spin this mixture for 5 min at 4°C at 13000 rpm a clear pellet of DNA should form. Wash 
the DNA with 70 % ethanol 3 times in 300 µl by reversing the tube in the centrifuge and 
spinning for 10 min at 13000 rpm.  Dry the pellet and resuspended in TE/Rnase buffer 30 µl
. 
7.2.1.1 TENS (500 mL) 
5 ml   1M Tris pH8.0 
12.5 ml 20% SDS 
5 ml   10N NaOH 
1 ml  0.5M EDTA 
Make up the volume to 500 ml with MilliQ H20. 
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 Restriction digests 7.2.2
100-300ng DNA 
1X Restriction Enzyme Buffer 
1U Restriction Enzyme 
Made up to 20 µl with nuclease water 
Standard digests from 1-2 hours at 37°C 
 
 Site directed mutagenesis (SDM) 7.2.3
7.2.3.1 SDM primers 
The signalling Ser1270A knock out mutation was created using the following primers, Figure 
7.1, with the aid of WATCUT (http://watcut.uwaterloo.ca/watcut, designed by Michael 
Palmer, University of Waterloo, Canada.) to create pBSK.S1270A. Primers were synthesised by 
Inqaba Biotechnical Industries (South Africa). 
 
7.2.3.2 PCR parameters for SDM 
Initial Denaturation: 95 ºC  2 min  
Denaturation: 98 ºC   20 sec 
Annealing: Tm of primers for  15 sec  
20 cycles of Denaturation and annealing 
Extension: 72 ºC   30 sec/kb  
Final Extension: 72 ºC   1 - 5 min 
  
 
Figure 7.1 S1270A signalling mutant primers. Both forward and reverse 
primers are indicated as well as the introduced NarI sight, which is underlined.  
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 Internal sACE primers 7.2.4
 
 E.coli growth and transformation 7.2.5
7.2.5.1 Luria-Broth (LB) 
Bacterial culture medium used to propagate and, if necessary select for transformed DH5α 
E.coli  
10 g Tryptone 
5 g Yeast Extract 
5 g  Sodium Chloride 
Made up to 1L of dH2O prior to autoclaving. Once cooled to sufficient temperature prior to 
ampicillin is added when necessary. 
7.2.5.2 Luria-Broth Agar 
Bacterial agar used to select single colonies of transformed or untransformed DH5α E.coli  
10 g Tryptone 
5 g  Yeast Extract 
5 g  Sodium Chloride 
12 g Agar 
Made up to 1L of dH2O prior to autoclaving. 
Once cooled to sufficient temp ampicillin is added when necessary.  
 
Figure 7.2 Internal sequencing primers. These primers are used routinely in our group to 
confirm the integrity of constructs after any site directed mutagenesis reactions have been 
performed. 
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7.2.5.3 DH5α Strain 
This strain has endogenous dam and dcm methylation, ideal for screening DNA mutated via 
site directed mutagenesis, with the methylation sensitive restriction enzyme DpnI.  
Genotype: F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1 Supplied by Promega (Madison, WI, USA). 
7.2.5.4 Calcium chloride competent cell preparation 
Competent cells were prepared in accordance with (Sambrook et al., 1989). A single DH5α 
colony from a plate streaking, was inoculated into 5 ml of LB and grown O/N whilst shaking at 
37°C.  Of this, 1 ml was used as an inoculum into 100 ml of LB, grown whilst shaking at 37°C 
until logarithmic growth phase occurs at an O.D600 of 0.5-0.6. Cells were pelleted at 5000 rpm 
for 10 minutes at 4°C,the supernatant discarded and the pellet resuspended in 100 ml of cold 
100 mM MgCl2 followed by incubation for 20-30min on ice. The cells are then pelleted once 
more for 10 minutes at 5000 rpm at 4°C, and resuspended in cold 100 mM CaCl2 in 15 % 
glycerol solution. Aliquots of 200 µl cell suspension were then frozen at -80°C for later use. 
7.2.5.5 Transformation of competent cells 
For the transformation of DH5α E.coli cell approximately 50-100 ng of DNA was added to 
100 µl of competent DH5α cells and incubated on ice for 20 minutes. The cells were heat 
shocked at 37°C for 5 minutes followed by 1 minute incubation on ice. The cells were then 
incubated in 450 µl of LB for 1 hour at 37°C for plasmid replication. The transformants are 
then plated onto selective LB agar plates containing 150 mg/ml ampicillin and incubated O/N 
at 37°C. Positive clones are picked and screened accordingly.  
7.3 Protein Expression and Purification 
 Buffers 7.3.1
7.3.1.1 Wash Buffer 
20 mM HEPES, pH 7.5, 0.5 M NaCl 
7.3.1.2 Elution buffer 
50 mM borate buffer pH 9.5 
7.3.1.3 Dialysis solution  
5 mM HEPES, pH 7.5, 0.1 mM PMSF (in ethanol) 
7.3.1.4 1X triton lysis buffer  
0.05 M HEPES, 0.5 M NaCl, 1% triton X-100, 1 mM PMSF 
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7.3.1.5 Protease Inhibitor Cocktail 
Set III, Calbiochem, USA, 0.2 mM AEBSF, 0.16 M Aprotinin, 0.01 mM Bestatin, 3 µM E-64, 4 µM 
Leupeptin and 2 µM Pepstatin A 
Bradford Protein Concentration Determination 7.3.2
Protein concentration of full-length sACE was determined using the IgG curve and for single 
domain ACE (Ndom and tACE), the albumin curve was used.  The curves were determined by 
linear regression analysis using GraphPad Prism 4.0 software. 
7.4 Assay Constituents 
 Substrates and working stock preparations. 7.4.1
Table 7.1 Sequence and manufacturer of all amyloid peptides used. 
7.4.1.1 Aβ(2-11) 
Dissolved in 100 % DMSO, to form a 4.31 mM Stock solution. This was then diluted in 1XHEPES 
Buffer to a final DMSO concentration of 1% prior to performing any assay. This peptide had an 
absorbance maximum of 0.6 at 225nm. 
Aβ peptides Amino Acid Sequence Manufacturer
Aβ(2-11) Ac-AEFRHDSGYE-NH2 A. K. Carmona
Aβ(4-10) H-FRHDSGY-OH China Peptides
Aβ(4‑10)Q Abz‑FRHDSG(Q)-EDDnp A. K. Carmona
Aβ(4‑10)Y Abz-FRHDSG -Y(3NO2)-OH Biopep™
Aβ(1-16)Bach H-DEAEFRHDSGYEVHHQK-OH © Bachem A G
*Aβ(1-42) H-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-OH rPeptide™
Figure 7.3 Representative Bradford standard curve. IgG was used as a standard 
measure for ACE concentrations. 
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7.4.1.2 Aβ(4-10) 
Received 20 µl of 20 mM stock, in water thus, a simple dilution to a 200 µM working stock was 
made. 
7.4.1.3 Aβ(4-10)Q 
A stock of 289 µl of 4.31 mM was made in DMSO. This was then diluted out into 1XHEPES 
buffer to a working stock concentration of 88 µM. 
7.4.1.4 Aβ(4-10)Y 
A 10.5 mM stock was made in 500 µl in DMSO. For the assays a working stock of 100 µM was 
made up in 1XHEPES buffer.  
7.4.1.5 Aβ(1-16) 
1mg of Aβ(1-16) was dissolved into 51.2 µl of DMSO to a final concentration of 10 mM.  
Aliquots of 6.75 µl of this stock was then frozen at -80°C until required. To make working 
stocks 1XHEPES buffer was added to a final concentration of 500 µM. 
7.4.1.6 Aβ(1-42) 
1mg of Aβ(1-42) was dissolved into 88.8 µl of DMSO to a final concentration of 2.5 mM. The 
stock was then sonicated for 5 min, aliquots of 8 µl of this stock was then frozen at -80°C until 
required.  
 Buffers 7.4.2
7.4.2.1 phosphate buffer  
100 mM KHPO4/KH2PO4 (pH 8.3), 300 mM NaCl, 10 µM ZnSO4 
7.4.2.2 IX HEPES assay Buffer  
50 mM HEPES buffer, 300 mM NaCl, 10 µM ZnSO4 
7.4.2.3 AST-assay Buffer 
100 mM KHPO4/KH2PO4 pH 8.3, 300 mM NaCl, 10 µM ZnSO4, 1 mg/ml albumin 
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7.5 Standard Curves 
 HL Standard Curve 7.5.1
An HL product standard curve was generated to determine ACE activity using the synthetic 
ZPHL or HHL substrates. 
 
ACE activity is measured in mU defined as: 
       
                                                        
                                                                 
 
 Abz-Gly Standard Curve 7.5.2
An Abz-product formation standard curve was generated for the determination of ACE activity 
on the two FRET substrates Aβ(4-10)Q and Aβ(4-10)Y.  
          
Figure 7.4 HL standard curve for the determination of ACE activity towards 
the substrates HHL and ZFHL 
  
Figure 7.5 A standard curve for the determination of product formed for all FRET 
substrates 
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 Calibration curve of Aβ(1-14) 7.5.3
7.6 Cooperativity Kinetics Curves. 
The Michaelis-Menten curves for the determination of all cooperative kinetics determined in 
Chapter 4. 
Figure 7.6 Calibration curve used to convert peak area to product formed of Aβ(1-16) 
Figure 7.7 Aβ(1-16) Michaelis-Menten curves for the determination of kinetic constants. 
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Figure 7.8 Aβ(4-10)Q Michaelis-Menten curves for the determination of kinetic constants. 
 
Figure 7.9 Aβ(4-10)Y Michaelis-Menten curves for the determination of kinetic constants. 
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7.7 Western blotting. 
7.7.1.1 Transfer Buffer  
20 mM Tris, 150 mM glycine, 20 % methanol 
7.7.1.2 Blocking buffer 
5% (w/v) skim milk, 0.1% (v/v) Tween-20, 0.2 M NaCl, 0.05 M Tris (pH7.4) 
7.7.1.3 TBS-T 
0.1% (v/v) Tween-20, 0.2 M NaCl, 0.05 M Tris (pH7.4) 
7.7.1.4 Laemmli Buffer  
20 % glycerol, 6 % SDS, 125mM Tris, 5 %β-mercaptoethanol, Bromophenol blue, pH 6.8 
7.7.1.5 SDS-PAGE Running conditions 
Protein detection of cell lysate or immunoprecipitation required that samples be mixed with 
laemmli buffer (20 % glycerol, 6 % SDS, 125mM Tris, 5 %β-mercaptoethanol, Bromophenol 
blue, pH 6.8) and separated by SDS-PAGE using the Mini PROTEANTM III system (BIO-RAD,USA). 
For the resolution of high molecular weight proteins like sACE, 8 % resolving gels (final 
concentrations of 0.4 %SDS, 1.5 M Tris, pH 8.8) and 3% stacking gels (final concentrations of 
0.1 %SDS, 125 mM Tris, pH 6.8) were used. 
7.8 Mass spectrometry. 
 Buffers 7.8.1
7.8.1.1 RIPA buffer  
150 mM NaCl, 50 mM triethylammonium bicarbonate, 1 % SDS, 0.5 % deoxycholate, (pH 8) 
 Representative Spectra and transitions 7.8.2
7.8.2.1 Representative traces from the TSQ-Vantage of lisinopril 
treatment and induced Ser1270-phosphoyrlation 
Lisinopril 200 nM treatment of sACE expressing CHO cells for 0, 5 and 7 minutes. Targeted 
mass spectrometry traces of the un-modified HSHGPQFGSEVELR (Figure 7.11) and Ser1270-
phosphorylated HSHGPQFGSEVELR peptides (Figure 7.10). The transition lists used to perform 
the targeted analysis are found in (Table 7.2). 
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Figure 7.10 The S1270 phosphorylated peptide, lisinopril 200 nM treatment, traces with poor 
transitions above background. The total ion count however correlated to the increase of the y6-
daughter ion well.A) Replicates peak area percentage bar graph as an indication of ion signal 
reproducibility or changes. B) The chromatogram trace from the TSQ-Vantage.  
Figure 7.11 The parent unphosphorylated peptide of lisinopril 200 nM treatment, traces with good 
transitions above background. A) Replicates peak area percentage bar graph as an indication of ion 
signal reproducibility or changes. B) The chromatogram trace from the TSQ-Vantage.  
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Table 7.2  Transition list and settings used on the TSQ-Vantage. 
 
Parent ion (m/z) Product ion (m/z) Collision Energy Start time Stop time Polarity Trigger Reference corresponding peptide
404.709 466.241 15 0 90 1 1 0 WGVFSGR
404.709 565.309 15 0 90 1 1 0 WGVFSGR
404.709 622.331 15 0 90 1 1 0 WGVFSGR
479.219 405.685 17 0 90 1 1 0 FVEEYDR
479.219 582.252 17 0 90 1 1 0 FVEEYDR
479.219 711.294 17 0 90 1 1 0 FVEEYDR
490.284 554.297 18 0 90 1 1 0 AILQFYPK
490.284 682.356 18 0 90 1 1 0 AILQFYPK
490.284 795.44 18 0 90 1 1 0 AILQFYPK
507.746 399.709 18 0 90 1 1 0 SEGPLPDSGR
507.746 531.252 18 0 90 1 1 0 SEGPLPDSGR
507.746 741.389 18 0 90 1 1 0 SEGPLPDSGR
507.746 798.41 18 0 90 1 1 0 SEGPLPDSGR
518.241 487.251 19 0 90 1 1 0 TQGDFDPGAK
518.241 634.32 19 0 90 1 1 0 TQGDFDPGAK
518.241 806.368 19 0 90 1 1 0 TQGDFDPGAK
527.259 209.126 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 258.66 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 323.182 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 366.698 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 395.208 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 417.245 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 468.743 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 516.313 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 532.772 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 581.298 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 609.809 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 645.356 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 678.338 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 732.388 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 789.409 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 936.478 27 0 90 1 1 0 HSHGPQFGSEVELR
527.259 1064.536 26 0 90 1 1 0 HSHGPQFGSEVELR
527.259 1161.589 25 0 90 1 1 0 HSHGPQFGSEVELR
527.259 1218.611 24 0 90 1 1 0 HSHGPQFGSEVELR
527.259 1355.67 23 0 90 1 1 0 HSHGPQFGSEVELR
553.914 209.126 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 258.66 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 323.182 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 406.681 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 417.245 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 435.192 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 508.726 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 516.313 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 572.755 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 621.281 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 645.356 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 649.792 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 718.322 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 812.354 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 869.376 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 1016.444 28 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 1144.503 26 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 1241.556 25 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 1298.577 25 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
553.914 1435.636 23 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
588.822 559.295 21 0 90 1 1 0 YVELINQAAR
588.822 672.379 21 0 90 1 1 0 YVELINQAAR
588.822 914.505 21 0 90 1 1 0 YVELINQAAR
676.815 620.273 23 0 90 1 1 0 LNGYVDAGDSWR
676.815 806.343 23 0 90 1 1 0 LNGYVDAGDSWR
676.815 905.411 23 0 90 1 1 0 LNGYVDAGDSWR
681.817 637.346 23 0 90 1 1 0 YNFDWWYLR
681.817 938.452 23 0 90 1 1 0 YNFDWWYLR
681.817 1085.52 23 0 90 1 1 0 YNFDWWYLR
708.813 753.368 24 0 90 1 1 0 QDGFTDTGAYWR
708.813 868.395 24 0 90 1 1 0 QDGFTDTGAYWR
708.813 969.442 24 0 90 1 1 0 QDGFTDTGAYWR
738.372 610.793 25 0 90 1 1 0 AALPAQELEEYNK
738.372 667.335 25 0 90 1 1 0 AALPAQELEEYNK
738.372 1220.579 25 0 90 1 1 0 AALPAQELEEYNK
762.847 561.314 26 0 90 1 1 0 ENYNQEWWSLR
762.847 747.394 26 0 90 1 1 0 ENYNQEWWSLR
762.847 876.436 26 0 90 1 1 0 ENYNQEWWSLR
766.907 688.337 26 0 90 1 1 0 VSFLGLDLDAQQAR
766.907 916.448 26 0 90 1 1 0 VSFLGLDLDAQQAR
766.907 1086.554 26 0 90 1 1 0 VSFLGLDLDAQQAR
790.384 209.126 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 258.66 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 323.182 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 366.698 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 395.208 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 417.245 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 468.743 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 516.313 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 532.772 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 581.298 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 609.809 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 645.356 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 678.338 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 732.388 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 789.409 30 0 90 1 1 0 HSHGPQFGSEVELR
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Table 8.2 continued. 
 
Parent ion (m/z) Product ion (m/z) Collision Energy Start time Stop time Polarity Trigger Reference corresponding peptide
790.384 936.478 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 1064.536 30 0 90 1 1 0 HSHGPQFGSEVELR
790.384 1161.589 29 0 90 1 1 0 HSHGPQFGSEVELR
790.384 1218.611 28 0 90 1 1 0 HSHGPQFGSEVELR
790.384 1355.67 27 0 90 1 1 0 HSHGPQFGSEVELR
827.837 195.608 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 252.15 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 280.661 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 337.203 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 387.727 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 390.209 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 423.245 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 472.779 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 503.293 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 529.322 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 560.314 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 585.864 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 621.382 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 673.399 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 677.924 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 706.435 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 762.977 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 774.446 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 836.511 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 845.483 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 893.053 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 944.552 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 949.595 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 1006.137 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 1057.636 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 1099.177 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 1163.206 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 1170.72 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 1241.757 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 1354.841 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
827.837 1411.863 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
830.367 209.126 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 258.66 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 323.182 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 406.681 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 417.245 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 435.192 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 508.726 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 516.313 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 572.755 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 621.281 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 645.356 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 649.792 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 718.322 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 812.354 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 869.376 32 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 1016.444 31 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 1144.503 30 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 1241.556 29 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 1298.577 29 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
830.367 1435.636 27 0 90 1 1 0 HSHGPQFGS[Phosphoryl]EVELR
862.962 604.284 29 0 90 1 1 0 IAFLPFGYLVDQWR
862.962 640.825 29 0 90 1 1 0 IAFLPFGYLVDQWR
862.962 1280.642 29 0 90 1 1 0 IAFLPFGYLVDQWR
877.967 489.257 29 0 90 1 1 0 IAFIPFSYLVDQWR
877.967 604.284 29 0 90 1 1 0 IAFIPFSYLVDQWR
877.967 1310.653 29 0 90 1 1 0 IAFIPFSYLVDQWR
1241.251 195.608 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 252.15 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 280.661 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 337.203 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 387.727 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 390.209 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 423.245 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 472.779 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 503.293 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 529.322 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 560.314 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 585.864 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 621.382 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 673.399 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 677.924 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 706.435 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 762.977 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 774.446 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 836.511 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 845.483 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 893.053 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 944.552 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 949.595 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 1006.137 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 1057.636 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 1099.177 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 1163.206 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 1170.72 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 1241.757 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 1354.841 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
1241.251 1411.863 35 0 90 1 1 0 VGQWLLLFLGIALLVATLGLSQR
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7.8.2.2 Representative traces from the Q-Exactive of lisinopril treatment 
and induced Ser1270-phosphoyrlation 
Using the shorter Easy column, optimisation targeted runs determined the best charge state 
for to reach the highest signal were doubly charged. The S1270-phosphorylation was detected 
here at 7 min treatment with lisinopril, and there appeared to be a retention time delay with 
the presence of the phosphor-Ser1270. 
Figure 7.12 Total ion peaks from targeted optimisation on the Q-Exactive, indicating the retention 
shift on phosphorylation of Ser1270 in ACE’s cytoplasmic tail. A) Group 2, histidine and phosphor 
Ser1270 combination traces, with a peak shift from 25.7 min (phosphor-S1270) to 26.2 min (parent with 
one histidine oxidation). B) Group 3, histidine and pSer1270 combination traces, with the same time 
shift found in group 2. Note the much larger signal intensity of these histidine oxidation modification 
peptides.  
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